Diagnostic, Prognostic and Therapeutic Value of Gene Signatures by Russo, A. et al.
 Current Clinical Pathology
Antonio Giordano, Md, Phd
SERIES EDITOR
For further volumes:
http://www.springer.com/series/7632
               
Antonio Russo ● Stefano Iacobelli ● Juan Iovanna
Editors
Diagnostic, Prognostic 
and Therapeutic Value 
of Gene Signatures
Editors
Antonio Russo, MD, PhD 
Section of Medical Oncology 
Department of Surgical and Oncological Sciences
University of Palermo
Palermo, Italy
antonio.russo@usa.net
Juan Iovanna, MD, PhD
INSERM U624
Marseille 13288, France
iovanna@marseille.inserm.fr
Stefano Iacobelli, MD
National Consortium for Research on Cancer (CINBO)
University D’Annunzio
Chieti 66013, Italy
iacobell@unich.it
ISBN 978-1-61779-357-8 e-ISBN 978-1-61779-358-5
DOI 10.1007/978-1-61779-358-5
Springer New York Dordrecht Heidelberg London
Library of Congress Control Number: 2011937026
© Springer Science+Business Media, LLC 2012
All rights reserved. This work may not be translated or copied in whole or in part without the written permission of the 
publisher (Humana Press, c/o Springer Science+Business Media, LLC, 233 Spring Street, New York, NY 10013, USA), 
except for brief excerpts in connection with reviews or scholarly analysis. Use in connection with any form of information 
storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter 
developed is forbidden.
The use in this publication of trade names, trademarks, service marks, and similar terms, even if they are not identified 
as such, is not to be taken as an expression of opinion as to whether or not they are subject to proprietary rights.
While the advice and information in this book are believed to be true and accurate at the date of going to press, neither 
the authors nor the editors nor the publisher can accept any legal responsibility for any errors or omissions that may be made. 
The publisher makes no warranty, express or implied, with respect to the material contained herein.
Printed on acid-free paper
Humana Press is part of Springer Science+Business Media (www.springer.com)
v Preface 
 Gene expression studies have revealed diagnostic profiles and upregulation of specific pathways in 
many solid tumors. Some gene-expression signatures are already used as predictors of relapse in 
early breast cancer patients. The explosion of new information in gene expression profiling could 
potentially lead to the development of tailored treatments in many solid tumors. In addition, many 
studies are ongoing to validate these signatures also in predicting response to hormonal, chemo-
therapeutic, and targeted agents in breast cancer as well as in other tumors. 
 This book has been carried out with the aim of providing readers a useful and comprehensive 
resource about the range of applications of microarray technology on oncological diseases. 
 The book is principally addressed to resident and fellow physicians, medical oncologists, molec-
ular biologists, biotechnologists, and those who study oncological diseases. The chapters have been 
written by leading international researchers on these topics who have prepared their manuscripts 
according to current literature and field experience with microarray technology.
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 Introduction 
 Soft tissue sarcomas represent an extremely heterogeneous group of tumors comprising more than 
70 different histotypes, as described in the current World Health Organization classification from 
2002  [ 1 ] . To date, the diagnosis of soft tissue sarcomas is still challenging and based on morphologi-
cal appearance; moreover, some conventional names included in the classification results pathobio-
logically inaccurate (e.g., synovial sarcoma) although they denote well-defined entities mutually 
understood by both pathologists and clinicians. 
 Some well-known inherited syndromes are associated with the onset of soft tissue sarcoma, 
underlining the importance of genetic alterations in the pathogenesis of this aggressive disease. For 
example, hereditary retinoblastoma syndrome  [ 2 ] , a rare genetic disorder deriving from an RB gene 
mutation, is known to be associated with a higher risk of developing osteosarcoma  [ 3 ] ; type 1 neu-
rofibromatosis  [ 4 ] , due to the mutation of NF1 gene on chromosome 17, bring to the onset of 
malignant peripheral nerve sheet tumors (MPNSTs) and gastrointestinal stromal tumors (GISTs), 
often multiples and arising from the small bowel  [ 5 ] . At the same time, Li–Fraumeni syndrome 
(deriving from a germ line p53 mutation)  [ 6 ] , Gardner syndrome  [ 7 ] (due to an APC mutation), and 
Beckwith–Wiedemann syndrome, the pathogenesis of which is still not completely understood  [ 8 ] , 
are associated with a higher incidence of soft tissue and bone sarcoma. 
 Despite these data, the majority of soft tissue sarcomas arise sporadically, but are often character-
ized by molecular aberrations. Genetically, sarcomas can be broadly divided into two groups: the first 
group, usually characteristic of older patients, comprise those with a complex karyotype bringing 
nonspecific genetic alterations, such as genetic deletions and amplifications, nonbalanced transloca-
tions, and changes in chromosome number. These aberrations are usually not helpful for diagnosis, 
but they are often prognostically relevants. The second group is made up of sarcomas characterized 
by simple karyotypes, which create specific genetic alterations usually represented by chromosomal 
translocations or oncogenic mutations (e.g., the KIT mutation in GISTs). These kinds of sarcomas 
often arise during childhood or adolescence and the detection of their tumor-specific genetic altera-
tions by cytogenetic or molecular genetic techniques are extremely diagnostically useful. 
 Chapter 1 
 Gene Signatures and Soft Tissue Sarcomas: Status 
of Art and Perspectives 
 Bruno  Vincenzi ,  Anna  Maria  Frezza ,  Daniele  Santini , and  Giuseppe  Tonini  
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 Soft Tissue Sarcoma with Complex Genomic Profiles 
 Soft tissue sarcomas with complex genomic profiles represent almost 50% of all soft tissue sarcomas, 
and they are mainly represented by sarcoma with spindle cell/pleomorphic differentiation. These 
kinds of sarcomas can harbor a wide variety of genetic alterations, such as gain or loss of chromo-
somes or chromosome regions and amplifications; these aberrations have been proven to play a key 
role in tumor progression, metastatic dissemination, and they often correlate with prognosis and 
treatment sensitivity  [ 9 ] . 
 Leiomyosarcoma 
 A subtype of sarcomas, characterized by a spindle cell differentiation, account for 8–10% of all 
adult soft tissue sarcomas  [ 10 ] . They usually show complex karyotypic alterations comprising 
mainly chromosomal imbalances and amplifications  [ 11 ] . Recent studies have proven that some of 
these modifications are associated with unfavorable prognosis (p16INK4 inactivation RASSF1A 
hypermethylation)  [ 12,  13 ] , and with a higher metastatic risk (upregulation of hypoxia inducible 
factor A); moreover, the identification of specific pathway disregulation has brought about the 
development of an interesting therapeutic implication: for instance, the upregulation of PI3K–
AKT–mTOR pathway identified in leiomyosarcoma (LMS) could justify the partial activity of 
everolimus (RAD001, mTOR inhibitor), as recently proven in different clinical trials. 
 Undifferentiated High-Grade Spindle/Pleomorphic Sarcoma 
 Undifferentiated high-grade spindle/pleomorphic sarcoma (UPS) is the term currently used to 
define high-grade soft tissue sarcoma, which have failed to show any specific line of differentiation 
(instead of malignant fibrous histiocytomas). It is a diagnosis of elimination comprising approxi-
mately 5–7%  [ 1 ] of adult sarcomas. UPS are characterized by a complex cytogenetic rearrangement 
involving 30–35% of the genome, and they have been proven to share many of the aberrations 
described for LMSs. Among the most common genomic imbalances found in UPS are the loss of 
chromosome 13q, RASSF1A hypermethylation, and the upregulation of several hypoxia-related 
genes. A recent study has evaluated the involvement of gene TRIO (coding for guanidine nucleotide 
exchange factor), usually upregulated in soft tissue sarcoma. TRIO, through the activation of Rho 
GTPase-mediated signaling pathway, plays an important part in the control of apoptosis, cytoskel-
eton organization, cell-to-cell adhesions, and many other basic cell functions, and it seems to be 
involved in sarcoma progression  [ 14 ] . Ezrin (villin 2) is a protein that works as a link between cell 
membrane and actin cytoskeleton and its overexpression has been found to correlate with a higher 
metastatic potential and reduced survival in many different tumors, as also seen in UPS. 
 Myxofibrosarcoma 
 For a long time,  myxofibrosarcoma have been included in malignant fibrous histiocytomas and for 
this reason, the data concerning the genetics of this kind of sarcoma are still poor. 
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 Myxofibrosarcomas are usually characterized by a complex karyotype that can be identified 
both in low grade and in high-grade subtypes. Recent studies have underlined how cytogenetic 
aberration in myxofibrosarcoma can be associated with an increased risk of local recurrence. 
Moreover, a better understanding of the myxofibrosarcoma genetic profile can help make a distinc-
tion between low-grade myxofibrosarcoma and cellular myxoma (not always easy on the basis of 
morphology) and may allow a correct identification of those myxofibrosarcomas previously 
 misclassified as UPS. 
 Pleomorphic Liposarcomas 
 Among liposarcoma,  pleomorphic liposarcomas are known to be characterized by a complex 
genomic profile. In fact, to date, no specific genetic alterations have been identified, although some 
frequent events have been pinpointed, such as the disregulation of RB1 pathway or the loss of neu-
rofibromatosis type 1 (NF1) gene  [ 15 ] . A better understanding of pleomorphic sarcoma genetic 
profiling could help to accurately distinguish between this kind of liposarcoma and one which is 
dedifferentiated; despite their morphological similarities, they show different chromosomal imbal-
ances. According to a recent study, a correct distinction could be done through the evaluation of 15 
differentially expressed genes, mainly located in the 12p13–p15 region  [ 16 ] ; however, further data 
are necessary to confirm these preliminary results. 
 Malignant Peripheral Nerve Sheet Tumors 
 MPNSTs originate from peripheral nerves or from extraneural soft tissue showing nerve sheath dif-
ferentiation. They are characterized by complex karyotypes and frequently show chromosomal 
losses, which have been proven to be more frequent than chromosomal gains  [ 17 ] , numerous break-
points involving different chromosomal regions, ring chromosomes, trisomy, and rearrangements, 
while amplification are rare. Of interest, more than 50% of MPNSTs occur in the setting of neuro-
fibromatosis 1, one of the most common mendelian disorders caused by heterozygous mutations of 
the NF1 gene; the NF1-associated MPNSTs show a higher rate of genetic complex rearrangements 
when compared with the sporadic forms. Finally, complex karyotypes are generally not observed in 
benign peripheral nerve sheath tumors (e.g., schwannoma) and this may help in the differentiation 
of benign and malignant forms. 
 Other subtypes of soft tissue sarcomas, such as angiosarcoma and pleomorphic rhabdomyosar-
coma, can be included in this wide group, but their characteristics are still poorly known and further 
studies are needed to define their genetic signatures. 
 Soft Tissue Sarcoma with Simple Genomic Profiles 
 Nearly 30% of all soft tissue sarcomas show a simple genomic profile and are characterized by 
specific chromosomic aberrations. These genetic abnormalities aid in the diagnosis of sarcoma, can 
assume a prognostic or predictive significance, and could also represent a target for the development 
of new biological drugs. Soft tissue sarcomas with simple karyotypes can be further divided in two 
groups on the base of the presence of reciprocal translocations involving or not involving the Ewing 
sarcoma breakpoint region 1 (EWSR1). 
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 Soft Tissue Sarcoma Associated with EWSR1 Translocation 
 The EWSR1 (also known as EWS) is the most commonly involved gene in sarcoma translocations, 
and it seems to play an important role in the pathogenesis of Ewing’s sarcoma/peripheral neuroec-
todermal tumor, clear cell sarcoma, angiomatoid fibrous histiocytoma, desmoplastic small round 
cell tumor, extraskeletal myxoid chondrosarcoma and myxoid/round cell liposarcoma (Table  1.1 ). 
The translocations involving the EWSR1 usually result in the fusion of the N-terminal transcription-
activating domain of EWSR1 and the C-terminal DNA-binding domain of the fusion partner, which 
brings a generation of a novel constitutively activated transcription factor. 
 Because of the difficulties often recognized in the diagnostic phase of sarcoma work-up, the 
identification of EWSR1 rearrangement through fluorescence in situ hybridization (FISH) is con-
sidered an extremely useful confirmatory diagnostic tool. 
 Ewing Sarcoma Family Tumors 
 Ewing’s sarcomas together with primitive neuroectodermal tumors (PNETs) constitute the  Ewing 
sarcoma family tumors (ESFTs) and share a similar biological behavior and therapeutical approach. 
Almost 80% of ESFTs harbor a recurring translocation, t(11;22) (q24;q12), that juxtaposes the FLI1 
and EWSR1 genes encoding a chimeric RNA and protein; the remaining part of ESFTs are charac-
terized by translocations always involving EWSR1 together with different transcription factors, 
such as ERG (9–14%) or other rarer variants (1–5%). On the basis of this data, ESFTs are consid-
ered the prototype of tumors with fusion genes involving the TET gene family, where TET was 
named from the initials of TLS/FUS, EWSR1, and TAFII68  [ 18 ] . The proteins derived from the 
TET gene family include an RNA-recognizing motif made up of 84 amino acids which is thought 
to bind RNA and participate in the transcription process. The evaluation of karyotype in order to 
identify the t(11;22) translocation must be considered today as necessary in the initial work-up of 
 Table 1.1  Soft tissue sarcoma associated with EWSR1 translocation 
 Tumor  Translocation  Fusion product 
 Ewing sarcoma/PNET  t(11;22)(q24;q12) 
 t(21;22)(q22;q12) 
 EWSR1–FLI1 
 EWSR1–ERG 
 t(20;22)(q13;q12)  EWSR1–NFATC2 
 t(2;22)(q33;q12)  EWSR1–FEV 
 t(7;22)(p22;q12)  EWSR1–ETV1 
 t(17;22)(q12;q12)  EWSR1–E1AF 
 t(2;22)(q31;q12)  EWSR1–SP3 
 t(1;22)(p36.1;q12)  EWSR1–ZNF278 
 t(6;22)(p21;q12)  EWSR1–POU5FI 
 Clear cell sarcoma  t(12;22)(q13;q12)  EWSR1–ATF1 
 t(2;22)(q34;q12)  EWSR1–CREB1 
 Angiomatoid fibrous histiocytoma  t(12;22)(q13;q12)  EWSR1–ATF1 
 t(2;22)(q34;q12)  EWSR1–CREB1 
 Desmoplastic small round cell tumor  t(11;22)(p13;q12)  EWSR1–WT1 
 t(21;22)(q22;q12)  EWSR1–ERG 
 Extraskeletal myxoid chondrosarcoma  t(9;22)(q22;q12)  EWSR1–NR4A3 
 Myxoid/round cell liposarcoma  t(12;22)(q13;q12)  EWSR1–DDIT3 
 EWSR1 Ewing sarcoma breakpoint region 1 
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an ESFT; moreover, where the histopathological findings strongly suggest a ESFTs diagnosis with 
a normal karyotype, the recourse to the FISH, using a break-apart probe targeting the EWSR1 gene, 
must be considered. Of interest, the detection of the precise translocation in ESFTs, through the use 
of a reverse transcription polymerase chain reaction  (RT-PCR), has been proven to hold an impor-
tant prognostic relevance; in fact, the EWSR1/FLI1 translocation seems to be associated with a 
better outcome when compared with the alternative fusions  [ 19 ] . 
 Soft Tissue Clear Cell Sarcomas 
 Soft tissue clear cell sarcomas (ST-CCS), also called melanoma of soft parts, represent a well-defined 
subtype of soft tissue sarcoma arising mainly from adolescents and young people’s aponeuroses of 
distal extremities. From a pathological viewpoint, they are constituted by nests and cords of pale 
cells, sharing many differentiation features with melanocite, including the presence of melanin and 
the immunohistochemical positivity for S100, HMB45, MART1, and MITF-1 in almost all cases, 
with the exception of the gastrointestinal tract forms which are usually positive only for S100  [ 20, 
 21 ] . ST-CCS are characterized by a specific translocation t(12;22)(q13;q12), fusing the EWSR1 gene 
with the activating transcription factor-1 gene (ATF1)  [ 22 ] . Recently, in the cases of ST-CCS deriving 
from the gastrointestinal tract, a different variant has been identified, involving EWSR1 and cAMP-
responsive element-binding protein (CREB1). In both translocations, EWSR1’s partners are repre-
sented by a leucine zipper superfamily of transcription factors: the translation of the chimeric 
transcripts leads to a proteinaceous product in which the basic leucine zipper domain is retained. 
 As for pathogenesis, the upregulation of MITF gene (a master regulator of melanocyte differentia-
tion) has been found in ST-CCS and the assessment of multiple histone deacetylase inhibitors activity 
in the suppression of MITF expression is today under evaluation. To date, it is still unclear if MITF 
upregulation derives from the EWSR1–ATF1 binding of MITF gene promoter site or it is a preexisting 
characteristic of ST-CCS  [ 22 ] . In order to achieve a correct diagnosis, the possibility of a malignant 
melanoma must be ruled out. The clinical history and the absence of junctional activity can be useful 
in this distinction; however, metastatic melanoma can exhibit complete morphologic overlap with 
ST-CCS, and in these cases the use of genetic analysis represents the only way to distinguish them. 
 Angiomatoid Fibrous Histicytoma 
 Angiomatoid fibrous histicytoma is a mesenchymal lesion of intermediate malignancy, rarely met-
astatizing and usually occurring in the superficial soft parts of the limbs. Of interest, despite a 
completely different morphologic aspect and biological behavior, angiomatoid fibrous histicytoma 
shares the same translocations detected in ST-CCS (EWSR1–CREB1 fusion, and more rarely, of a 
EWSR1–ATF1 fusion)  [ 23 ] . This observation leads to the supposition of preexisting differentiation 
programs in the two progenitor cells. 
 Desmoplastic Small Round Cell Tumors 
 As ESFTs and ST-CCS, also  desmoplastic small round cell tumors, usually harbor a t(11;22) trans-
location which brings to the fusion of EWSR1 gene, on chromosome 22, with the WT1 gene, on 
chromosome 11  [ 24 ] . The identification of the WT1 as a partner of EWSR1 throughout the DNA 
amplification at the breakpoint allows a differential diagnosis between these two sarcoma subtypes. 
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Moreover, WT1 has been proven to act as a transcription factor activated by EWSR1, which leads 
to the upregulation of oncogenic factors, such as the platelet-derived growth factor (PDGF). This 
mechanism is thought to play a key role in desmoplastic small round cell tumors which are histo-
logically characterized by an abundant collagenous stroma, including cord and nest of small round 
cells; furthermore, this could represent a rationale for experimentation with PDGF inhibitors, such 
as imatinib  [ 25 ] , in the treatment of this complex disease. 
 Extraskeletal Myxoid Chondrosarcoma 
 Extraskeletal myxoid chondrosarcoma is a histotype of sarcoma with a yet undefined origin, involv-
ing mainly deep soft tissue of limbs and limb girdles. The translocation t(9;22)(q22;q12), fusing 
EWSR1 with CHN (also known as NR4A3), is found in almost 70% of extraskeletal myxoid chon-
drosarcomas  [ 26 ] , even if additional fusion partners to CHN have been subsequently identified 
(TAF2N, TCF12, and TFG)  [ 27,  28 ] . Of interest, the translocation characterizing extraskeletal myx-
oid chondrosarcoma has been found to be absent in the skeletal form, confirming that these two 
forms must be considered different entities  [ 29 ] . Recent findings suggest that the EWSR1/CHN 
fusion protein could activate the PPARG nuclear receptor gene. Aside from the pathogenetic impli-
cations, these data could suggest the identification of a new potential therapeutic target  [ 30 ] . 
 Myxoid Liposarcoma 
 Myxoid liposarcoma , also called hypercellular liposarcoma because of the increase in the cellularity 
so that individual tumor cells lie in direct continuity with each other without matrix interposition, 
accounts for 30–35% of all liposarcoma and arise mainly in limbs  [ 31 ] . Myxoid liposarcomas har-
bor two different translocations: the first, t(12;16), fuses the DDIT3 gene on 12q13 with the FUS 
gene on 16p11  [ 32 ] , the second, t(12;22), fuses DDIT3 with EWSR1 on 22q12  [ 33 ] . The DNA-
damage-inducible transcript 3 (DDIT3) gene is a member of the CCAAT/enhancer-binding protein 
family which is physiologically involved in adipocyte differentiation and exerts an antiproliferation 
activity; this gene is lost in the chimeric product deriving from the translocations. 
 Soft Tissue Sarcoma with Non-EWS Translocations 
 Apart from soft tissue sarcomas associated with EWSR1 translocations, many other histological 
subtypes of sarcomas are characterized by specific translocations, not involving the Ewing sarcoma 
region, that have been proven to play a key part in the pathogenesis, by disrupting basic cellular 
functions, such as proliferation, growth, and survival, and to codify for important possible new 
therapeutic targets. In this group, we find synovial sarcoma, alveolar rhabdomyosarcoma, alveolar 
soft part sarcoma, dermatofibrosarcoma protuberans, low-grade fibromyxoid sarcoma, and inflam-
matory myofibroblastic tumor (Table  1.2 ). 
 Synovial Sarcoma 
 Despite the improper name,  synovial sarcoma does not arise from synovium but it can occur in 
almost any anatomical location, usually derived from connective periarticular tissue. It represents 
almost 10% of all sarcomas and typically affects patients between 15 and 35 years of age. Synovial 
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sarcomas harbor a specific translocation, t(X;18)(p11.2:q11.2)  [ 34 ] , in which eight amino acids at 
the carboxy terminal of the SYT (SS18) gene on chromosome 18 are replaced with 78 amino acids 
of the carboxy terminal of the SSX gene on the X chromosome. SSX recognize five different vari-
ants: those involved in the translocation of synovial sarcoma are SSX1, detected in two thirds of all 
cases, SSX2, and more rarely SSX4  [ 35 ] . Three different subtypes of synovial sarcomas can be iden-
tified, characterized by different genetic signatures: the monophasic variant made up of vimentin-
expressing spindle cells, usually carrying the SS18–SSX2 translocation, the biphasic variant 
comprises a mixture of vimentin-expressing spindle cells and keratin expressing glandular epithelial 
cells harboring the SS18–SSX1 or SS18–SSX2 translocation, and a poorly differentiated represent-
ing 20% of synovial sarcoma cases  [ 36 ] . To date, the exact function of the genes identified in syn-
ovial sarcoma is still unclear and other events might be required for sarcomagenesis. The diagnosis 
of synovial sarcoma is frequently challenging because of the morphological similarities with the 
other small round cell sarcomas, lymphomas, neuroendocrine carcinoma, and neuroblastoma. 
Detection of the t(X;18) translocation is an extremely useful tool. 
 Rhabdomyosarcoma 
 Rhabdomyosarcoma is the most common kind of sarcoma in children, and it occurs mainly in the 
deep muscles of the extremities. Among rhabdomyosarcoma, three different subtypes can be distin-
guished: embrional rhabdomyosarcoma (60% of all cases), alveolar rhabdomyosarcoma (20%), and 
pleomorphic rhabdomyosarcoma (20%)  [ 37 ] . Alveolar rhabdomyosarcoma is known to be charac-
terized by a specific translocation which leads to the fusion of 5 ¢ end of a member of the PAX gene 
family, encoding for a transcription factor that promotes the myogenesis in muscle stem cells, with 
the 3 ¢ end of the FOXO1A gene that provides the transactivation domain. The fusion’s product 
causes an enhancement of cellular proliferation and invasion  [ 38 ] . The t(2;13)(q35:q14), involving 
the PAX3 gene, is detected in almost 70% of alveolar rhabdomyosarcomas while the t(1;13)
(p36;q14) translocation, involving PAX7, in 10%; the remaining 20% usually do not show any 
specific genetic aberration. Today, in the initial assessment of rhabdomyosarcoma, genetic analysis 
is mandatory because it allows a distinction between the embryonal and the alveolar form, which 
often share a similar immunohistochemical phenotype but have different biological behavior with 
the alveolar subtype being much more aggressive, and because the alveolar rhabdomyosarcoma 
harboring the PAX7–FKHR translocation has been proven to be associated with longer event-free 
survival and longer overall survival in both locoregional  [ 39 ] and metastatic disease  [ 40 ] . 
 Table 1.2  Soft tissue sarcoma associated with non-EWSR1 translocation 
 Tumor  Translocation  Fusion product 
 Synovial sarcoma  t(X;18)(p11;q11)  SS18–SSX1 (SYT–SSX1) 
 SS18–SSX2 (SYT–SSX2) 
 Alveolar rhabdomyosarcoma  t(2;13)(q35;q14)  PAX3–FOXO1 (PAX3–FKHR) 
 t(1;13)(p36;q14),  PAX7–FOXO1 (PAX7–FKHR) 
 Alveolar soft part sarcoma  t(X;17)(p11;q25)  ASPSCR1–TFE3 (ASPL–TFE3) 
 Inflammatory myofibroblastic tumor  Translocations involving 2p23 locus  ALK activation 
 Dermatofibrosarcoma protuberans  Ring chromosome 17 or 22  COL1A1–PDGFB 
 t(17;22)(q21;q13)  COL1A1–PDGFB 
 Low-grade fibromyxoid sarcomas  t(7;16)(q34; p11)  FUS–CREB3L2 
 t(11;16)(p11;p11)  FUS–CREB3L1 
 EWSR1 Ewing sarcoma breakpoint region 1 
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 Alveolar Soft Part Sarcoma 
 Alveolar soft part sarcoma is a rare subtype of sarcoma that mainly affects children and young 
adult’s deep muscles and is associated with an extremely poor prognosis. To date, the pathogenesis 
of alveolar soft part sarcoma is still poorly understood; however, cytogenetic studies have identified 
a recurrent translocation, t(X;17)(p11;q25), detected in majority of alveolar soft part sarcomas. This 
translocation fuses alveolar soft part sarcoma chromosome region candidate 1 (ASPSCR1; ASPL) 
gene on the long arm of chromosome 17 to the transcription factor for immunoglobulin heavy-chain 
enhancer 3 (TFE3) located at Xp11. Even if the function of the fusion product is still unknown, the 
consistent detection of the t(X;17) in alveolar soft part sarcoma is now considered a useful molecu-
lar diagnostic marker; moreover, recent studies have identified an MET activation mediated by 
ASPL–TFE3 fusion protein  [ 41 ] . On the basis of these data, the efficacy of MET kinase inhibitors 
(such as sunitinib malate)  [ 42 ] in the treatment of this aggressive tumor is currently under examina-
tion. In support of this hypothesis, a response has been reported in clear cell sarcoma in a phase II 
study of the MET inhibitor ARQ197  [ 43 ] . 
 Dermatofibrosarcoma Protuberans 
 Dermatofibrosarcoma protuberans is a relatively common sarcoma characterized by a low-grade 
malignant behavior, which tends to recur locally (especially if incompletely resected) instead of 
giving distant metastasis. From the genetic viewpoint, it harbors a specific translocation, t(17;22) 
(q11;q13.1), or a supernumerary ring chromosome always derived from t(17;22), which determine 
the fusion of the COL1A1 gene on chromosome 17 with PDGFB1 gene (encoding the beta chain of 
PDGF, a homodimer) at 22q13  [ 44,  45 ] . The breakpoint is specific for the PDGFB1 gene while it 
is extremely changeable for the COL1A1 gene. This finding suggests that COL1A1 acts as an 
upregulator of PDGFR expression which exerts an auto or paracrine growth factor activity. Even if 
genetic analysis is usually not necessary for the diagnosis of dermatofibrosarcoma protuberans, the 
search for the translocation can be useful in order to identify the best therapeutic option. In fact, in 
cases harboring the translocation, the inhibition of PDGFR tyrosine kinase through imatinib has 
yielded extremely good results both in the locally advanced and in the metastatic setting  [ 46 ] . In 
this disease, imatinib is thought to work through the inhibition of PDGFRB and can be useful in 
controlling locally advanced tumors with a response rate of almost 50%. Currently, sunitinib and 
sorafenib are under evaluation  [ 47 ] . Conversely, in rare cases of fibrosarcomatous or pleomorphic 
sarcomatous transformation, in which the translocation is absent, the same therapy would be unsuc-
cessful  [ 48 ] . 
 Low-Grade Fibromyxoid Sarcoma 
 Low-grade fibromyxoid sarcomas , also known as Evans tumors, arise in the deeper soft tissues of 
extremities (especially the thigh), characterized by an extremely heterogeneous morphologic 
appearance. In fact, many different histological subtypes once considered as different entities, such 
as hyalinizing spindle cell tumor with giant rosettes, have been included in this group after the 
identification of a common translocation, t(7;16)(q34; p11), with the 5 ¢ part of FUS from chromo-
some 16 with 3 ¢ part of CREB3L2 on chromosome 7. In a few cases, the translocation t(11,16)
(p11;p11), with an FUS–CREB3L1 fusion gene, has been identified  [ 49 ] . Of interest, in contrast to 
all the other translocation sarcomas, the breakpoint of the t(7;16) is mainly localized within the exons. 
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To date, no correlation has been found between the different morphological aspect of low-grade 
fibromyxoid sarcomas and its genetic signatures and more studies are needed to clarify the pathogenetic 
role and the potential therapeutic value of these findings. 
 Inflammatory Myofibroplastic Tumor 
 Inflammatory myofibroblastic tumor originates principally in the retroperitoneum mainly during the 
first decade of life, although some cases have been described in adult ages. This subtype of sarcoma 
has been proven to be associated with a translocation involving the C-terminal kinase domain of 
anaplastic lymphoma kinase (ALK) gene, located on 2p23. The ALK gene encodes for a tyrosine 
kinase oncogene which becomes constitutively activated in inflammatory myofibroblastic tumors, 
thanks to the fusion with many different partners, such as TPM3 or CLTC. Apart from the diagnos-
tic utility of these genetic findings, recent studies have underlined the difference in the morphology 
and in the biological behavior of ALK-positive and ALK-negative inflammatory myofibroblastic 
tumors. In fact, ALK-negative tumors occur more frequently in adults and display more nuclear 
pleomorphism and atypical mitoses  [ 50 ] . Moreover, given the pathogenetic relevance of ALK-
mediated signaling in ALK-rearranged tumors, the efficacy of crizotinib in this subgroup of sarco-
mas is currently under evaluation  [ 51 ] . 
 Summary 
 The identification of the association between soft tissue sarcomas and translocations or specific 
genetic signatures makes this rare disease an extremely attractive field of research, both for the pos-
sibility of better understanding the pathogenetic processes (their onset and progression), both for 
diagnostic and therapeutical implications. To date, the use of modern molecular techniques in the 
diagnosis of soft tissue sarcomas appears mandatory, mainly in order to distinguish subtypes that 
share similar morphological phenotypes and immunohistochemical patterns. Furthermore, the iden-
tification of specific translocations leading to the upregulation of pathways probably exerting a key 
role in sarcomatogenesis makes soft tissue sarcomas particularly susceptible to molecularly targeted 
therapies, which represent today a promising hope for those patients affected by this poor-prognosis 
disease. Further studies are needed in order to better understand the pathogenetic mechanisms and 
the possible treatment options of these sarcomas, which are still defined as associated with complex 
genomic profiles. 
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 Introduction 
 The initial steps into a better understanding of the heterogeneity and biology of breast cancer were 
made at the onset of 2000, with the first identification of distinct molecular subtypes of human breast 
tumors possessing different outcome  [ 1– 3 ] . Gene expression profiling and microarray analysis 
opened a road leading to the new molecular classification of breast cancer, recognizing at least five 
reproducible subtypes: luminal A, luminal B, ERBB2, basal, and normal-like  [ 3– 6 ] . This revolution-
ary concept was triggered from an intense research driven by the evidence that 60–70% of all breast 
cancers are classified as “not otherwise specified” infiltrating ductal carcinomas (IDC NOS)  [ 4 ] . 
 The methodology of microarray has been soon supported by other tools like array comparative 
genomic hybridization (array-CGH), single-nucleotide polymorphism (SNP), high-throughput 
screening (HTS) techniques and the increasing availability of multiple tools for pathways analysis. 
The combination of these advanced technologies is constantly applied to in vitro and in vivo 
research in order to improve our knowledge of breast cancer biology and our understanding of the 
complex process of metastasis. The ultimate goal is to create strategies and algorithms guiding a 
tailored management of patients with both early and advanced breast cancer. 
 The focus of this chapter is to provide a general summary of the genomic signatures available 
for breast cancer and to function as a tool for clinicians for the interpretation of gene signatures. 
Moreover, we also give a brief overview of the emerging tools designed to capture and study the 
heterogeneity of breast cancer (next-generation sequencing). 
 Chapter 2 
 Heterogeneity of Breast Cancer: Gene Signatures 
and Beyond 
 Gaia  Schiavon,  Marcel  Smid,  Gaorav  P.  Gupta,  Stefania  Redana,  Daniele  Santini, 
and  John  W.M.  Martens  
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 Genomic Signatures and Microarray Analysis 
 From Binary to Bedside 
 In the last decade or so, there has been a slow switch from analyzing a gene-at-a-time, to higher 
throughput procedures. To establish which genes were active in a biological context, traditional 
methods like Northern and Southern Blotting were gradually replaced by the so-called microarrays. 
These started out as large membrane sheets spotted with cDNA, but these have evolved substantially 
to much smaller chips which can contain millions of oligonucleotides. mRNA of a biological 
sample can be hybridized to these chips, which yields the expression levels of thousands of genes 
in one single experiment. 
 This in turn necessitates a specialized field to measure, collect, transform, analyze, and evaluate 
these data using statistically sound methods. Enter bioinformatics. Although part of the bioinfor-
matics field is concerned with the (pre)processing steps to extract reliable data from the microar-
rays, a big part focuses on applicable analyses. Demanding as it can be, dealing with millions of 
data-points, it does provide a very rich platform to build solid conclusions. 
 If one considers that the expression of a few markers like estrogen receptor (ER) or HER2/neu 
(together with tumor size, grading, nodal involvement, and other few other prognostic marker) will 
determine the best treatment regimen, it is easy to envision that by measuring thousands of genes in 
hundreds of samples, valuable markers or combinations of markers can be identified, linked with 
many, if not all, clinical aspects of the patients involved. However, teasing out statistically sound 
differentially expressed genes or reliable signatures hiding in the ranks of thousands of genes does 
entail a considerable challenge, one that has admittedly met with its pitfalls, but more so with con-
siderable successes. 
 To start on a cautionary note, it is still a very good idea to uphold the scientific principle to vali-
date one’s results thoroughly. The most notorious example to date is the paper describing expression 
signatures guiding the choice of chemotherapy in cancer patients which was heralded in 2006  [ 7 ] , 
but ultimately proved unreliable and was retracted in 2011. Indeed, bioinformatics is a powerful 
tool, which obliges researchers to wield it in a correct manner. 
 One of the most abundantly used bioinformatics analysis is “hierarchical clustering,” in which order 
is created out of the chaos of gene expression patterns of tumor cells. By grouping tumors according 
to the similarity of their gene expression levels, Perou et al. were able to reflect the notorious hetero-
geneity which is found in the clinical outcome of breast cancer patients, in five distinct molecular 
subtypes  [ 1 ] . This landmark paper was among the first which put the power of bioinformatics analysis 
on the map. The five molecular subtypes have since then been studied extensively, and many clinical 
relevant observations are ascribed to the subtypes, among which prognosis  [ 1,  3 ] response to therapy 
 [ 8 ] , and site-specific relapse  [ 9 ] . Thus, the overall gene expression patterns can be quite distinct in 
patients suffering from breast cancer. By linking the expression of specific genes to the clinical param-
eters of patients, any range of clinically relevant questions can be addressed. Milestone examples are 
gene expression signatures able to predict prognosis  [ 10,  11 ] , of which Food and Drug Administration 
(FDA) approval has been granted for the first multigene model, signatures for response to therapy 
 [ 8,  12 ] , and signatures for breast cancers relapsing to bone  [ 13– 15 ] , lung  [ 16,  17 ] , and brain  [ 18 ] . 
 One dimension higher is the analysis of interacting genes. Similar gene functions or signaling 
cascades – pathways – can be identified from the expression data. Although more suited to increase 
understanding in the biological processes about breast cancer, clinical associations with specific 
pathways have been described  [ 19 ] . Finally, similar bioinformatics analyses can be applied to 
miRNA, DNA copy-number, SNPs, sequence, and methylation data. Gathering all these data from 
the same tumor and integrating all this knowledge is the upcoming challenge. When available, a 
detailed tumor blueprint for each individual breast cancer patient could be constructed, which will 
guide the physician to treat future patients with the most tailored strategy. 
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 Multiple Gene Signatures: Do Not Get Lost 
 As already mentioned, the identification of breast cancer molecular subtypes was the first insight 
into the biologic heterogeneity of breast cancer  [ 20 ] . Gene-expression profiling resulted to be – and 
still is – a very appealing approach, but the clinical utility of classifying breast cancer into molecular 
subtypes using unsupervised cluster analysis has limitations. For example, with the addition of a 
new case to the data, the dendrograms of hierarchical cluster analysis are reorganized, and therefore 
it is not possible to prospectively classify new cases using this methodology  [ 21 ] . If larger sample 
sets are used, more clusters and molecular subtypes of breast cancer could become evident  [ 22 ] . 
In this perspective, several large studies gave the major clinical contribution of gene-expression 
profiling in predicting prognosis and response to therapies. Different approaches have been used 
and different questions have been addressed. For example, some signatures were derived from the 
gene profiling of human breast cancer cell lines with particular propensity to metastasize to one or 
another organ and/or mouse models of breast cancer and then applied to breast cancer patients. 
In other cases, the signature was directly derived from the profiling of fresh-frozen tissues from 
breast cancer patients (test set) and then validated in one or more independent datasets. Samples are 
selected on the basis of a specific aim: identification of molecular subtype, prediction of prognosis, 
resistance to chemo/hormonal-therapy, risk of relapse, etc. Table  2.1 provides a large overview of 
the most relevant signatures produced by breast cancer research. Of note, a source of concern has 
been the little or absent overlap between the different gene sets, when compared to each other. For 
example, the 70-gene signature and the 21-gene RS have only the SCUBE2 gene in common 
 [ 10,  23,  32 ] . The reasons for this lower-than-expected overlap are not completely known, but they 
probably include differences in the patient cohorts (e.g., 70-genes and 76-genes prognostic signa-
tures), microarray platforms, the large number of genes associated with prognosis, and bioinfor-
matics–mathematical methods used for analysis  [ 10,  11,  23 ] . To answer the question whether these 
predictors are concordant with respect to their predictions for individual patients, Fan et al. analyzed 
a single dataset on which five prognostic or predictive gene-expression-based models were simul-
taneously compared (the 70-gene signature model, the wound-response model, the 21-gene RS 
model, the intrinsic-subtype model, and the two-gene-ratio model)  [ 1– 3,  5,  10,  11,  23– 26,  32,  33 ] . 
With this analysis, all gene-expression-based models with the exception of the two-gene ratio 
model, significantly predicted relapse-free survival and overall survival. A limitation of this study 
was that the 21-gene RS and two-gene ratio models were developed to be used in different clinical 
scenarios than was represented in this patient cohort  [ 20 ] . In fact, the two-gene ratio and the 21-gene 
RS models were designed to predict outcomes in patients with ER-positive disease receiving tamoxifen 
as an adjuvant treatment. However, the Fan dataset included only 40 such patients and a substantial 
portion of it was used as the training set for the development of the intrinsic-type, 70-gene signature, 
and wound-response models. 
 Despite the lack of gene overlap, four of the five models showed significant agreement in predict-
ing outcome for individual patients leading to the hypothesis that different gene sets may predict a 
biologically similar breast cancer phenotype. The concordance among the models in the identifica-
tion of patients with a genomic high-risk for recurrence was excellent, but it remains unknown how 
much clinical utility these predictive models provide over standard clinicopathologic features. 
While in multivariate analysis, three of the gene-based models proved to be more predictive for 
outcome than standard clinicopathologic criteria, features routinely used by physicians, especially 
in clinically intermediate-risk cancers (e.g., progesterone receptor (PR) status, HER2 status, lym-
phovascular invasion, and mitotic rate) were not included in the analysis. On-going clinical trials 
will help to clarify the potential benefits of these genomic tools over standard clinicopathologic 
assessment. In fact, what we have learned from this field is the importance of clinical validation of 
gene signatures in independent datasets with long follow-up available and a subsequent prospective 
validation (see section “Clinical Application of Gene Signatures: Ongoing Trials”). 
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 An interesting point of view is that gene expression signatures can reflect the activation status of 
several oncogenic pathways. Yu et al. suggested that it might be more appropriate to interrogate the 
gene lists for biological themes, rather than individual genes  [ 19 ] . Moreover, identification of the 
distinct biological processes between subtypes of cancer patients is more relevant to understand the 
mechanism of the tumorigenesis and metastatic capability and for targeted drug development. They 
resampled their dataset numerous times to get multiple gene lists whose expression correlated with 
patients’ outcome. For example, based on these gene lists, they identified overrepresented pathways 
defined in gene ontology biological process (GOBP) for ER-positive or ER-negative breast cancer 
patients, separately. Then, they compared the pathways represented by different published prognos-
tic gene signatures with the overrepresented pathways associated with metastatic capability. This 
study also demonstrated that it is feasible to construct a gene signature from the key pathways to 
predict clinical outcomes. Clustering tumors based on pathway signatures defines prognosis in dif-
ferent patient subsets, demonstrating that patterns of oncogenic pathway deregulation underlie the 
development of the oncogenic phenotype and reflect the biology and outcome of specific cancers. 
According to Bild et al., prediction of pathway deregulation in cancer cell lines is also able to pre-
dict the sensitivity to therapeutic agents that target components of the pathway. Linking pathway 
deregulation with sensitivity to therapeutics that target members of the pathway likely allows using 
these oncogenic pathway signatures to guide the choice of targeted therapeutics  [ 31 ] . 
 Triple Negative Breast Cancer: Any Signature Available? 
 Among the 4–5 molecular subgroups, basal-like tumors present the worst outcome. According to 
current estimates, triple negative breast cancers (TNBCs) account for 10–17% of all breast carci-
nomas, depending on thresholds used to define ER and PR positivity and HER2 overexpression 
 [ 34 ] . In different series and patient populations TNBC may range 6–28% of breast cancers, but 
higher incidence rates are reported for some ethnical groups, such as African–Americans and for 
younger patients, as well as for BRCA-mutation carriers  [ 35 ] . Despite its relatively small propor-
tion among all breast cancers, TNBC is responsible for a large fraction of breast cancer deaths, 
because of the aggressive tumor phenotype(s), only partial response to chemotherapy and present 
lack of clinically established targeted therapies. It should be emphasized that TNBC currently 
includes a heterogeneous group of tumors. By simple morphology, a group of TNBC patients 
with a more favorable outcome can be identified, for example patients with invasive adenoid 
cystic, apocrine, and typical medullary tumors. Even within the relatively homogeneous group of 
patients with triple-negative invasive ductal carcinoma (IDC), patients with higher or lower risk 
may be identified, based on specific molecular markers. For example, Viale et al. found that epi-
dermal growth factor receptor (EGFR) immunoreactivity significantly correlates with worse 
prognosis in 284 patients with triple-negative IDC  [ 35 ] . This underscores the importance of defin-
ing underlying risk factors for TNBC as a crucial step toward its prevention. While several poten-
tial therapeutic targets have recently surfaced from the gene expression profiling of the 
triple-negative tumors, the search is still onto unravel the modifiable and nonmodifiable risk fac-
tors associated with this aggressive disease. Also, additional tumor markers might allow identifi-
cation of patients at higher risk of relapse  [ 36 ] . 
 A TNBC metastasis-associated signature, currently nonavailable, would be extremely useful in 
clinical setting, to select patients that probably have benefit from treatment and patients that can 
avoid toxicity of not necessary treatments. Recent discoveries in this field have been presented from 
three groups at San Antonio Breast Cancer Symposium 2010. 
 Lehmann and colleagues analyzed 386 TNBC gene-expression profile training sets from 
21 independent breast cancer studies and identified six stable clusters that display unique 
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gene-expression patterns and gene ontologies  [ 37 ] . These clusters are: two basal-like subtypes 
characterized by cell cycle and DNA damage response genes; two mesenchymal-like subtypes 
enriched in cell differentiation, epithelial–mesenchymal transition and growth factor pathways; 
an immunomodulatory subgroup defined by immune cell surface antigens, receptors, and signal 
transduction genes; and a luminal subgroup driven by androgen-receptor signaling. Lehmann 
et al. after the identification of representative cell lines to model each of the subgroups, treated 
xenografts of these TNBC subtypes and found that basal-like triple-negative disease is sensitive 
to cisplatin, mesenchymal-like TNBC may preferentially respond to Src and PI3K/mTOR 
inhibitors, and the luminal subtype is sensitive to the androgen-receptor antagonist bicalutamide 
and to HSP90 inhibitors. These data for the target selection in drug discovery, clinical trial 
design, and selection of biomarkers represent a potential approach to assign a personalized treat-
ment to patients with TNBC. 
 Interestingly, another group of investigators evaluated 28 breast cancer datasets with gene-
expression data and identified 12 different molecular phenotypes among 579 TNBC samples  [ 38 ] . 
The analysis showed that 73% of TNBC are basal-like tumors, with the rest classified into pheno-
types according to gene function (e.g., immune activity, angiogenesis, proliferation, apocrine activ-
ity, inflammation). Notably, there were no outcome differences between basal-like tumors and 
nonbasal-like tumors. However, high B-cell (immune system) and low IL-8 (inflammation) meta-
gene expression were able to identify a subset of patients (32% of all tumors) with a favorable 
prognosis and a 5-year metastasis-free survival of 84%. The inhibition of the related pathways 
might provide new therapeutic approaches. Only the metagene ratio and lymph node status signifi-
cantly predicted of prognosis in the multivariate analysis. 
 Goga A, on the basis of gene-expression arrays of 149 patients from the I-SPY trial, demon-
strated that TNBC with high expression of MYC have worse clinical outcomes  [ 39 ] . The oncogene 
MYC, whose genomic locus is amplified in 20–50% of all breast tumors, is associated with poorly 
differentiated tumors and abundant in TNBC. In the trial, patients with tumors expressing high 
MYC signatures had worse outcome. Disease-free survival at 5 years was approximately 95, 80, and 
55% for patients with low, intermediate, and high MYC expression, respectively. In a multivariate 
analysis considering receptor status and MYC pathway activation as a continuous variable, triple-
negative status, and MYC pathway activation had a hazard ratio of 1.5 and 16.7, respectively. The 
CDK1 inhibitor SCH-727965, currently in phase II trials, is a promising agent targeting MYC path-
way via upregulation of the proapoptotic Bcl2 family member BIM. The cooperation between MYC 
overexpression and CDK1 inhibition induces cell death in triple-negative breast cancer cells and 
regression of tumor xenografts. 
 In conclusion, on the basis of transcriptomic analyses, TNBCs seem to represent a molecularly 
and clinically heterogeneous disease and not all of them have an unfavorable prognosis  [ 37 ] . 
 The results of these mentioned and other studies are enthusiastically awaited to discover driving 
pathways involved in TNBC progression and to better individualize therapy for these patients. 
 Clinical Application of Gene Signatures: Ongoing Trials 
 Adjuvant treatment for early-stage breast cancer is offered to the majority of patients after definitive 
surgery, assuming the presence of residual microscopic disease. Clinical–pathological prognostic fac-
tors (tumor stage, hormone receptors and HER2 expression, tumor grade, proliferative rate) are useful 
tools to estimate the risk of disease recurrence and thus, to decide whether to use adjuvant chemo-
therapy (CT), hormone therapy (HT), or biologic agents. However, during the last decade, a deeper 
insight into breast cancer biology led to the classification of breast cancer into different subtypes, 
characterized by different biological features and prognosis  [ 1 ] . Several gene signatures proved to 
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better estimate the risk of disease recurrence (Table  2.1 ), when compared to classic prognostic factors, 
and some of them are recommended from the American Society of Clinical Oncology (ASCO) and 
the NCCN Guidelines both as a prognostic and predictive tool in patients with node negative, endo-
crine positive disease. One of the priorities in breast cancer management is to identify patients with 
good-prognosis early-stage disease who could be spared adjuvant CT. Hence, the application of gene 
signatures in predicting the benefit of CT and identifying patients who will mostly benefit from a 
specific cytotoxic agent is an extremely active research field. Promising data suggesting a role in pre-
dicting benefit from adjuvant CT over endocrine therapy alone prompted the development of two large 
randomized phase III trials [MINDACT (Fig.  2.1 ) and TAILORx (Fig.  2.2 )], actually ongoing. 
 MammaPrint™ 
 The 70-gene expression profile was developed in the Netherlands, applying DNA-microarray tech-
nology to 78 frozen tumor samples from untreated node-negative breast cancer patients. Patients 
relapsing within 5 years from definitive surgery were defined as “poor prognosis,” those who 
remained disease-free after 5 years were considered as “good prognosis.” Researchers selected 70 
genes that demonstrated to accurately classify tumors in either the poor or good-prognosis group 
 [ 10 ] . The prognostic value of the 70-genes signature was validated in retrospective case series, 
showing that the use of MammaPrint could reduce misclassification of patients’ risk, hence the 
overtreatment of the low-risk group  [ 40 ] . 
 Fig. 2.1  MINDACT trial design 
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 MammaPrint identifies a low-risk group of patients having a 10-year breast cancer survival prob-
ability  ³ 88% if their tumor had ER expression >1%, and of at least 92% if ER negative  [ 41 ] . 
Recently, the role of MammaPrint to predict CT benefit in addition to HT was assessed: patient in 
the high-risk group derived a greater benefit from CT in terms of distant disease-free survival 
(DDFS) and breast cancer specific survival (BCSS), compared to high-risk patients treated with HT 
alone  [ 42 ] . Moreover, the application of the 70-gene profile in the neoadjuvant setting further pro-
vided evidences of the predictive value of the signature  [ 43 ] . 
 A prospective validation of MammaPrint is ongoing in a large, multicentric, randomized, con-
trolled, phase III trial: the microarray in node negative disease may avoid chemotherapy (MINDACT) 
trial. Primary objective of the trial is to confirm that patients with molecular low risk can safely be 
spared adjuvant CT even if they have clinical high-risk tumor. 
 The risk of relapse of 6,000 breast cancer patients (0–3 lymph nodes involved) will be assessed 
using both traditional clinical–pathological criteria (Adjuvant!Online) and the MammaPrint signa-
ture. Patients estimated low risk with both methods will be spared CT; patients estimated high risk 
with both methods will be proposed CT; if the methods are discordant, patients are randomized to 
be treated according to the clinical–pathological or the genomic result. Estimating a 35% rate of 
discordance between Adjuvant!Online and MammaPrint, it is expected that a third of them will not 
be treated with CT, while it would be recommended using the conventional risk assessment criteria. 
Patients defined as high clinical and low genomic risk will not receive CT, and will be closely fol-
lowed. The role of MammaPrint in predicting benefit from a specific chemotherapeutic agent will 
be assessed in a second randomization: patients will be randomly treated with an anthracycline-
based CT or the combination of docetaxel and capecitabine. A third randomization, offered to all 
ER positive patients, will compare 2 years of T followed by 5 years of letrozole to 7 years of upfront 
letrozole (see Fig.  2.1 for trial design). The whole genome will be analyzed for all the 6,000 
patients, aiming at discovering new signatures with prognostic and predictive value. 
 Accrual started in February 2007 and is still ongoing. Results of this ambitious trial are eagerly 
awaited. 
 Fig. 2.2  TAILORx trial design 
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 OncotypeDx 
 OncotypeDx is the most widely used gene signature in everyday practice. It is an RT-PCR assay 
 performed on formalin-fixed, paraffin embedded tissues that evaluate expression of 21 genes (16 cancer 
related and 5 reference genes). Levels of gene expression are combined to provide a continuous vari-
able: the recurrence score (RS). The assay was developed in a population of patients with node-negative 
ER positive disease, treated with tamoxifen (T). Thus, the RS quantifies the likelihood of 10-year dis-
tant recurrence (10 yDR) in patients with the aforementioned characteristics  [ 32 ] . Patents with an RS 
<18 are considered low risk with a 10 yDR of 6.8%; an RS  ³ 18 and <31 defines the intermediate risk 
group, with 10 yDR of 14.3%; finally, an RS  ³ 31 is associated with a 10 yDR rate of 30.5%. The prog-
nostic value of the assay was validated in several retrospective trials  [ 44 ] . OncotypeDx to predict the 
benefit of CT over T in ER positive breast cancer patients has been assessed using samples from the 
NSABP B20 and the SWOG S8814 trials. In both cases, patients with a high RS derived the greater 
benefit from the addiction of CT to T, while it did not affect outcome of low-risk patients, suggesting 
that the later ones could safely be spared C  [ 45,  46 ] . The later study was run in node-positive patients 
and proved an increase of both disease-free survival (DFS) and BCSS when CT was added to T only 
in the high-risk group (10-years BCSS in the high-risk group 73% vs. 54% for CAF+T vs. T alone, 
respectively)  [ 46 ] . The predictive value of OncotypeDx has been confirmed in the neoadjuvant setting, 
proving that low RS tumors are less likely to obtain pathologic complete response than high RS  [ 47 ] . 
 Trial assigning individualized options for treatment (Rx) (TAILORx) trial is a prospective, ran-
domized, controlled, phase III trial that aims at identifying the best individual treatment for patients 
with ER positive, HER2 negative, node negative breast cancer (see Fig.  2.2 for trial design). Primary 
objective of the trial is to compare DFS and distant recurrence-free interval (DRFI) of patients in 
the intermediate risk group treated with CH + HT vs. HT alone, other than create a tissue bank 
repository. Other objectives are to determine DFS, DRFI, and overall survival of patients with low 
RS and determine whether HT alone can be considered the optimal treatment for these patients. 
 The definitions of low, intermediate, and high risk utilized in this trial are slightly different than 
those previously defined:
 Low-risk patients (RS <11) will receive HT alone. A RS <11 is associated with a 10 yDR rate <5%, • 
on average, if treated with T alone, and no benefit from CT has been demonstrated in this group. 
 Intermediate-risk patients (RS 11–25) will be randomly assigned to receive CT and HT vs. HT alone. • 
The risk of 10 yDR is approximately 10% if treated with T alone, and is considered sufficiently high 
to recommend CT even if CT benefit has not been clearly established for this group. The treating physi-
cian can chose the CT regimen among all those recommended from ASCO and NCCN guidelines. 
 High-risk patients (RS > 26) will be assigned to receive CT. An RS >26 was selected because it • 
is associated with a 10 yDR >20%, on average, and because CT has been shown to be beneficial 
in this group. 
 Accrual of the 11,248 was started in early 2007 and was very rapid. Actually, the study is ongo-
ing but not accruing (clinicalTrials.gov – last assessed 4/1/2011). 
 Next-Generation Sequencing: An Emerging Tool to Characterize 
the Molecular Heterogeneity of Breast Cancer 
 Mutation Signatures: Mountains and Hills 
 Advances in whole genome sequencing technology have led us into an era of cancer genome dis-
covery  [ 48 ] . Systematic Sanger sequencing of over 13,000 genes in 11 human breast cancers has 
revealed preliminary insights into the breast cancer genome  [ 49 ] . According to this analysis, the 
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average tumor harbors approximately 90 point mutations in gene coding regions. Only small 
minorities of these mutations were recurrent, and were in genes already known to be important in 
breast cancer, including  p53 and  PIK3CA . These relatively common mutations figuratively reflect 
“mountains” in the mutation landscape of breast cancer  [ 50 ] . In contrast, much more numerous in 
this landscape are the “hills,” which represent infrequent mutations in a diversity of genes that are 
much more numerous in any given tumor, and may or may not be contributing to the oncogenesis. 
Indeed, clarifying the drivers from the passengers in this complex landscape will likely be necessary 
to understand the heterogeneity of breast cancer, and remains one of the biggest challenges of can-
cer genomics. 
 Contrasting Paths of Genomic Evolution 
 Luminal and basal-like breast cancers exhibit distinct gene expression signatures, biology, and clini-
cal behavior. Next-generation resequencing now suggests that genomic evolution during tumor 
progression might also follow divergent patterns between these biologic subtypes. 
 Comprehensive paired-end deep sequencing and transcriptome sequencing was performed of a 
metastatic lobular ER-positive breast cancer specimen  [ 51 ] . Thirty-two nonsynonymous coding 
sequence mutations were identified. Significantly, 19 of these mutations were not present in the 
patient’s primary tumor, which had been surgically excised 9 years prior to emergence of the metas-
tasis. Notably, no significant genome rearrangements were identified in the tumor samples, when 
compared to normal tissue DNA. These findings suggested that a relatively small number of point 
mutations might be responsible for tumorigenesis in this breast cancer, and that additional mutations 
arose after intervening therapy and several years of dormancy. The contribution of these mutations 
to metastatic recurrence remains unclear, although it seems plausible that some of these might have 
biologic importance. 
 Contrasting insights have been gleaned from deep resequencing of a basal-like primary breast 
cancer and its associated brain metastasis that arose in an African–American woman who suc-
cumbed to a particularly rapid and aggressive clinical course of disease  [ 52 ] . The primary breast 
cancer in this case was ER-negative, lacked ERBB2 amplification, and was classified as an 
inflammatory breast cancer. Clinically, this tumor exhibited resistance to chemotherapy, and 
gave rise to brain metastases within 8 months, resulting in fatality shortly thereafter. In this pair 
of primary and metastatic specimens, only two de novo mutations distinguished the metastasis 
from the primary tumor. Nonetheless, the relative abundance of shared mutations varied between 
the metastasis and primary tumor, suggesting that selective processes during metastasis emer-
gence were operative on preexisting dominant clones within the primary tumor. Somatic 
genomic rearrangements and copy number alterations were also abundant in this primary tumor, 
and most of these were also shared in the metastasis. However, there was evidence of increased 
copy number alterations and structural variants during the course of tumor progression, which 
might contribute to metastasis emergence, or alternatively might be a byproduct of chemother-
apy or ionizing radiation exposure. 
 Indeed, a comparison of genomic profiles from primary tumor to metastasis in luminal and basal-
like breast cancer reveals more differences than similarities. Further analysis of primary tumor–
metastasis–normal tissue triads will determine the generality of these observations. An improved 
understanding of the differing rates of genome mutation and evolution among breast cancers would 
likely have implications for prognosis, and may possibly also reveal novel approaches to therapeutic 
intervention. 
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 Genome Rearrangement Profiles: Diversity and Complexity 
 Paired-end sequencing and structural genomic rearrangement analysis has been performed on a 
cohort of 24 primary breast tumors and immortalized breast cancer cell lines  [ 53 ] . This high-
resolution analysis revealed, for the first time, the landscape of chromosomal rearrangements in 
breast cancer. A striking discovery was the abundance of intrachromosomal rearrangements, which 
could not be readily characterized by previous techniques. Also apparent were distinct patterns of 
rearrangements in the various biologic subtypes of breast cancer. Hormone receptor-positive breast 
cancers exhibited either minimal genomic instability or rearrangements that almost exclusively 
involved amplified segments of the genome. In contrast, TNBCs exhibited rampant instability, fre-
quently predominated by intrachromosomal tandem duplications. Sequence analysis of these break-
points generally revealed short segments of microhomology at the junction of these rearranged 
segments, implicating DNA repair processes in their etiology. Of note,  BRCA1 and  BRCA2 null 
tumors did not exhibit this preponderance of tandem duplications, suggesting that a distinct pathway 
may be deranged in this subgroup of tumors. 
 Do these distinct patterns of genomic instability have implications for patient prognosis? An 
analysis by the Borreson-Dale group using multiple cohorts of array-CGH data suggests that it does. 
In this study, the authors characterized two quantitative indexes of genomic instability – a whole 
arm aberration index (WAAI) and a complex arm aberration index (CAAI) – that can be applied 
across array CGH platforms  [ 54 ] . These two instability indices were used to segregate 595 breast 
tumors into distinct subgroups. Significantly, both indices correlated with poorer patient prognosis 
in univariate and multivariate analyses. These findings suggest that patterns of genomic instability 
may reflect an underlying biology of breast cancer that has implications for the likelihood of cancer 
recurrence, as well as the clinical responsiveness to DNA-damaging therapies. 
 Summary 
 Interestingly, particular gene classifiers able to predict the aggressiveness of a tumor and the tumor’s 
ability to home and proliferate in an organ-specific manner have been identified. Gene-expression 
profiling has already provided important contribution into the biologic heterogeneity of breast can-
cer. The combination of several advanced genomic tools with new approaches described in this 
chapter has to be optimally incorporated. Whether this is feasible and effective will depend on trials, 
such as TAILORx and MINDACT. Moreover, technical and economic issues need to be examined, 
and optimization of the eventual use of these tools in decision-making process is necessary. 
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 Introduction 
 Colorectal cancer (CRC) is one of the most common causes of cancer-related death with a worldwide 
incidence of almost a million cases annually in both males and females  [ 1 ] . 
 The accelerated decrease in CRC incidence rates from 1998 to 2006 largely reflects the advances 
in diagnosis and treatment that have enabled to detect and remove precancerous polyps  [ 2 ] . 
However, the screening technology has not resulted in major improvements in the prognosis of 
patients with advanced cancer, and liver metastasis remains the major cause of death in CRC  [ 3 ] . 
Approximately 25% of patients have detectable liver metastasis at diagnosis, that are classified as 
“synchronous” lesions and approximately 70% of patients develop a liver recurrence during the 
course of their disease – identified as “metachronous” lesions  [ 4 ] . Despite the development of dif-
ferent treatment modalities, the outcome for patients with unresectable metastatic lesions is still 
unfavorable and the metastatic spread to the liver is the major contributor to mortality in CRC  [ 5 ] . 
Therefore, elucidation of the molecular mechanism involved in the development of metastases, by 
the identification of a specific gene signature for liver metastasis in CRC, could allow prediction of 
the onset of metastatic disease in patients with localized tumors and lead to designing new strategies 
for diagnosis and treatment of CRC. 
 Molecular Nature of Liver Metastasis in CRC 
 Most cancer, including CRC, might have a single clonal origin at the initial stage of the disease; 
however, a malignant tumor contains multiple cell populations with different properties and acquires 
the ability to invade and develop metastases. This heterogeneity determines a variation in clinical 
patterns and treatment efficacies because these cells have acquired the ability to regulate their adhe-
sion or motility. Clones with metastatic potential show genetic properties that are different than 
clones without metastatic potential. Therefore, in recent years many researchers aimed to identify 
genetic markers of metastatic clones. 
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 Although little is known, two models have been proposed to explain the biological mechanisms 
of metastases. The genetic selection model proposes that only a subset of tumor cells acquire meta-
static potential during the late stages of multistep tumorigenesis  [ 6,  7 ] . Alternately, another model 
proposes that tumor cells acquire metastatic capacity during a relatively early stage of tumorigenesis 
depending on the genetic background. Recent gene expression analyses of clinical tumor samples 
support this hypothesis  [ 8,  9 ] . Several biomarkers for CRC have been identified, including KRAS2, 
p53, p21/WAF/CEP1, cyclin D1, PCNA, COX-2, MMP-9, CD44, CK-19, VEGF-C, and E-cadherin 
 [ 10– 12 ] . 
 Liver metastasis in CRC occurs in multiple steps, including the ability of cancer cells to release 
the primary site, to achieve a specific type of tissue through blood flow, and to establish a distant 
secondary tumor  [ 13 ] . This event has been characterized as a complex process in which each step 
is characterized by several changes in gene expression profiling  [ 14,  15 ] and in which multiple 
genes play a significant role. Carcinogenesis and progression of CRC involves multiple genetic and 
epigenetic changes in many genes, including common alterations in  TP53 ,  K-RAS ,  b - catenin ,  APC , 
and  AXIN2  [ 16,  17 ] . 
 Microarray studies, through the analysis of gene expression profiling, have successfully shed 
light on various aspects of the molecular mechanisms involved in the development of different 
human tumors  [ 18 ] . In CRC, the DNA array technology has allowed the identification of differences 
in gene expression profiles between normal mucosa, benign adenoma, and malignant carcinoma, 
and the creation of a molecular model of multistep carcinogenesis  [ 19 ] . However, although much is 
known about genes in which mutation is responsible for the onset of CRC  [ 16,  20 ] , less is known 
about the specific molecular events that are crucial for the development of CRC liver metastasis. 
Nevertheless, although the mechanisms responsible for metastasis of CRC to the liver are yet to be 
elucidated, different recent microarray studies have identified several genes that are crucial for 
metastasis formation, leading to the identification of a possible gene expression signature that could 
differentiate between tumors that do or do not metastasize  [ 21 ] . 
 Gene Expression Profile Studies Related to CRC Liver Metastasis 
 The acquisition of a metastatic signature is often related to the loss of various activities, and genes 
associated with metastasis may already be expressed in early tumors. In order to identify specific 
metastatic gene signatures that can be used as a prognostic marker of metastatic spread using 
microarray technologies, several studies have been carried. The first studies were conducted com-
paring the gene expression profile of primary CRC from metastasis-free patients to those of patients 
affected by metastatic disease during a 5-year follow-up period  [ 5 ] . 
 Bertucci et al. have identified a total of 219 genes down- and 25 genes up-regulated, respectively, 
in metastatic samples as compared to nonmetastatic samples and additionally have identified a gene 
signature of 46 genes that discriminate CRC with and without lymph node metastases  [ 22 ] . 
 D’Arrigo et al. have found a different gene expression signature between ten primary CRCs from 
patients who did not develop metastases within a 5-year follow-up period and ten primary CRCs 
from patients with synchronous liver metastasis. This study identified 37 genes differentially 
expressed between the two groups of primary tumors, of which 29 genes distinguished nonmetasta-
sizing tumors from metastases. In support of the existence of specific gene expression profiling 
distinguishing primary tumors from CRCs with a metastatic potential, the genes encoding for man-
nosyl ( a -1,3-)-glycoprotein  b -1, 4- N -acetyl-glucosamynyl-transferase were significantly up-regulated 
in metastatic tumors  [ 23 ] . 
 To identify specific metastatic gene signatures, another approach entails comparing the gene 
expression profile in primary tumors and in corresponding metastases. 
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 These studies show the identification of a similar gene expression profile between primary 
tumors and their matched metastases, supporting the notion that the metastatic potential is geneti-
cally encoded in primary tumors  [ 24 ] . 
 To investigate whether the expression profile in primary CRC reflected the metastatic status, 
Yamasaki et al. have analyzed the chronological gene expression profiles of 104 colorectal samples 
corresponding to oncogenic development, including normal mucosa, localized and metastatic 
tumors, and liver metastasis, using microarray technologies. The hierarchical clustering obtained 
has shown that the metastatic potential of CRC is not acquired in correlation to cancer progression, 
but rather the gene expression profile in the primary tumors reflect the ability to trigger the meta-
static process  [ 21 ] . 
 In their work, Lin et al. evaluated the gene expression changes in primary CRC and CRC after 
metastasis to the liver, in order to determine how the cancer cells adapt to the liver microenviron-
ment  [ 25 ] . Using genome-wide microarray analysis, the authors have compared the gene expres-
sion profile of 48 primary tumors and 28 liver metastases and have identified 778 genes differentially 
expressed. The gene ontology analysis has revealed that the genes involved in immune response 
(innate and adaptive) and tissue remodeling are statistically up-regulated in liver metastasis relative 
to primary tumors. The genes involved in immune response, including proteoglycan 3 ( PRG3 ), 
natural killer cell receptor ( NCR3 ), B-cell membrane protein CD22, chemokine receptor ( CXCR4 ) 
and its ligand  CXCL12 , and the genes associated with tissue remodeling mainly encode extracel-
lular matrix proteins such as fibronectin, osteopontin, and ADAM17. Additionally, this study has 
shown that the genes associated with proliferation are down-regulated in liver metastasis suggest-
ing that the tumor cells are not proliferating in the liver metastasis as rapidly as in the primary 
tumors  [ 25 ] . 
 In order to identify genes that may be involved in tumor progression and liver metastasis of CRC 
patients, Ki et al. have analyzed gene expression profiles of 27 colorectal primary tumors, corre-
sponding to 27 liver metastasis tumors, 25 normal colon mucosa, and 13 liver tissues from CRC 
patients with liver metastasis  [ 26 ] . In this study, the investigators identified 46 liver metastasis-
specific genes with an accuracy of 83.3% by comparing the gene expression levels of paired primary 
colorectal tumors and liver metastases using a cDNA microarray containing 17,104 known genes. 
These selected genes could help to more effectively pinpoint therapeutic targets for CRC. Several 
known oncogenes were included among the 46 selected genes. Of the 46 identified genes, 36 seem 
to be down-regulated and 8 up-regulated in liver metastasis tumors.  WNT5A , a gene involved in 
carcinogenesis and several developmental processes, showed significantly lower expression in liver 
metastasis tumors and higher expression levels in primary tumors than in the normal colon. 
 Conversely, the most significantly up-regulated gene in liver metastasis was tissue inhibitor of 
metalloproteinase 1 ( TIMP1 ), an inhibitor of  MMP-1 that plays an important role in cancer metas-
tasis. Other identified cancer-related genes that showed variation in gene expression levels were 
 MMP-1 ,  MMP-2 ,  COX-2 and  HIF-1 a , MMP-1 and  MMP-2 , known to be up-regulated in carcino-
genesis, were up-regulated in primary tumors but not in normal colon tissue. However, they showed 
decreased expression levels in liver metastasis tumors. Furthermore, 21 of the 46 genes were dif-
ferentially expressed in primary tumors with synchronous liver metastasis compared with primary 
tumors without liver metastasis. These 21 genes were mainly involved in the regulation of cellular 
process (47.1%), cell development (35.3%), and cellular morphogenesis (17.7%). 
 Moreover, 4,583 selected organ-specific genes, differentially expressed between 13 paired nor-
mal colon and normal liver tissue, were identified; 2,236 of these genes were up-regulated and 2,347 
were down-regulated in normal liver compared with the normal colon tissues. The genes showing 
differences in gene expression were those related to metabolism, cellular physiological process, cell 
communication, response to stimulus, and organism physiological processes  [ 26 ] . 
 In their study, Pantaleo et al. have evaluated the gene expression profiling of ten synchronous and 
eight metachronous liver metastatic lesions, by using the Affymetrix platform  [ 27 ] . The gene 
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expression analysis identified 49 up-regulated genes in metachronous and 55 up-regulated genes in 
synchronous metastases under which the main alterations were found in two pathways – EGFR 
signaling and eicosanoid metabolism. The key genes involved in this pathway are EGFR, COX-2, 
and COX-1; specifically, EGFR was overexpressed in metachronous lesions and the COX-2 gene 
was overexpressed in synchronous metastases. These results showed that the molecular background 
of liver metastases may be differentially related to differential expression of these genes and this 
observation may have clinical implications, allowing a more targeted treatment of patients with 
synchronous or metachronous lesions. Therefore, the identification of a specific metastatic gene 
signature could result in the choice of selective and differential chemotherapy treatment  [ 27 ] . 
 In a recent study, Koh et al. have analyzed 12 matched primary and metastatic colorectal carci-
nomas, and have identified 80 genes differentially expressed by means of a supervised hierarchical 
clustering  [ 28 ] . The metastasis was distinguished from the corresponding primary tumor in half of 
the metastases analyzed using a specific set of genes identified. Among 80 genes,  MMP1 ,  MMP-2 , 
 MMP3 ,  MMP-13 ,  COL1A2 , and  CXCL3 were up-regulated in primary colon carcinoma, and 
 SOX15 ,  LIMS1, SERPINA3, CYP1B1, NAT5 ,  SPP1 , and  SERPINA1 were up-regulated in metastatic 
colon carcinoma. SERPINA1 and SERPINA3 were associated with a poor prognosis in colon can-
cer and are overexpressed in metastatic breast carcinoma. Furthermore, the up-regulated genes in 
metastatic colon cancer include genes involved in embryonic development ( GA17 ), cell adhesion 
( ADRM1 ), RNA binding ( SNRPB2 ), transcriptional activity ( TWIST1 and  ETV4 ), cell cycle and 
proliferation ( CKS2 ), DNA repair ( RPA3 ), signal transduction ( PRDX4 ), and prefolin complex 
( VBP1 ). Down-regulated genes in metastatic colon cancer included genes involved in the cell–cell 
adhesion ( ICAM4 ), extracellular region ( GUCA2A ) and carbonate dehydratase activity ( CA4 ). 
Genes defined with high metastatic potential encode proteins influencing cell growth and prolifera-
tion (GAS1, ITLN1, IL1B, and IL24), extracellular proteases (MMP family), cell adhesion 
(COL12A1 and PAP), and cell motility (VIP and WNT5A). This molecular profiling may be useful 
for the differentiation of primary and metastatic carcinoma and the proteins encoded by these genes 
could be effective biomarkers for early metastasis detection. 
 Recently, Fritzmann et al. conducted a gene expression-profiling experiment to identify genetic 
markers of risk and to elucidate the molecular mechanisms of CRC metastasis. In particular, they 
have compared the gene expression patterns between metastatic and nonmetastatic matched CRC 
by microarray analysis. This study allowed the identification of 115 gene signatures that differenti-
ated metastatic from nonmetastatic primary tumors. Among these, the transforming growth factor 
(TGF)  b inhibitor BAMBI was noted to be highly expressed in half of the metastatic primary tumors 
and metastases but not in nonmetastatic tumors and it was observed an inverse correlation between 
the level of BAMBI expression and metastasis-free survival time of patients. BAMBI is a target of 
Wnt signaling and its inhibition of TGF- b pathway could directly drive the metastasis formation in 
CRC. Therefore, the metastatic gene signatures obtained in this work made it possible to identify a 
specific gene that could be used as a powerful prognostic indicator in CRC  [ 29 ] . The most important 
genes involved in liver metastasis formation in CRC and reported in several studies are shown in 
Table  3.1 . 
 Gene Signature: Potential and Limits 
 Studies of gene signatures have the potential to identify specific genes that may play a key role in the 
onset of liver metastases and, therefore, be used both to clarify the molecular mechanisms respon-
sible for the development of metastases, and as prognostic indicators in CRC. However, the determi-
nation of metastatic expression signatures by microarray technologies must take into consideration 
different factors that can lead to differences among the results obtained by various groups. 
313 Gene Signatures in CRC and Liver Metastasis
 Table 3.1  The most important genes involved in liver metastasis formation whose expression is altered in 
colorectal cancer 
 Gene  Gene name  Function 
 PRG3  Proteoglycan 3  Immune response 
 NCR3  Natural killer cell receptor  Immune response 
 CD22  T-cell surface antigen Leu-14  Immune response 
 CXCR4  Chemokine receptor 4  Response to stimulus 
 CXCL12  CXCR4 ligand  Response to stimulus 
 CXCL3  Chemokine (C–X–C motif) ligand 3  Response to stimulus 
 FN1  Fibronectin 1  Tissue remodeling 
 OPN  Osteopontin  Tissue remodeling 
 ADAM17  A disintegrin and metalloproteinase domain 17  Tissue remodeling 
 TIMP1  Tissue inhibitor of metalloproteinase 1  Tissue remodeling 
 MMP-1  Matrix metallopeptidase 1  Proteolysis 
 MMP-2  Matrix metallopeptidase 2  Proteolysis 
 MMP-3  Matrix metallopeptidase 3  Proteolysis 
 MMP-7  Matrix metallopeptidase 7  Proteolysis and invasion 
 MMP-13  Matrix metallopeptidase 13  Proteolysis 
 COX-1  Cyclooxygenase 1  Cellular metabolism 
 COX-2  Cyclooxygenase 2  Cellular metabolism 
 CYP1B1  Cytochrome P450, family 1, subfamily B, polypeptide 1  Cellular metabolism 
 HIF-1  Hypoxia-inducible factor 1  Signal transduction 
 BAMBI  BMP and activin membrane-bound inhibitor homolog  Signal transduction 
 WNT5A  Wingless-type MMTV integration site family, member 5A  Signal transduction 
and cell motility 
 PRDX4  Peroxiredoxin 4  Signal transduction 
 GUCA2A  Guanylate cyclase activator 2A  Signal transduction 
 COL1A2  Collagen, type I, alpha 2  Cell adhesion 
 LIMS1  LIM and senescent cell antigen-like domains 1  Cell adhesion 
 ADRM1  Adhesion regulating molecule 1  Cell adhesion 
 ICAM4  Intercellular adhesion molecule 4 (Landsteiner–Wiener 
blood group) 
 Cell adhesion 
 SERPINA3  Serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, 
antitrypsin), member 3 
 Blood coagulation 
 SERPINA1  Serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, 
antitrypsin), member 1 
 Blood coagulation 
 SNRPB2  Small nuclear ribonucleoprotein polypeptide B  RNA binding 
 TWIST1  Twist homolog 1 (Drosophila)  Transcriptional activity 
 ETV4  ETS variant 4  Transcriptional activity 
 RPA3  Replication protein A3  DNA repair 
 VBP1  Von Hippel-Lindau binding protein 1  Transport 
 CA4  Carbonic anhydrase IV  Carbonate dehydratase activity 
 VIP  Vasoactive intestinal peptide  Cell motility 
 CKS2  CDC28 protein kinase regulatory subunit 2  Cell cycle and proliferation 
 GAS1  Growth arrest-specific 1  Cell growth and proliferation 
 ITLN1  Intelectin 1 (galactofuranose binding)  Cell growth and proliferation 
 IL1B  Interleukin 1, beta  Cell growth and proliferation 
 IL24  Interleukin 24  Cell growth and proliferation 
 EGFR  Epidermal Growth Factor Receptor  Cell growth 
 VEGF  Vascular Endotelial Growth Factor  Angiogenesis 
 SOX15  Sex determining region Y (SRY)-box 15  Embryonic development 
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 The main differences are due to the use of different array platforms (Affymetrix, cDNA nylon 
membranes) or experimental conditions. The ability to have tissue samples suitable for the analysis 
is a major problem. Availability of frozen tissues is not the norm in many institutions. Formalin-
fixed or paraffin-embedded tissues usually yield low quality RNA and/or DNA. This stressed the 
need for creating frozen-tissue tumor banks. In addition, different methodologies for RNA isolation 
can lead to varying results, and the number of samples used varies enormously among the different 
studies. Selection of homogeneous samples among heterogeneous tumors can often also be a prob-
lem. Macrodissection techniques include tumor tissue with both tumor cells and tumor stroma, 
which may justify the variability of CRC gene expression profiles obtained. Microdissection tech-
niques help to avoid this problem. Laser capture microdissection (LCM) allows isolation of only 
tumor cells and is considered the gold standard in microdissection procedures  [ 30 ] . 
 The analysis of data obtained by microarray is another point that may lead to impairment of the 
results of gene signature. Analysis of differentially expressed genes can be altered by the use of 
different normalization procedures, different baseline references for ratio calculations, and arbitrary 
criteria for cut-off values applied to fold-change and significance level. During this selection, infor-
mation about the quantitative levels of gene expression can be lost. For this reason, different selec-
tion algorithms should be tested in order to improve the accuracy of the gene analyzed  [ 19 ] . 
 In conclusion, to obtain a genetic signature for liver metastases in CRC need to be implemented 
different measures in order to improve reproducibility, to increase consistence of data and to validate 
the results. 
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 Introduction 
 Gastrointestinal stromal tumors (GISTs) constitute a rare heterogeneous group of the most common 
mesenchymal neoplasm of gastrointestinal tract (GI). GISTs have emerged during the recent years 
as a distinct sarcoma entity due to advances in the understanding of molecular mechanism of their 
pathogenesis  [ 1– 4 ] . They are believed to originate from precursors shared with interstitial cells of 
Cajal (ICC) – the pacemaker cells of the gut (for which CD117 antigen is the immunohistochemical 
marker), and they may arise along all GI (most commonly in the stomach or the small bowel) or 
rarely elsewhere. Their biological behavior is difficult to predict, ranging from clinically benign to 
malignant. The treatment of choice in primary resectable GISTs is radical surgery, but majority of 
GISTs are associated with a risk of recurrences  [ 1,  5 ] . The main criteria of aggressive behavior of 
GIST are based on the presence of invasion of surrounding structures and/or metastases (overtly 
malignant cases), as well as on primary tumor site, size, and mitotic index  [ 6 ] . A Consensus 
Conference held at the National Institutes of Health (NIH) in 2001 provided the first evidence-based 
definition and a practical scheme for the assessment of the risk in the clinical course of this disease. 
The risk categorization was based on evaluation of the size and mitotic rate (evaluated per 50 high-
powered fields; HPF) of the tumors as the most reliable prognostic factors  [ 7 ] . Its utility has been 
supported by analyses of some large series of patients  [ 1,  8 ] . Additional analyses of patients with 
primary tumor after complete macroscopic resection confirmed the significance of tumor anatomic 
location as independent prognostic factor. Miettinen and Lasota from the Armed Forces Institute of 
Pathology (AFIP) created their own classifications for risk assessment in gastric, duodenal, and 
intestinal GISTs  [ 9– 12 ] , adopted then for use by National Comprehensive Cancer Network (NCCN) 
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and constituting the basis for new staging system of American Joint Committee on Cancer (AJCC) 
 [ 13 ] . In particular, this system reflects the fact that gastric GISTs show a much lower rate of aggres-
sive behavior than jejunal and ileal GISTs of comparable size and/or mitotic rate  [ 9,  12 ] . In the 
series of 1,055 gastric, 629 small intestinal, 144 duodenal, and 111 rectal GISTs from the pre-
imatinib era, large (>10 cm) gastric GISTs with a low mitotic rate (<5 per 50 HPF) had only a 12% 
risk for metastasis, whereas similar tumors originating from the small bowel had a high risk for 
aggressive behavior (>50%). Recurrent and/or metastatic and/or unresectable cases had a very poor 
prognosis until the beginning of twenty-first century, when advances in the understanding of the 
molecular mechanisms of GIST pathogenesis have resulted in the development of a treatment 
approach, which has become a model of targeted therapy in oncology. The introduction of imatinib 
mesylate [inhibiting KIT/platelet-derived growth factor receptor- a (PDGFRA) and their down-
stream signaling cascade] has revolutionized the therapy of advanced (inoperable and/or metastatic) 
GISTs  [ 13– 18 ] . Imatinib at initial dose of 400 mg daily has now become the standard of care in the 
treatment of patients with advanced GIST and as compared to historical clinical data with median 
survival of advanced patients being 10–19 months, current survival dramatically improved with 
median overall survival (OS) reaching approximately 5 years and median progression-free survival 
(PFS) in the range of 2–3 years. Recently, imatinib has been also registered for use in adjuvant 
therapy in patients after resection of primary GIST at significant risk of relapse, based on the pub-
lished results of one clinical trial demonstrating significant reduction of the risk of recurrence 
without impact on OS  [ 19 ] . The spectacular response to imatinib therapy is time-limited and sec-
ondary resistance to imatinib therapy (after initial stabilization or response) develops in majority of 
patients. There are several therapeutic strategies in patients showing progression during imatinib 
treatment, such as escalation of the dose of imatinib to 800 mg daily, surgical removal of focus 
progression-lesions, and therapy with registered second-line drug sunitinib malate (multitargeted 
tyrosine kinase inhibitor with antiangiogenic properties)  [ 20,  21 ] . 
 Molecular Aspects 
 The majority of GISTs are associated with activating, somatic, mutually exclusive mutations of two 
genes,  KIT and  PDGFRA , which are the early oncogenic events during GIST development  [ 22– 30 ] . 
Cytogenetically, GISTs are characterized by losses of chromosomes and this feature is accumulat-
ing with tumor progression, usually starting from chromosome 14, then chromosome 22 and short 
arm of chromosome 1. In highly aggressive/overtly malignant cases, are present losses of chromo-
somes 13, 15, and 18, simultaneously with partial deletions of chromosome regions 9p [where 
suppressor genes  CDKN2A ( p16  INK4A  and  p14  ARF  ) and  CDKN2B ( p15  INK4B  ) are located] and 
11p, altogether with gain of 5p, 8q, and 17q  [ 22,  31– 38 ] . 
 The permanent, ligand-independent activation of transmembrane receptors with tyrosine kinase 
activity – KIT (receptor for stem-cell factor; SCF) (Fig.  4.1 ) or PDGFRA as a consequence of gene 
mutation is a characteristic molecular feature of GISTs  [ 22,  24,  26,  30,  38 ] . This process leads to 
changes in receptor conformation, cross-phosphorylation and subsequent triggering of intracellular 
signaling transduction pathways, such as PI3K/AKT, MEK-mitogen-activated protein kinase 
(MAPK), and signal transducer and activator of transcription (STAT). The reported frequency varies 
widely, depending on fresh/embedded tissue used for screening, methods of detection, and tumor 
selection. In 70–80% of cases, tumor cells have detectable mutations in  KIT and usually these muta-
tions are heterozygous. The most frequent mutations in juxtamembrane domain coded by exon 11 
of  KIT gene were reported in the range of 20–92%. Exon 11  KIT mutations include deletions, dele-
tions associated with insertions, point mutations, and duplications (most often in gastric GISTs). 
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Less frequent are mutations in extracellular domain coded by exon 9 of  KIT (5–12%). They are 
mainly present as insertions that result in duplication of Ala 501 and Tyr 502 . Exon 9  KIT mutations 
occur preferentially in GISTs originating from small bowel and are related to more aggressive 
behavior  [ 39,  40 ] , as well as poorer response to imatinib (see below). In rare cases (1–2%), muta-
tions in kinase I domain (exon 13  KIT ) or the activation loop of kinase domain (exon 17  KIT ) are 
detected. The alternative mutations in  PDGFRA gene are identified in 5–7% GIST cases. The most 
common  PDGFRA mutations occur in activation loop kinase domain coded by exon 18, followed 
by mutations in juxtamembrane domain coded by exon 12 or in first kinase domain coded by exon 
14. GIST with  PDGFRA mutations are often CD117-immunonegative and originate from the stom-
ach, presenting low-aggressive clinical behavior and epithelioid morphology  [ 41,  42 ] . In approxi-
mately 10–15% of GISTs,  KIT and  PDGFRA mutations are not detected (the so-called wild-type 
(WT) GISTs). In this subgroup of patients, excessive activation of KIT also occurs, but the mecha-
nism has not been elucidated yet. Wild-type GISTs constitute the majority of pediatric and adoles-
cent GISTs, GIST in neurofibromatosis type 1 (von Recklinghausen disease), Carney’s triad and 
GISTs in Striatiakis-Carney syndrome  [ 43– 46 ] . In some of these wild-type cases (especially pedi-
atric), overexpression of insulin-like growth factor 1 receptor (IGF1R) has been observed  [ 47 ] . Few 
cases of adult wild-type GISTs were reported to carry mutations in  BRAF exon 15. 
 The determination of mutation types in GISTs may have prognostic role in primary GISTs, 
although at present the insufficient data exist to incorporate the kinase mutation status into stratifica-
tion of the risk of primary tumors. Several authors reported an association between the presence of 
some types of  KIT mutations (especially deletions in exon 11 involving codons 557–558 and 
homozygotic KIT exon 11 mutants) and more aggressive clinical course of disease  [ 48– 51 ] . 
Similarly, exon 9  KIT mutants seem to be characterized by more aggressive behavior. However, the 
true prognostic significance of these mutations is not well elucidated because KIT mutations are 
common even in small, incidentally discovered, clinically benign GISTs  [ 28,  29 ] . 
 In advanced GISTs, the associations between tumor mutational status and PFS during tyrosine 
kinase inhibitors therapy are well established as well as the molecular characteristic of primary 
gain-of-function genes encoding KIT or PDGFRA is the most important predictive factor for the 
response to imatinib  [ 18,  52 ] . Patients with tumor harboring exon 11  KIT mutants have the best 
 Fig. 4.1  Activating mutations of KIT receptor and PDGFRA described in human primary GISTs 
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response to imatinib, with the highest rate of objective responses (70–85% of patients) and the 
longest overall and PFSs  [ 53– 55 ] . On the contrary, approximately 15–30% of cases with tumors 
with exon 9  KIT mutations and 25–50% of patients without detectable  KIT or  PDGFRA mutations 
show primary resistance to imatinib therapy. Moreover, the response of patients with GIST with 
exon 9  KIT is dependent on the dose of the drug and these patients been identified as needing higher 
dosages of imatinib (800 mg/day) for achieving longer PFS  [ 56,  57 ] . Clinical and laboratory studies 
demonstrated that tumors with exon 18  PDGFRA D842V mutation are insensitive to imatinib and 
sunitinib, whereas other PDGFRA-mutant GISTs show variable response  [ 23 ] . 
 There are two forms of resistance to the first-line therapy with imatinib, with different pathophys-
iological mechanisms: primary and secondary resistance. Early tumor progression within the first 
6 months of therapy is primarily caused by an intrinsic mechanism related to the presence of spe-
cific  KIT or  PDFRA mutations (which favor the kinase in the active conformation which is not 
conductive for imatinib binding) or to lack of mutations in both kinase genes  [ 52,  53 ] . Tumors 
demonstrating primary resistance to imatinib include WT GISTs, tumors with exon 9  KIT mutation 
and GISTs with point mutations of the codon 842 of  PDGFRA gene (D842V). Secondary resistance 
to imatinib occurs mainly due to selection or acquisition of secondary  KIT or  PDGFRA mutations, 
which hamper imatinib affinity  [ 58– 61 ] . The most common secondary  KIT mutations are reported 
in the ATP-binding pocket of the kinase domain (coded by exon 13 and 14) or in the kinase activa-
tion loop (exon 17 and 18). In at least some cases, multiple secondary  KIT mutations were detected 
with a distinct new mutation in each separate anatomical site of progressing disease. Secondary 
mutations develop more frequently in tumors harboring primary exon 11, rather than exon 9 mutated 
 KIT (60% and 20% of cases, respectively), probably because patients with initially imatinib- 
sensitive tumors have been treated for longer periods, providing both the selection pressure and time 
for the emergence of imatinib resistant clones. Table  4.1 shows a summary of the molecular features 
of GISTs and their behavior with imatinib related to the mutational status. There are also other pos-
sible mechanisms for the development of resistance to imatinib, such as (1) bypass of inhibitory 
effect of imatinib through activation of other, alternative genes (AXL, IGFR-1, BRAF, IGFBP-3, 
 Table 4.1  Molecular features of gastrointestinal stromal tumors (GISTs) 
 KIT mutations  80–85% of sporadic GISTs 
 Exon 11  The most common mutation in sporadic GISTs, with the best response to imatinib; 
reported also in familial GISTs 
 Exon 9  Mutation more common in GISTs originating from small bowel; intermediate response to 
imatinib, patients may benefit from higher dose (800 mg) of imatinib; good response to 
sunitinib 
 Exon 13  Observed clinical responses to imatinib; reported in familial GISTs; more often as 
secondary mutations in imatinib-resistant tumors 
 Exon 17  Observed clinical responses to imatinib (with exception of D816V); it was described in 
familial GISTs; more often as secondary mutations in imatinib- and sunitinib-resistant 
tumors 
 PDGFRA mutations  5–10% of sporadic GISTs 
 Exon 12  Observed clinical responses to imatinib 
 Exon 14  Only few tumors described in literature 
 Exon 18  Majority originate from stomach, often related to indolent clinical behavior; D842V is most 
common (80% of  PDGFRA mutants) and resistant to imatinib and sunitinib; other types 
of mutations are sensitive to imatinib 
 Wild-type  Poor response to imatinib, better to sunitinib; frequent in pediatric GISTs, typical for 
GISTs related to neurofibromatosis type 1 or Carney’s triad (gastric GIST + pulmonary 
chondromas +/− paraganglioma); in part of the cases associated with amplification of 
 IGF1R or  BRAF mutation 
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FAK) and signaling pathways, and usually associated with loss of KIT expression in previously 
KIT-positive tumors, (2) genomic amplification or overexpression of KIT, outweighing inhibitory 
capacity of imatinib, (3) overexpression of drug-efflux pump, leading to decreased intratumoral 
imatinib levels, (4) high blood level of  a 1 -acid glycoprotein, which binds and inactivates imatinib, 
(5) increased clearance of imatinib over time, causing decreased systemic imatinib concentrations. 
As it was proved for imatinib,  KIT mutation status appears to serve as a predictor of tumor response 
also to sunitinib  [ 62 ] . Contrary to imatinib, however, there is evidence that tumors initially 
 (pre-imatinib) bearing an exon 9  KIT mutation or with wild-type genotype have a higher chance to 
respond to sunitinib. Furthermore, patients with tumors harboring a secondary mutation in  KIT exon 
13 or exon 14 have a longer PFS than patients with resistant to sunitinib therapy  KIT exon 17 or 18 
mutations. Ex vivo assays have demonstrated that sunitinib potently inhibits KIT kinase activity of 
V654A and T670I mutants and suppresses proliferation of the cells expressing these mutations, 
which was also confirmed by further clinical experience. In contrast, sunitinib did not potently 
inhibit the D842V  PDGFRA mutant or secondary mutations in the KIT activation loop (such as 
D820Y, D820E, N822K, or D823A)  [ 63 ] . 
 Treatment of children and adolescents with GISTs is an additional clinical challenge. Primary 
resistance or lesser responsiveness (stable disease) to imatinib is reported in this group of patients, 
which is predictive given the fact that most cases are wild-type. Sunitinib has been reported to show 
activity in a small series of imatinib-refractory pediatric patients  [ 64 ] . 
 Gene Signatures 
 General Overview 
 In the past decade, gene expression profiling has been applied to GIST to better understand their 
pathogenesis and to identify clinically useful diagnostic, prognostic, and predictive markers. 
 One of the earliest studies compared GIST gene expression profiles with gene signatures of other 
high-grade sarcomas of different histopathological subtypes  [ 65,  66 ] . Of interest was the up- 
regulation of KIT and genes in the KIT signaling pathway, such as the protein kinase C Theta 
(PRKCQ) and G-protein-coupled receptor 20 (GPR20), both being suggested as mediators of KIT 
kinase function. Several subsequent sarcoma gene expression studies included significant numbers 
of GISTs  [ 67– 72 ] . In all these studies, GISTs showed a uniform and rather noncomplex gene 
expression profile, with homogeneous unsupervised hierarchical clustering of a set of defined 
genes, which is consistent with the notion of GIST separate biological entity. The list of top ranking 
genes dissected from these studies is shown in Table  4.2 . 
 Most of these studies have been set up to enhance delineation of diagnosis or to identify expres-
sion differences according to  KIT or  PDGFRA mutation status (Table  4.3 ). The later identified not 
only gene expression profiles characteristic of different mutation types  [ 70,  77 ] , but also associated 
with distinct tumor anatomic site  [ 74 ] . Accordingly, Subramanian et al.  [ 77 ] performed gene expres-
sion profiling on 26 GISTs with known KIT/PDGFRA status and identified gene expression profiles 
characteristic of different mutation types. To investigate the consequences of the distinct KIT geno-
type and anatomic site of tumors on gene expression profiles, Antonescu et al.  [ 74 ] characterized 
transcriptional levels in a cohort of 24 GISTs, including tumors with different KIT genotypes and 
origin. Notably, GISTs signature was highly dependent on the anatomic site of the tumor. A number 
of genes involved in muscle contraction and development, genes involved in modulating digestive 
enzymes and secretion, as well as cell cycle regulators, growths factors, and mediators of growth 
factor signaling were found to be on the list of discriminatory genes. Interestingly, the set of genes 
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identified was distinct from that described by Subramanian et al., which most likely reflects the 
impact of used methodology and biological differences between diverse subset of analyzed tumors. 
Similarly, the differences in expression profile of 22 gastric GISTs were investigated by Kang et al. 
 [ 70 ] and 70 genes were differentially expressed in GISTs with KIT mutations compared to GISTs 
with PDGFRA mutations. In parallel, Li et al.  [ 71 ] provided the first evidence that gene expression 
profile is indistinguishable in familial and sporadic GISTs. 
 More recently, based on the analysis of 31 GISTs, Ostrowski and coworkers  [ 75 ] compared the 
expression signature of tumors with low  versus high KIT expression level. The expression of genes 
annotated to synaptic transmission, blood level development, and G-protein signaling were at least 
twofold higher in the former compared to later. 
 One of the few studies that attempted the integrative analysis of the genome and transcription 
profiling in GISTs was based on 25 mutants or KIT/PDGFRA wild-type tumors  [ 76 ] . This study 
aimed to identify target genes located within commonly altered genomic regions that have been 
described in GISTs within the last 15 years. The majority of discriminative genes were down- regulated 
 Table 4.3  GIST signatures according to different genotype and/or tumor anatomic site 
 First author 
[Reference]  GIST type  E  Gene symbol 
 Gene function/Biological process 
 Allander  [ 65 ]  KIT mutants  ↑  KIT, GPR20, 
PRKCQ, 
ANXA3 
 Signal transduction 
 ↑  BCHE  Cocaine metabolic process 
 ↑  DMN  Structural support in muscle 
 ↑  PFKM  Regulation of glycolysis, glycogen 
metabolic process 
 Subramanian  [ 72 ]  KIT exon 11 mutants  ↑  TM4SF12  Unknown 
 ↑  DIO2  Selenocysteine incorporation, thyroid 
hormone generation, hormone 
biosynthetic process 
 ↑  CAPNS2  Integrin signaling pathway 
 ↑  CCKBR  Calcium signaling pathway, 
neuroactive ligand–receptor 
interaction 
 ↑  LCN2  Transporter activity 
 KIT exon 9 mutants  ↑  IGSF4, DSG2  Cell adhesion 
 ↑  ALDH1A2  Retinol metabolism 
 ↑  MAP1B  Protein folding 
 ↑  EPHA4  Signal transduction, transmembrane 
receptor protein tyrosine kinase 
signaling pathway 
 PDGFRA mutants  ↑  SPON1  Cell adhesion, multicellular 
organismal development 
 ↑  IGFBP5  Signal transduction, regulation of cell 
growth 
 ↑  ANGPTL1  Signal transduction, transmembrane 
receptor protein tyrosine kinase 
signaling pathway 
 ↑  LUM  Collagen binding, extracellular matrix 
structural constituent, transferase 
activity 
 ↑  KIAA0534  Receptor activity, sugar binding 
(continued)
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 First author 
[Reference]  GIST type  E  Gene symbol 
 Gene function/Biological process 
 Antonescu  [ 68 ]  Mutant GIST  ↑  RAC2, Shp1  Growth factor signaling genes 
 Wild-type GIST  ↑  BCL2, GLUT1/
VEGF, MCSF, IL2, 
MAGE1 
 Apoptosis/angiogenesis and 
proliferation 
 KIT Exon 9 mutants  ↑  GGT1/MPF/FZD2, 
FZD3 
 mRNA processing/cell adhesion/Wnt 
signaling 
 KIT Exon 11 mutants  ↑  STAT3, CTNNB1, 
NTAK (NRG2), 
PDGF1 
 Signal transduction 
 Familial GIST  ↑  CALCYON, NOS1  Synaptic transmission 
 ↑  PIB5PA  Phosphatidylinositol signaling system 
 ↑  CACNA1H  Muscle contraction and development 
 ↑  GLIPR1  GLI pathogenesis-related 1 (glioma) 
 Gastric GIST  ↑  TNNI2, TPM1, 
SMTN, LAMM, 
ESG 
 Muscle contraction and development 
 ↑  CCKBR, PLAG2G4B  Digestive enzymes modulation and 
secretion 
 ↑  PDGFRA, TGFRBR3, 
LTBP-4, TSC22 
 Growth factor receptors 
 ↑  CD34  Cell-cell adhesion, leukocyte 
migration 
 Small bowel GIST  ↑  MyHC-eo (Myosin 
heavy-chain 
polypeptide) 
 Muscle contraction and development 
 ↑  PIK3C2B, VAV2, 
Shp1, RAC1, 
RAC2, RAC3 
 Mediators of growth factor signaling 
 Epithelioid GIST  ↑  SOX11  Nervous system development, 
regulation of transcription 
 ↑  Cancer Testis Antigen 
2 (CAMEL) 
 – 
 ↑  VEGF/PDGF1/BCL2, 
BCL-G, CASP10 
 Proliferation/proliferation and signal 
transduction/apoptosis 
 Kang  [ 70 ]  PDGFRA mutants 
(gastric) 
 ↑  ASB2, PDGFRA, 
MX1/ISG15/
SPON1, TGFBI, 
THY1 
 Signal transduction/protein 
metabolism/cell adhesion 
 KIT mutants (gastric)  ↑  S100A1  Signal transduction 
 Ostrowski  [ 75 ]  KIT mutants  ↑  PRKCQ (PKC-theta)  Regulation of cell growth, signal 
transduction 
 ↓  PKC-alpha  Induction of apoptosis, regulation of 
progression through cell cycle 
 Astolfi  [ 76 ]  Mutant GISTs(both 
KIT and 
PDGFRA) 
 ↓  RTN1  Neuron differentiation, apoptosis 
 ↓  DACT1  Inhibition of Wnt/beta-catenin 
signaling 
 ↓  DAAM1  Cell motility, action cytoskeleton 
 E level of gene expression in reference to control group of tumors, ↑ = gene up-regulation, ↓ = gene down-regulation 
Table 4.3 (continued)
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in mutated samples. Not surprisingly, many of these genes have a role in cancer progression. RTN1, 
DAAM1, and DACT1, located in 14q23.1 cyto-band, showed the strongest down-regulation in mutant 
samples. 
 It has been proved that GISTs from children and young adults express different expression pro-
file compared to adult GISTs. Thus, Agaram et al.  [ 78 ] performed recently microarray analysis 
using a U133A Affymetrix chip platform on 13 pediatric GIST tumor nodules derived from 8 
patients. The expression values were compared to a control group of adult GISTs, with available 
array data. In an unsupervised hierarchical clustering analysis, pediatric GIST tumors formed a tight 
cluster distinct from the adult GIST tumors. A number of the overexpressed genes in the pediatric 
GISTs showed a high fold change difference compared to adult tumors, including  BAALC, IGF1R, 
CRLF1, PLAG1, FGF4 , and  FGF3. Also IGF1 expression was fivefold higher in pediatric GIST 
compared with adult WT GIST. The authors speculated that this might be one of the mechanisms 
that induce the expression of IGF1R. 
 GIST Signature for Diagnosis 
 Expression profiling was used as a diagnostic tool in soft tissue sarcoma/GIST classification. Along 
these lines, West et al.  [ 79 ] identified DOG1 (named also TMEM16A) as a validated marker for 
CD-117-immunonegative GIST. Recently, Price et al.  [ 80 ] performed gene expression profiling on 
a large collection of GISTs and leioyosarcomas (LMS) and created a novel paired gene analysis that 
was highly discriminative for the two tumor types. Two genes were identified (Obscurin and Prune 
2) that could accurately distinguish GIST and LMS from one another. 
 GIST Signatures for Prognosis 
 The development of a reliable method of GIST prognostication is essential for the proper clinical 
management of GISTs patients. This is especially imperative given the necessity of appropriate 
selection of patients for imatinib mesylate therapy to avoid possible development of tumor resis-
tance to treatment, the existence of possible alternative treatment and resource waste. There is a 
need to more deeply understand the biology underlining the aggressiveness of GISTs in order to 
identify objective biomarkers that enhance the specificity and the reproducibility of outcome predic-
tion. To achieve this purpose, genomic and expression profiling has been used, but heterogeneous 
results have been obtained (Table  4.4 ). 
 One of the earliest expression profiling study  [ 81 ] detected changes related to GISTs progression 
and revealed 27 overexpressed genes in malignant GISTs compared with benign tumors. These 
genes included proliferation markers, cell cycle regulators, and several kinases (CCNB1, CENP-F, 
FAK, HMG2, TSG101, DTRK2, and ezrin). 
 At the genomic level, it has been shown that the genome complexity level increases with tumor 
stage, but no threshold has ever been defined and no specific alteration has been proposed except 
for p16 INK4A alterations  [ 87,  88 ] . Inactivation of the later was confirmed on the transcript and protein 
level to be associated with increased risk for GIST progression  [ 87 ] . 
 To identify prognosis associated gene-expression signature, Yamagushi and colleagues  [ 17 ] per-
formed expression profiling in a series of 32 GISTs and identified CD26 as a prognosis marker in 
GISTs of gastric origin. Nevertheless, this signature is limited as it has not been compared to histo-
pathologic staging methods considered as the “gold standard.” Arne et al.  [ 86 ] performed global 
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 Table 4.4  Genomic and expression profi ling of different genes in GIST related to different biological function in 
which they are involved to 
 First author 
[Reference]  Reference tissue  E  Gene symbol 
 Gene function/Biological process 
 Koon  [ 81 ]  Malignant vs. benign 
GISTs 
 ↑  CCNB1, CENPF  Cell cycle and mitosis control 
 ↑  FAK (PTK2)  Angiogenesis, apoptosis, microtubule 
cytoskeleton organization 
 ↑  HGM2 (high-mobility group 
box 2) 
 DNA ligation, DNA repair, DNA 
replication 
 ↑  TSG101  Cell growth and differentiation 
 ↑  EZR (VIL2)  Regulation of actin cytoskeleton, 
cell adhesion molecule binding 
 Yamaguchi 
 [ 82 ] 
 Gastric GISTs 
validation set 
 ↑  DPP4 (dipeptidyl peptidase IV) 
gene encoding CD26 protein 
 Positive regulation of cell 
proliferation, cell adhesion 
 Hur  [ 83 ]  Low vs. intermediate 
vs. high-risk 
GIST groups 
 ↑  DNASE1L2/NCBP1, HSF2BP/
FGF17, GCGR, RIPK2/
MUC11/HYAL4/PPP3CA/
A4GNT 
 Cell proliferation/regulation of 
transcription/signal transduction/
regulation of cell growth/
carbohydrate metabolism/
cell cycle control, calcium ion 
transport/transferase activity 
 ↓  CPE/HTRA1/ANXA9/PTH/
CYB5R3/TLR6, GABRA5, 
CD48/HSPA5/HIVEP2 
 Biosynthesis of hormones and 
neurotransmitters/regulation of 
cell growth/cell adhesion/signal 
transduction, cell–cell signaling/
metabolism of vitamins and 
cofactors/inflammatory response/
regulation of transcription 
 Chibon  [ 84 ]  Low vs . intermediate 
vs . high-risk 
GIST groups 
 ↑  ANLN, ASPM, AURKA, 
AURKB, BIRC5, BUB1, 
BUB1B, C13orf34, CCNA2, 
CCNB1, CCNB2, CDC2, 
CDC20, CDC45L, CDC6, 
CDC7, CDCA2, CDCA3, 
CDCA8, CENPA, CENPE, 
CENPL, CEP55, CHEK1, 
CKS2, ECT2, ESPL1, FBXO5, 
FOXM1, H2AFX, HP1BP3, 
KIAA1794, KIF11, KIF14, 
KIF15, KIF18A, KIF20A, 
KIF23, KIF2C, KIF4A, KIFC1, 
MADL2L1, MCM2, MCM7, 
MELK, NCAPH, NDE1, 
NEK2, NUF2, OIP5, PAK3, 
PBK, PLK4, PRC1, PTTG1, 
RAD51AP1, RNASEH2A, 
RRM2, SGOL2, SMC2, 
SPAG5, SPBC25, TOP2A, 
TPX2, TRIP13, TTK, ZWINT 
 Mitosis and control of chromosome 
integrity 
 Ylipaa  [ 85 ]  Leiomyosarcoma  ↓  AKAP13  Intracellular signaling, regulation of 
Rho signal transduction 
 ↓  C15orf5  Unknown 
 ↓  OXA1L  Protein export 
 ↑  SMARCA3  Chromatin modification, regulation 
of transcription 
 Arne  [ 86 ]  KITex11 del vs. 
KITex9 and 
PDGFRA and 
wild-type GISTs 
 ↑  CD133 (prominin – 1)  Stem cell marker; organization of 
plasma membrane 
 E level of gene expression in reference to control group of tumors, ↑ = gene up-regulation, ↓ = gene down-regulation 
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gene expression profiling on GISTs arranged into two separate groups, i.e., tumors with  KIT exon 
11 deletions and without  KIT exon 11 mutations. Among the differentially regulated genes were 
previously known markers for GIST, including KIT, DOG1, and CD34, which were up-regulated in 
GISTs carrying KIT exon 11 deletions. Notably, one highly up-regulated gene in the group of 
tumors carrying KIT exon 11 deletions was CD133 (prominin-1), which was also associated with 
gastric location and poor prognosis. Hur et al.  [ 83 ] reported the gene expression profiling according 
to the GISTs malignant potential through direct comparison between various risks of GISTs (based 
on NIH consensus criteria) and human universal RNA as a reference. A total of 181 genes were 
identified to be expressed differentially according to GIST risk category. 
 Importantly, Chibon and coworkers  [ 84 ] recently reported a 67 genes-expression prognostic 
signature related to genome complexity (CINSARC for Complexity INdex in SARComas). Gene 
ontology analysis of CINSARC genes showed that all annotated genes are involved in the same 
biological process, i.e., cell cycle/mitosis and control of chromosome integrity. As a continuation of 
this work, using a training/validation set strategy gathering 99 GISTs, Lagerde et al.  [ 89 ] demon-
strated that CINSARC signature and a new one-gene-expression signature (AURKA expression 
level) predict metastatic outcome in GIST, and that their combination with genome imbalances 
outperform current histopathological grading method in determining patient prognosis. More spe-
cifically, these molecular signatures identify “at risk patients” within cases stratified as of intermedi-
ate risk according to the AFIP classification. Application of the signature will permit more selective 
imatinib mesylate adjuvant therapy leading to decreased iatrogenic morbidity and improved out-
comes for individual patients. 
 GIST Signatures Response to IMATINIB 
 GISTs signatures may be used not only to better understand the molecular basis of GISTs tumori-
genesis and for the identification of prognostic biomarkers, but also to identify a novel target mol-
ecule for effective curative treatments. 
 Evaluation of surrogate markers of imatinib response in clinical GIST samples, using core biop-
sies from patients both before and after initiation of therapy, was performed by Frolov and cowork-
ers  [ 90 ] . Down-regulation of Sprouty homolog 4 (SPRY4A) and up-regulation muscle atrophy 
F-box protein (MAFbx) transcripts were found to be highly reliable predictors of immediate 
response to the drug. 
 Based on expression profiling analysis of treated with imatinib GIST cell lines, Trent et al.  [ 91 ] 
identified insulin-like growth factor binding protein 3 (IGFBP3) as an important early marker of 
antitumor activity of imatinib in GIST. 
 Mahadevan et al.  [ 92 ] performed global expression profiling of GIST882 cell line subclones, 
sensitive (expressing KIT) and resistant (that lost KIT expression) to imatinib mesylate. Differential 
expression of a number of cytoskeletal, cell adhesion, and extracellular matrix proteins genes were 
hypothesized to contribute to the imatinib-resistant phenotype. Importantly, AXL receptor tyrosine 
kinase overexpression was found in the subline with the KIT expression loss, pointing to kinase 
switch as an alternative mechanism of imatinib resistance and AXL as a new possible therapeutic 
target. 
 Affymetrix microarray analysis was performed also on ten nodules from three responsive GIST 
patients and compared with a group of 34 nontreated GISTs  [ 93 ] . Genomic signature of imatinib 
response identified alterations of genes involved in cell cycle control and overexpression of genes 
involved in muscle differentiation and function. Galanin receptor 2 (GALR2) and glypican 3 
(GPC3) were the two top genes overexpressed in responsive GIST. 
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 Recently, Rink et al.  [ 94 ] were able to elucidate a gene expression profile that is unique to 
patients whose tumors are less responsive to imatinib mesylate in comparison with those that rap-
idly respond. This profile consists of 32 annotated genes, 18 of which encoded Krüppel-associated 
box (KRAB) domain containing zinc finger (ZNF) transcriptional repressors. Importantly, ten 
KRAB-ZNF genes mapped to a single locus on chromosome 19p, and a subset predicted response 
to imatinib mesylate-based therapy in a naïve panel of GIST. 
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 Introduction 
 Cancer of the pancreas is the fourth leading cause of death by cancer in Western countries. 
In France, 7,200 persons die from this disease every year and more than 70,000 in Europe; in the 
USA, the annual death rate is about 30,000  [ 1 ] . With an incidence/death ratio of 0.99, pancreatic 
cancer is a crucial public health issue  [ 2 ] . Although perioperative radiation therapy and chemo-
therapy can be slightly advantageous in terms of survival, they have no proven effect on prognosis 
 [ 3 ] . Surgery offers the only possible cure if resection margins remain healthy. But only 10–15% of 
patients have localized resectable tumors at diagnosis  [ 4 ] and most operated patients rapidly develop 
locoregional or metastatic disease progression  [ 5 ] . Screening for pancreatic cancer, which could 
result in early diagnosis and thus increase the chances of curative treatment, is not currently avail-
able. There is no known biological or clinical screening test with a proven efficacy and the risk 
factors associated with the sporadic forms of the disease are unknown. Thus, this tumor has a very 
poor prognosis. A better understanding of the mechanisms of development of pancreatic cancer 
could probably contribute to the identification of new molecular targets and the improvement of 
diagnosis and treatment. A large body of work has been devoted to the identification of genetic 
alterations and their role in the development of pancreatic cancer. In this chapter, we focus on 
genetic anomalies associated with two well-recognized precancerous pancreatic lesions, pancreatic 
intraepithelial neoplasia (PanIN) and intraductal papillary mucinous neoplasm (IPMN). Both 
anomalies mainly involve alterations of oncogenes or tumor suppressor genes. Oncogenes are genes 
which favor the expression of malignant transformation. These genes are either mutated genes or 
mutation-free genes which are abnormally overexpressed. Tumor suppressor genes are genes which 
normally protect cells from degeneration. Their mutation or their inhibition favors the development 
of cancer cells. We first focus on gene expression changes occurring in pancreatic cancer tissues and 
on microRNA (miRNA) expression changes in pancreatic cancer cells. Then, we describe genes 
involved in the rare familiar cases of pancreatic adenocarcinoma. Finally, we describe all known 
genetic anomalies present in germ line DNA that increase susceptibility to pancreatic adenocarci-
noma development. 
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 Genetics of PanIN and IPMN Precancerous Lesions 
 Pancreatic Intraepithelial Neoplasia 
 Although precursor lesions of pancreatic cancer were already well documented more than a century 
ago, a rigorous classification of these lesions was not obtained until the last decade. Morphological 
analyses of resected pancreatic cancers suggest that pancreatic adenocarcinomas do not develop de 
novo but are a result of a stepwise progression leading to the generation of invasive lesions  [ 6– 8 ] . 
In the late 1990s, a plethora of often biologically imprecise terms were used to describe these 
lesions. In 2001, an international agreement  [ 9 ] was reached on the nomenclature used for a vast 
spectrum of lesions ranging from low-grade lesions (PanIN-1) to in situ carcinomas (PanIN-3), 
considered as the stage preceding invasion of the neighboring stroma. A detailed description of the 
histological features of PanINs is beyond the scope of this chapter. However, it should be noted that 
the histological progression of PanINs is (with a few exceptions) associated with progressive accu-
mulation of the same molecular anomalies than those observed in invasive cancer  [ 10 ] . These 
molecular alterations have been helpful in demonstrating that PanINs are clonal precursors of pan-
creatic adenocarcinoma. Although the exact natural history of PanINs has been difficult to establish, 
these lesions are thought to exist well before the appearance of the adenocarcinoma. Because of the 
poor prognosis of pancreatic cancer, it is important to obtain a genetic characterization of the pan-
creatic tissue harboring PanIN lesions, and in particular PanIN-3 lesions, before they transform into 
malignant lesions. The identification of molecular anomalies specific to PanINs would enable early 
screening of the pancreatic transformation process and might provide important information for 
selecting new therapeutic targets. While animal models have not yet been developed for IPMNs, 
several genetically modified mouse models of PanINs are currently available. These models have 
shown that PanIN lesions develop into pancreatic adenocarcinomas. The process has always 
involved expression of the mutated  KRAS gene in pancreas  [ 11– 13 ] . Expression of the mutated 
 KRAS gene induces the formation of PanINs but not their malignant transformation, which is only 
obtained after loss of activity of a tumor suppressor gene ( CDKN2A/p16 ,  SMAD4 or other mole-
cules participating in the  TGF beta and  TP53 signaling pathways)  [ 14– 20 ] or in the presence of 
chronic pancreatic inflammation  [ 21 ] . 
 Genetic Alterations in PanIN 
 The characterization of genetic alterations observed in PanINs has progressed further than that for 
IPMN. 
 Oncogenes 
 ERBB2 encodes a tyrosine kinase growth factor receptor, whose activation induces cell proliferation. 
The ERBB2 protein is thus considered as a powerful oncogene. Its overexpression is one of the 
earliest events in the oncogenic process in the pancreas. It is detected in 82% of PanIN-1A lesions 
and in 100% of PanIN-3 lesions  [ 22 ] . The  KRAS oncogene is activated in approximately 90% of all 
pancreatic adenocarcinomas. These mutations affect codons 12 (the most common mutation), 13, 
and 61  [ 23 ] . The mutated KRAS protein facilitates progression along the cell cycle via activation of 
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MAP kinases and AKT kinase  [ 24 ] . These  KRAS gene mutations also appear very early in pancreatic 
cancer. They are found in 36% of PanIN-1A lesions, 44% of PanIN-1B and PanIN-2 lesions, and 
87% of PanIN-3 lesions  [ 25 ] . It is important to note that PanIN lesions carrying different mutations 
can coexist in the same organ; these mutations belonging to different clones  [ 26 ] . Nevertheless, only 
one of the clones progresses toward an invasive form, the clone with the mutations always found in 
pancreatic adenocarcinomas. 
 Tumor Suppressor Genes 
 A certain number of tumor suppressor genes are inactivated in PanINs. They are also inactivated in 
adenocarcinomas. The  CDKN2A/p16 gene encodes a protein which binds to cyclin-dependent 
kinases Cdk4 and Cdk6, thus inhibiting their linkage with cyclin D1 and stopping the cell cycle at 
G1/S  [ 27 ] . This loss of activity, which is observed in more than 90% of pancreatic adenocarcino-
mas, can occur through at least three mechanisms (a) homozygous deletion, (b) mutation of one 
allele plus deletion on the second, or (c) hypermethylation of its promoter resulting in nearly total 
suppression of its expression  [ 28– 30 ] . Loss of CDKN2A/p16 expression is also observed in PanIN 
lesions with an incidence of 30% in PanIN-1A and PanIN-1B, 55% in PanIN-2 and more than 70% 
in PanIN-3  [ 31 ] .  TP53 tumor gene suppressor is inactivated in more than 50% of pancreatic adeno-
carcinomas. The mechanism of inactivation is often associated with the loss of one allele and an 
inactivating mutation of the other  [ 32 ] . Inactivation of  TP53 is rarely observed in PanIN-1A or 
PanIN-1B lesions, indicating that the loss of TP53 function occurs late in the tumorigenesis process 
 [ 33 ] .  SMAD4 tumor suppressor gene is frequently inactivated in pancreatic adenocarcinomas  [ 34 ] . 
The SMAD4 protein is implicated in the signaling cascade of TGF- b ; its inactivation blocks the 
inhibitor effect of TGF- b and other members of its family on cell growth, thus allowing uncontrolled 
growth of tumor cells  [ 35 ] . SMAD4 expression is preserved in PanIN-1 and PanIN-2 lesions, but 
lost in 40% of PanIN-3 lesions  [ 36 ] . 
 Other Anomalies Observed 
 Loss of telomere integrity in the ductal epithelium is probably the cause of the genomic instability 
observed in PanIN  [ 37 ] . Telomeres are TTAGGG repeats that cap the ends of chromosomes, induc-
ing a certain degree of stability during cell division  [ 38 ] . Telomere shortening is one of the first 
genetic aberrations detected in PanIN lesions, occurring in more than 90%  [ 37 ] . Intact telomeres 
act like “guardians” of the pancreatic ductal genome; their shortening in PanIN leads to progres-
sive accumulation of chromosomal anomalies and finally malignant transformation. In addition, 
other proteins are overexpressed during the stepwise progression toward PanIN; these proteins 
could thus be interesting markers of pancreatic carcinogenesis. Expression of protein Ki-67 is 
associated with cell proliferation. Ki-67 is expressed more frequently in the nuclei of high-grade 
PanIN cells (22% in PanIN-3) than in early forms (0.7% in PanIN-1A)  [ 33 ] . The index is 35–40% 
in adenocarcinomas  [ 39 ] . Expression of topoisomerase II, necessary for DNA relaxation before 
replication, follows that of protein Ki-67  [ 33 ] . Cyclin D1, which is a key element of the cell cycle, 
is overexpressed in 80% of pancreatic adenocarcinomas, 50% of PanIN-3, and 30% of PanIN-2 
 [ 40 ] . The expression of these markers is not due to a genomic or epigenetic event. It is simply the 
consequence of accelerated cell proliferation due to the malignant transformation at an intensity 
directly related to the transformation. 
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 PanIN and Accumulation of Genetic Anomalies 
 Progression from PanIN-1A to PanIN-3 then to pancreatic adenocarcinoma is associated with pro-
gressive accumulation of genomic alterations. This model of progression has been described by 
several laboratories  [ 33,  41,  42 ] and appears to be well established, with new characterizations of 
new anomalies in precancerous lesions regularly published. Activation of the  KRAS oncogene and 
amplification of ERBB2 are the earliest genetic alterations observed in PanIN-1A. Telomere short-
ening is also observed at an early stage. Loss of CDKN2A/p16 activity comes slightly later in stages 
PanIN-1B and PanIN-2. Cyclin D1 overexpression is seen in PanIN-2. The latest events, observed 
in PanIN-3, are inactivation of  TP53 and  SMAD4 and expression of Ki-67 (Fig.  5.1 ). 
 Intraductal Papillary Mucinous Neoplasm 
 IPMN is a relatively uncommon lesion. The macroscopic appearance is a dilated pancreatic duct 
filled with mucus; there is a strong potential for degeneration  [ 43 ] . IPMN can also be seen as a small 
cyst in the lumen of a secondary pancreatic duct or as a set of large multicystic lesions involving 
the main pancreatic duct and several secondary ducts. Malignant transformation is mainly seen in 
this second type  [ 44 ] . IPMNs occur more readily in older men and less frequently in women  [ 45 ] . 
Discovery is generally fortuitous; sometimes made because of acute obstructive pancreatitis result-
ing from mucus-filled ducts  [ 43 ] . 
 Fig. 5.1  Genetic alterations in pancreas cancer. At the  upper part are shown the genetic alterations present in the 
precancerous lesions PanIN and IPMN, and at the  lower part are showed the genes implicated in the familiar forms 
of pancreas cancer. Gain of function is represented in  red and loss of function is represented in  blue 
555 Pancreatic Cancer Genetics
 Microscopically, IPMNs are composed of a mucin-producing ductal type epithelium. IPMNs are 
classed by architecture into four types: gastric, intestinal, pancreaticobiliary, and oncocytic  [ 46 ] . 
Ductal cells show diverse degrees of atypia ranging from low-grade to high-grade lesions, the latter 
corresponding to in situ carcinoma. In 1996, the World Health Organization defined four groups of 
IPMN as a function of cell atypia: adenomas, borderline tumors, in situ carcinomas, and invasive 
tumors. Disease prognosis depends upon the presence of invasive carcinoma at diagnosis. 
Unfortunately, invasive carcinoma progresses much like classic adenocarcinoma. 
 Genetic Alterations in IPMN 
 Three oncogenes ( KRAS ,  ERBB2 , and  AKT ) and five tumor suppressor genes ( CDKN2A/p16 ,  TP53 , 
 SMAD4 ,  LKB1 , and  DUSP6 ) are involved. 
 Oncogenes 
 The oncogene  KRAS is activated by mutation in approximately 72% of IPMN lesions  [ 47 ] . This 
mutation has been identified in low-grade and high-grade lesions. Although it is not particularly 
specific, this mutation appears to be necessary for the development of IPMN. It is interesting to note 
that different mutations which activate  KRAS are sometimes observed in the same patient at differ-
ent IPMN foci. There could be several explanations for this, including polyclonal development of 
IPMN and  KRAS mutation secondary to the development of the lesions. Yoshizawa and colleagues 
have suggested that low-grade forms arise via a polyclonal mechanism while high-grade forms 
develop from low-grade lesions in a clonal manner  [ 48 ] . Overexpression of ERBB2, which is a 
common and early event in pancreatic cancer as mentioned above, has been observed in 63% of 
IPMN lesions  [ 49 ] . AKT is a protein kinase involved in KRAS signaling. It plays a key role in cell 
growth and survival. A recent study showed that the activated (phosphorylated) form of this kinase 
is found in 63% of lesions (versus 70% in adenocarcinomas). In addition, AKT activation is slightly 
more frequent in high-grade than in low-grade forms  [ 50 ] . 
 Tumor Suppressor Genes 
 As mentioned above,  CDKN2A/p16 plays a major role in cell cycle arrest.  CDKN2A/p16 expression 
is lost in about half of all IPMN lesions  [ 51 ] . Such diminished expression results in most cases from 
hypermethylation of its promoter  [ 52 ] . The tumor suppressor gene  TP53 is a transcription factor 
which induces the expression of several genes involved in cell cycle arrest, DNA repair, and apop-
tosis induced by DNA damage. TP53 activation is lost in half of human tumors, either by deletion 
or mutation of its gene, or by proteosomal hyperdegradation. Loss of TP53 activity is observed in 
half of IPMNs with a higher frequency in high-grade lesions  [ 46,  47,  53 ] . The current hypothesis is 
that loss of TP53 activity in this type of lesion induces loss of genome integrity which in turn leads 
to malignant transformation. Chromosome region 18q21.1 frequently exhibits deletion of its two 
alleles in pancreatic adenocarcinomas  [ 54– 56 ] . The tumor suppressor  SMAD4 is located in this 
region. Nevertheless, homozygous mutations of  SMAD4 are rare in IPMN. Moreover, expression of 
the SMAD4 protein is generally preserved in these lesions, independent of the degree of atypicity 
 [ 57 ] . When IPMN transformation involves the SMAD4 pathway, loss of SMAD4 function is a very 
late event. The  LKB1 gene is responsible for Peutz-Jeghers syndrome (transmitted by autosomal 
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dominant inheritance, this syndrome associates periorificial lentiginosis and intestinal polyposis; 
the development of several types of cancer, including pancreatic cancer can be observed during the 
course of the disease). The role of  LKB1 involves preservation of cell polarity  [ 58 ] . Mutation of 
 LKB1 has been identified in 25% of IPMN lesions in patients without Peutz-Jeghers syndrome and 
also in a few cases of pancreatic adenocarcinomas  [ 59 ] .  LKB1 might thus play a role in the develop-
ment of IPMNs in some patients. Finally, the expression of DUSP6, a phosphatase which interacts 
with the kinase MAPK1 regulating its activity, appears to be lost or greatly diminished in a few 
IPMNs  [ 52 ] . 
 Differences Between PanINs and IPMNS 
 PanINs and IPMNs are both intraductal lesions with a potential for malignant degeneration. They 
are nevertheless very different lesions. The most important difference is their size. PanINs are 
microscopic lesions while IPMNs are macroscopic. At the present time, PanINs cannot be detected 
by routine endoscopic or radiological methods. They are discovered fortuitously during histological 
analysis of surgical specimens. Immunoreactivity can also distinguish between the two types of 
lesions. MUC2 is found in most IPMNs but never in PanINs. SMAD4 expression, often lost in 
PanIN-3, is almost systematically preserved in both degenerated and nondegenerated IPMNs  [ 57 ] . 
DUSP6 expression is preserved in PanINs but strongly reduced in most IPMNs  [ 46 ] . These differ-
ences suggest that the developments of these two precancerous lesions occur through distinct 
molecular mechanisms (Fig.  5.1 ). 
 Hence, PanINs and IPMNs are different precancerous lesions. For the time being, the diagnosis 
of PanIN is based on pathological analysis of a surgical specimen. A set of genetic markers of PanINs 
is needed to obtain a simple, specific, and early diagnosis so that prophylactic measures can be taken, 
particularly in the context of familial pancreatitis. Although the diagnosis of IPMN is more and more 
early, the decision for surgery is still a major challenge. If genomic or proteomic markers of IPMNs 
could be detected in endoscopic ultrasound fine needle aspirations, patients at high risk of malignant 
degeneration could be identified soon enough that the most appropriate preventive intervention could 
be proposed. These observations illustrate the importance of obtaining a better knowledge of the 
genetic alterations in PanINs, which could be useful for familial screening. If the genetic alterations 
of IPMNs were better understood, patients could be selected for close monitoring or surgery. It is also 
important to note that most genetic anomalies observed in PanINs and IPMNs do not differ from 
those observed in established pancreatic adenocarcinomas, except for major chromosomal alterations 
(duplications, deletions, rearrangements) which are only present in adenocarcinomas. These anoma-
lies may result from anomalous mitosis, with poor redistribution of the genetic material between the 
two daughter cells, which most probably occurs in advanced adenocarcinoma. This suggests that 
genetic alterations are necessary for the malignant transformation of precancerous lesions but are not 
sufficient for progression to cancer. Other factors are required. Characterizing these factors, expected 
to be similar to other predisposing factors for cancer (chronic inflammation, cigarette smoking, cer-
tain diets, etc.), could result in better prophylaxis for pancreatic cancer. 
 Gene Expression Changes Occurring in Pancreatic Cancer 
 Since the development of the first microarray systems in 1995  [ 60 ] , their use was widespread in 
cancer research in general and especially in pancreatic cancer. Pan-transcription profiling of pancreatic 
cancer tissues were conducted with different types of platforms and approaches, such as microarrays, 
575 Pancreatic Cancer Genetics
SAGE, and more recently by exhaustive exome sequencing using second-generation sequencing 
analysis. Results have suggested that, unlike other types of tumors whose appearance is triggered 
by altering a single oncogene, as in certain types of leukemia, in pancreatic cancer development 
results from genetic alteration of a large number of genes although these genes are involved in a 
limited number of specific pathways and processes (see above). They also suggest that the number 
of paths or processes involved increases during progression of the lesion. 
 The numerous studies on pancreatic cancer involving a critical postgenomic vision can be clas-
sified into three main categories (1) studies using a single platform type; (2) studies that combined 
data from two or more types of platforms; and (3) studies that analyzed data already available in 
public databases, or studies in silico. 
 IGH-Throughput Genomic Studies 
 The capacity to analyze the entire transcriptome of tumors has given researchers a powerful tool to 
better understand the pathophysiology of pancreatic cancer. Soon, these tools have enabled the 
exploration of diagnostic and therapeutic targets. Thus, overall, genomic studies can be divided 
according to their objectives in three main categories: (a) identification of specific genes for diag-
nostic, prognostic, or therapeutic purposes; (b) decoding of complex patterns of gene expression to 
better understand the pathophysiology of the disease; and (c) use of the genetic profiling to identify 
new subtypes or classes of diseases that are not detectable by routine clinical procedures. These 
three groups are also referred to as candidate gene selection, class prediction, and class discovery, 
respectively  [ 61 ] . Several postgenomic studies have been performed to search for new prognostic 
markers or diagnostic tools of pancreatic cancer (a comprehensive compilation of these studies is 
given in papers  [ 62– 64 ] ). The most recent of these studies  [ 64 ] , analyzed the expression profiles of 
44,000 genes in 34 primary tumors and their metastases, and selected a small set of six genes 
(FOSB, KLF6, NFKBIZ, ATP4A, GSG1, and SIGLEC11) whose expression seems to predict meta-
static potential. The expression pattern of these genes used as a “training set,” was subsequently 
validated on a “test set” of 67 new tumors. According to the results, this “gene signature” would 
select pancreas cancer patients with high or low survival potential. The first group had a survival at 
1 year of 55%, compared to 91% for those classified as low risk. This detection system appears to 
be more sensitive than the current TNM classification and could be particularly useful for targeting 
more aggressive therapeutic measures. 
 Studies Using Several Types of Platforms Simultaneously 
 Because of the vast genetic heterogeneity of pancreatic cancer  [ 65 ] , genetic alterations may be very 
different among pancreatic tumors. In fact, a finding common in publications of global gene expres-
sion analysis is that gene lists reported vary greatly between studies and even between patients 
within a group. In this context, a remarkable study provides some interesting answers. This study 
analyzed 24 human pancreatic cancers by performing simultaneously exome sequencing, transcrip-
tional analysis, and quantification of amplifications and deletions by microarray  [ 66 ] . Coding 
regions of 20,661 genes were sequenced in the tumors and respective normal tissues of 24 individual 
presenting with advanced pancreatic adenocarcinoma. Analysis of exomes has detected 1,562 
changes in tumor DNA compared to DNA from normal tissue (“germline sequence variations”). 
More than 60% of these mutations produce a change in amino acids (missense mutation). Of 924 
mutations described, 55 affected the function of genes carrying the mutation, and 160 had already 
been associated with tumorigenesis in other studies. 
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 Moreover, the authors also investigated the variations in the copy number of genes and their 
expression levels in the genomes of 24 individuals. This high-throughput method identified 144 
amplifications associated with overexpression of the respective genes, and 198 homozygous dele-
tions of DNA fragments with an average size of 335,000 base pairs. These structural changes are 
followed by changes in expression levels of 541 genes, grouped in 69 sets, and present in 90% of 
the 24 tumors. Among these genes, 54 encode secretory proteins or cell surface proteins, and their 
expression level is more than 10 times overexpressed compared to normal ductal cells. This could 
provide new targets for diagnosis and treatment of pancreatic cancer. More interestingly, the colos-
sal amount of information obtained by combining these three types of technology, demonstrated that 
12 signaling pathways and cellular processes were altered in 67% of pancreatic cancer (apoptosis, 
DNA damage, regulation of G1/S phase transition, hedgehog signaling, homophilic cell adhesion, 
integrin signaling, c-Jun N-terminal kinase signaling, KRAS signaling, regulation of invasion, small 
GTPase-dependent signaling other than KRAS, TGF- b signaling, and Wnt/Notch signaling). The 
key to identifying these 12 pathways was to assume that any alteration of genes involved in the same 
pathway or process results in similar tumor effects, rather than considering the function of each gene 
individually. In fact, it is important to say that the identified genes are not common to all tumors, 
but the experimental information currently available allows them to alter the pathway. However, the 
key to interpreting data from pancreatic cancer is integration and reduction. Integrating genomics, 
epigenetics, the transcriptome and proteomics studies, and reducing the mass of information on 
functional, metabolic and ontologic pathways. 
 In a second study from the same team, authors studied the germ line exome from an individual 
with a hereditary pancreatic cancer  [ 67 ] . After identification of the candidate gene, they sequenced 
the same region in 96 individuals with hereditary pancreatic cancer. They could show that a 4 bp 
deletion within the gene “Partner and Localizer of BRCA2” or PALB2 was present in the germ line 
DNA of all these individuals. This discovery makes PALB2 the second most frequently mutated 
gene in hereditary pancreatic cancer after BRCA2. 
 In spite of the limitation that the exome represents only 1% of the genome, the two works 
described above clearly demonstrate the potential of this approach in studying pancreatic cancer by 
identifying genes responsible for triggering sporadic and hereditary pancreatic cancer. 
 In Silico Studies 
 Recently, efforts have been made to integrate the wealth of data produced by high-throughput tech-
nologies and undertake systematic validation of most frequently detected molecules, with the aim 
to discover their potential clinical utility  [ 62,  68,  69 ] . In this line, results from high-throughput stud-
ies at the genomic, epigenomic, transcriptomic, and proteomic level in pancreatic cancer were 
reanalyzed by Ranganathan and colleagues. A subset of ten molecules frequently overexpressed in 
pancreatic tumors was identified (CEACAM5, ITGA2, MMP11, MSLN, MUC5AC, S100A11, 
S100P, SPARC, TFF2, and SFN). Almost all of these genes are involved in cell cycle, cell growth 
and proliferation, and represent potential markers for diagnosis and prognosis (see Table  5.1 ). 
 A similar study was specifically directed to the identification and validation of specific markers 
of pancreatic tumors  [ 68 ] . It showed that more than 441 genes overexpressed at the mRNA and 
protein level, measured and validated by different methods are reported in at least four different 
publications. Antibodies against 60 of these genes, all coding for proteins associated with the cell 
membrane, are being tested as potential tumor markers, and possibly as therapeutic tools. 
 Databases to compile different types of “omics” for cancer of the pancreas are available on the 
Web owing to international efforts ( http://www.pancreasexpression.org )  [ 70 ] , which allows inte-
grated data mining. It is hoped that similar efforts are made on other pancreatic diseases and on 
other types of cancer, which would allow working on more complex queries. 
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 miRNA Expression Changes Occurring in Pancreatic Cancer 
 Structure, Genomic Organization, and Biosynthesis of miRNAS 
 miRNAs are a particular class of noncoding RNA molecules implicated in various gene silencing 
pathways. Their size ranges from 19 to 24 nucleotides and they are expressed in a large variety of 
organisms. The first miRNA described in 1993 was lin-4. It was shown to be a key regulator in the 
developmental timing of  C. elegans  [ 71 ] . Lin-4 was shown to interact with the 3 ¢ untranslated region 
(3 ¢ UTR) of the lin-14 mRNA and to repress its expression  [ 72 ] . Today, we know that miRNAs regu-
late their targets by direct mRNA cleavage or translational inhibition. miRNAs are coded by genes 
and are transcribed by RNA polymerase II (pol II). They have their own regulatory elements and 
appear as transcriptional units containing either unique (e.g., miR-21) or multiple miRNAs (e.g., the 
miR-17-92-1 cluster)  [ 73,  74 ] . The primary miRNA transcript (pre-miRNA) contains a cap structure 
and a poly(A) tail. It is initially transcribed as part of a much longer primary transcript (>1 kb). 
miRNAs represents 1–3% of the human genome  [ 75– 77 ] , controlling about 20–30% of protein-
coding genes in the human genome. Most of the miRNAs (70%) are located in introns and/or exons 
(miR-10b, miR-33, and miR-198), and the remaining 30% are situated in intergenic regions  [ 78,  79 ] . 
miRNA primary transcripts are cleaved in the nucleus by the enzyme Drosha before being exported 
to the cytoplasm  [ 80,  81 ] . They are further processed by the enzyme Dicer, resulting in a mature 
duplex containing 19–24 base pairs, one strand of which is incorporated into an effector complex 
called RNA-Induced Silencing Complex (RISC)  [ 82,  83 ] , whereas the opposite is eliminated  [ 84, 
 85 ] . Animal miRNAs are often only partially complementary to the 3 ¢ UTR of their target sites and 
the level of base pairing conditions the efficacy of sequence-specific cleavage by RISC. The miRNA–
mRNA interaction is restricted to the miRNA 5 ¢ end sequence. Strong complementarity between 
nucleotides 2–8 of the miRNA (“seed” sequence) and the 3 ¢ UTR of the targeted mRNA is essential 
for recognition  [ 86 ] . Translational regulation by miRNAs of a given mRNA is also a function of the 
number of target sites of these miRNAs into the 3 ¢ UTR of the mRNA  [ 87 ] . 
 When miRNA and mRNA interact, three scenarios are possible (1) the target can be cleaved; (2) the 
translation of the target can be inhibited by the miRNA at the initiation step or at a postinitiation 
step or (3) the miRNA can lead to the deadenylation or decapping of the mRNA  [ 88 ] . In conse-
quence, the level of target mRNA in the cell can remain constant, be increased or diminished, the 
protein level decreasing in all cases. On a structural standpoint, miRNAs are grouped into several 
families that share common seed sequences and have similar target specificity. miRNAs expressed 
in the same polycistron do not belong to the same structural family but frequently act in synergy to 
regulate the expression of functionally related genes. 
 Table 5.1  Ten molecules frequently overexpressed in pancreatic tumors 
 Symbol  Gene name 
 CEACAM5  Carcinoembryonic antigen-related cell adhesion molecule 5 
 ITGA2  Integrin, alpha 2 (CD49B, alpha 2 subunit of VLA-2 receptor) 
 MMP11  Matrix metallopeptidase 11 (stromelysin 3) 
 MSLN  Mesothelin 
 MUC5AC  Mucin 5AC, oligomeric mucus/gel-forming 
 S100A11  S100 calcium binding protein A11 
 S100P  S100 calcium binding protein P 
 SPARC  Secreted protein, acidic, cysteine-rich (osteonectin) 
 TFF2  Trefoil factor 2 
 SFN  Stratifin 
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 miRNA Expression Profiling in Pancreatic Ductal Adenocarcinoma 
 Pancreatic cancer is characterized by multiple genetic alterations associated with the different steps 
in pancreatic cancer progression, from the noninvasive precursor lesions to pancreatic ductal adeno-
carcinoma (PDAC)  [ 89 ] . Understanding decisive shifts in the behavior of early lesions and how they 
relate to underlying molecular alterations indicative of the disease stage would help designing new 
markers and therapeutic targets that could have a profound impact on clinical practice and patient 
outcome  [ 90,  91 ] . The problem with pancreatic cancer is that specific markers allowing its detection 
are scarce. Analysis of miRNA expression in PDAC showed that it presented with a specific miRNA 
signature that can be monitored by profiling miRNAs at different stages of cancer. The expression 
pattern of miRNAs seems to be a better way to identify the cancer type than mRNA expression pat-
terns  [ 92 ] . Over the past years, a number of different approaches, including DNA microchips and 
RT-PCR have been described to quantify miRNAs. By these techniques, several studies demon-
strated the tissue-specificity of miRNA expression and deregulation of miRNA expression in pan-
creatic cancer  [ 93,  94 ] . Monitoring differential miRNA expression might therefore be useful in the 
differential diagnosis of pancreatic cancer from other tumors. Expression of the miR-376 precursor 
was highest in the human pancreatic cancer cell line Panc-1, compared to other cell lines studied 
 [ 95,  96 ] . Large-scale miRNA profiling in 540 samples of solid tumors (breast, colon, lung, pancreas, 
prostate, and stomach) showed that the spectrum of miRNA expression varied in different solid 
tumors and was different from that of normal cells (43 of 137 miRNAs, 31%). miR-21, miR-191, 
and miR-17-5p were significantly overexpressed in all six tumor types, whereas miR-218-2 was 
consistently downregulated in colon, stomach, prostate, and pancreatic cancers, but not in lung and 
breast carcinomas. This observation indicated that colon, pancreas, prostate, and stomach have simi-
lar miRNA signatures, different from those of breast and lung cancer. Similarly, upregulation of 
miR-142-3p, miR-142-5p, miR-155, and miR-146a expressions was observed in human pancreatic 
neuroendocrine tumors (PNETs) as compared with normal human islets  [ 97 ] . Lee and colleagues 
reported the aberrant expression of one hundred miRNA precursors in pancreatic cancer or desmo-
plasia, including the miRNAs previously reported in other human cancers (miR-155, miR-21, miR-
221, and miR-222) as well as the first reported miR-376a and miR-301 for the differential expression 
of cancer  [ 98 ] . A significant upregulation of miR-196a, miR-190, miR-186, miR-221, miR-222, 
miR-200b, miR-15b, and miR-95 in most pancreatic cancer tissues and cell lines was reported. miR-
155 and miR-21 were significantly upregulated in 15 IPMNs vs. matched controls  [ 99 ] . The expres-
sion pattern of miR-155 in 53 of 64 (83%) IPMNs compared to 4 of 54 (7%) normal ducts only, and 
that of miR-21 in 52 of 64 (81%) IPMNs compared to 1 of 54 (2%) normal ducts, respectively. The 
expression of miR-216 has also shown to be specific to the pancreas  [ 100 ] . Let-7 miRNA was found 
expressed in pancreatic cancer cells but did not inhibit the epithelial–mesenchymal transition 
(EMT)  [ 101 ] . Therefore, miRNAs play vital roles not only in different kinds and stages of pancre-
atic tumors, but also in many diseases, including cancers, cardiovascular diseases, and immune 
disorders. Epigenetic modifications, DNA copy number changes and genetic mutations may regu-
late the expression of miRNAs. The conclusion of these data is that PDAC miRNAomes associated 
with normal and tumor tissues are different. Differences are tumor-specific and, in some cases, 
indicators of prognosis. These findings suggest that miRNA expression patterns constitute a signa-
ture of the disease which could offer new clues about pancreatic cancer occurrence and also provide 
new molecular markers that would improve diagnosis and orient the treatment. A very promising 
diagnostic strategy could arise from miRNAs if they are found in serum and can be detected by 
RT-PCR. In a remarkable study Lu and colleagues  [ 92 ] showed that expression data for 217 miR-
NAs only performed better at identifying cancer types than analysis of 16,000 mRNAs. They con-
cluded that miRNAs might help detecting cancer better than other strategies presently available 
because miRNAs are only several hundred, compared to tens of thousands for mRNAs and proteins. 
One single miRNA can modulate the expression of many genes rendering miRNAs powerful 
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molecules regulating several related pathways, each miRNA playing multiple but coherent roles in 
the cell. Also, miRNAs are shorter than mRNAs, and therefore more resistant to ribonuclease deg-
radation. miRNAs can remain intact in formalin-fixed, paraffin-embedded (FFPE) tissues or in 
serum. Pilot studies using endoscopic ultrasound-guided fine needle aspiration and FFPE specimen 
help evaluating the diagnostic value of candidate biomarker miRNAs. Finally, miRNA analysis 
requires no expensive and time-consuming detection strategies using antibodies or mass spectrom-
etry. Simple, extremely sensitive methods, such as PCR, in situ hybridization, or real-time PCR, are 
sufficient for their detection. A summary of up- and downregulated miRNAs in pancreas cancer 
tissue is presented in Table  5.2 . 
 miRNAS in the Molecular Mechanisms Associated with PDAC 
 Recent studies have shown deregulation of many miRNAs during pancreatic cancer and their associ-
ated targets as well as underlying molecular mechanisms now begin to be elucidated. 
 miR-34a: miR-34a expression was assessed in pancreatic cancer cells which frequently exhibit 
p53 loss of function. Two nontransformed pancreatic ductal epithelial cell lines and 15 pancreatic 
cancer cell lines were analyzed by northern blotting. miR-34a was highly expressed in nontrans-
formed pancreatic ductal epithelial cell lines, showing that this miRNA is normally expressed in this 
cell type. By comparison, all 15 pancreatic cancer cell lines presented at least a twofold reduction 
in miR-34a expression. Eleven of the 15 cell lines exhibited a tenfold reduction or complete absence 
 Table 5.2  MicroRNAs frequently misregulated 
in pancreatic cancers 
 Up  Down 
 miR-155  miR-375 
 miR-100  miR-345 
 miR-376a  miR-142-P 
 miR-125b-1  miR-139 
 miR-181a  miR-148a 
 miR-181c  miR-148b 
 miR-146a  miR-141 
 miR-196a  miR-96 
 miR-25  miR-29c 
 miR-214  miR-130b 
 miR-222  miR-216 
 miR-29b-2  miR-217 
 miR-128b  miR-107 
 miR-200  miR-34a 
 miR-95  Let-7 
 miR-15b  miR-218-2 
 miR-32 
 miR-30c 
 miR-21 
 miR-17-92 
 miR-191 
 miR221 
 miR190 
 miR186 
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of this miRNA. Although p53 loss is expected to reduce miR-34a expression, it could hardly account 
for the reduced miR-34a expression observed in all pancreatic cancer cell lines. In fact, there is no 
direct correlation between biallelic loss of p53 and the magnitude of miR-34a downregulation, and 
cell lines with wild-type p53 status also exhibit low levels of miR-34a. It is therefore likely that other 
mechanisms, in addition to p53 inactivation, contribute to the reduction in miR-34a abundance. In 
fact, miR-34a expression was absent from several types of tumors due to the aberrant CpG methyla-
tion of its promoter  [ 102 ] . Nineteen out of 24 primary prostate carcinomas displayed CpG methyla-
tion of the promoter sequence of the miR-34a gene, which resulted in the loss of its expression. CpG 
methylation of the miR-34a promoter was also detected in breast, lung, colon, kidney, bladder, pan-
creatic carcinoma cell lines, melanoma cell lines, and primary melanoma samples. After DNA dam-
age, silencing of miR-34a was dominant over its transactivation by p53. In summary, miR-34a plays 
an important role in modulation and fine-tuning of gene expression initiated by p53. Lack of tran-
scriptional transactivation by p53, deletion or CpG methylation should contribute to the decreased 
expression of miR-34a that acts as a tumor suppressor gene in pancreatic cancer. 
 miR-155: Another interesting study concerns the association between miR-155 and TP53INP1 
(Tumor Protein 53-Induced Nuclear Protein 1). miR-155 is known as oncogenic (oncomir) and it is 
overexpressed in pancreatic cancer as well as in other tumors. The stress-induced gene TP53INP1 
is downregulated in pancreatic cancer  [ 103 ] . This gene is transcriptionally induced by p53 and regu-
lates p53 activity  [ 104– 106 ] . TP53INP1 is also implicated in colorectal cancer since TP53INP1-
deficient mice show high susceptibility to colorectal cancer induction  [ 107 ] . Moreover, TP53INP1 
is downregulated in other tumors, such as breast and gastric cancer, and was proposed as a tumor 
suppressor gene  [ 108,  109 ] . In our laboratory, we have demonstrated that the TP53INP1 protein 
disappears at a precancerous step during PDAC development, whereas its mRNA expression per-
sists in tumors. In fact, we have shown that TP53INP1 loss is due to the activity of the oncogenic 
miR-155 which is overexpressed in pancreatic cancer cells. Finally, we identified the target site for 
miR-155 into the 3 ¢ UTR of TP53INP1 and confirmed its functionality in vitro and in vivo. These 
results are very exciting because TP53INP1 is the first miR-155 target gene with antitumoral activ-
ity which could account for the oncogenic potential of miR-155. 
 Let-7: Let-7 is downregulated in PDAC samples, as compared to adjacent tissue and its complete 
loss in poorly differentiated cancer samples. Overexpression of let-7 in pancreatic cancer-derived 
cell lines strongly inhibits cell proliferation, K-ras expression, and mitogen-activated protein kinase 
activation  [ 110 ] . 
 miR-21: miR-21 was found significantly upregulated in pancreatic cancer  [ 99,  111 ] and targets 
the phosphatase and tensin homologue 2 (PTEN), programmed cell death 4 (PDCD4), trophomyo-
sin 1 (TPM1), and tissue inhibitor of metalloproteinases 3 (TIMP3) leading to inhibition of apopto-
sis and therefore to an increased tumorogenicity  [ 112 ] . Overexpression of miR-21 precursor in 
pancreatic cancer cells showed increased proliferation, invasion, and chemoresistance to gemcit-
abine compared with control cells, and the reverse was observed when the mir-21 was knocked 
down in pancreatic cancer cells  [ 113 ] . 
 miR-17-92: The miR-17-92 cluster is upregulated in lymphomas and breast, lung, colon, stom-
ach, and pancreatic cancers. This miRNA cluster targets E2F1, BIM, and PTEN leading to increased 
proliferation of cancer cells  [ 100,  114,  115 ] . 
 miR-107: Ectopic expression of miR-107 in pancreatic cell lines MiaPACA-2 and Panc-1 results 
in decreased growth rate due to downregulation of cyclin-dependent kinase 6 by miR-107  [ 116 ] . 
 miRNA-200: Transcriptional suppression of miRNA-200 family members, such as miR-141 and 
miR-200c by zinc-finger E-box binding homeobox 1 (ZEB1)  [ 117 ] strongly activate epithelial differ-
entiation in pancreatic, colorectal, and breast cancer cells by targeting EMT activators, such as trans-
forming growth factor beta 2 and ZEB1. These results indicate that ZEB1 triggers miRNA-mediated 
stabilization of EMT and promotes the invasion of cancer cells. Questions regarding the association of 
miRNAs and their role in cancer development remain unresolved but it is suggested that a set of miR-
NAs might be associated with pancreatic tumorigenesis by acting as tumor suppressors or oncogenes. 
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 Targeting miRNA Expression in PDAC as a Potential Therapeutic Strategy 
 When miRNA overexpression is associated with PDAC progression, synthetic, chemically modified 
antisense oligonucleotides targeting mature miRNAs or their precursors might be considered for 
therapy. Several modifications of anti-miRNA oligonucleotide structure have been designed to sta-
bilize the molecules and protect them from degradation  [ 118 ] . They include 2 ¢ - O -methyl, 
2 ¢ - O -methoxyethyl, cholesterol conjugated (antagomirs) or locked nucleic acid (LNA) oligonucle-
otides. Recent publications illustrate the application of these inhibitors. Cheng and colleagues  [ 119 ] 
used a library of modified anti-miRNA oligonucleotides to successfully identify miRNAs involved 
in the control of cell growth and apoptosis in various cell lines. Chan and colleagues used 
2 ¢ - O -methyl and DNA/LNA-mixed oligonucleotides to specifically knock down an miRNA and 
demonstrate that its aberrant expression contributes to the malignant phenotype of glioblastoma 
cells  [ 120 ] . In a more recent publication, Krutzfeldt and colleagues have shown that antagomirs 
inhibit miRNA function in vivo  [ 121 ] . The authors observed that silencing this single miRNA 
results in an increased expression of several hundred genes, many of them containing in their 3 ¢ 
UTRs the corresponding miRNA recognition sequences. However, about 300 genes were down-
regulated in response to this antagomir. This led the authors to speculate that the mechanism related 
to such downregulation could reflect the suppression of a transcriptional repressor. This example 
illustrates the complexity of the miRNA regulation pathways. Furthermore, these works indicate 
that therapeutic adjustment of miRNA overexpression may become feasible but the precise mecha-
nisms by which modified oligonucleotides cause the depletion of targeted miRNAs remains 
unknown. Data presently available are not conclusive but provide some information. For example, 
when high levels of miRNA and anti-miRNA duplexes are present in the cell, degradation products 
of these duplexes can be detected  [ 121 ] . This observation is in agreement with previous works 
showing that gene-silencing mechanisms are triggered by short double-stranded RNA species 
(a process known as RNA interference). Thus, the simplest explanation for the effectiveness of the 
anti-miRNA is its hypothetical ability to bind and promote rapid degradation of the target miRNAs 
by nucleases normally present in the cells. Treatment of mice with anti-miRNA was shown to selec-
tively remove the targeted miRNA but not other miRNA species. Furthermore, another interesting 
observation is that antagomir injection leads to broad and sustained distribution (up to 23 days), 
allowing effective and long-lasting silencing of the targeted miRNA in most tissues. 
 Conversely, if the function of underexpressed miRNAs, due to deletion or loss of function, has 
to be restored, a therapeutic approach could involve exogenous delivery of corrective synthetic 
miRNAs. They could be delivered in the form of (siRNA-like) double-strand oligoRNAs, directly 
or via viral systems  [ 122 ] . One example was given by Takamizawa and colleagues, who showed that 
forced expression of let-7 inhibited in vitro the growth of the lung adenocarcinoma cell line A549 
 [ 123 ] . This holds the promise that constructs designed to promote the synthesis of mature miRNAs 
could be useful in cancer therapy. 
 Genetics of the Familial Pancreatic Adenocarcinoma 
 In addition to sporadic adenocarcinoma, an increased risk of pancreatic cancer has been demon-
strated among persons with a family history of pancreatic cancer. Coughlin and colleagues  [ 124 ] 
reported an increased risk of developing pancreatic cancer for individuals who reported a positive 
family history of pancreatic cancer at baseline, with an RR of 1.5 after adjusting for age. 
Furthermore, a population-based cohort study demonstrated that the risk of pancreatic cancer 
increased 1.72-fold for individuals with a parent who developed a pancreatic cancer. The risk was 
not elevated when a more distant relative had been diagnosed with pancreatic cancer. Thus, some 
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studies strongly support the hypothesis that familial aggregation and genetic susceptibility play an 
important role in the development of pancreatic cancer. However, the relative contributions of 
genetic risk factors and environmental risk factors to pancreatic cancer risk that cluster within the 
families (i.e., smoking) remain unclear (see below). 
 Discovering the genetic basis of inherited pancreatic cancer is an active area of research. In 2001, 
a multicenter linkage consortium, PACGENE, was established to conduct linkage studies aiming at 
localization and identification of pancreatic cancer susceptibility genes  [ 125 ] . Other groups have used 
linkage studies to suggest that the paladin gene ( PALD ) on chromosome 4q32 predisposes to pancre-
atic cancer  [ 126 ] ; however, this finding has not been validated in subsequent studies  [ 127– 131 ] . 
 The complex nature of pedigree data makes it difficult to accurately assess risk based upon the 
simple counting of the number of affected family members, as it does not account for family size, 
current age or age of onset of pancreatic cancer, and the exact relationship between affected family 
members. Computer-based, risk-assessment tools have been developed to integrate this complex 
risk factor and pedigree data into risk assessment. These models can provide more precise risk 
assessment than guidelines or models that rely on counts of affected family members, such as the 
Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (HNPCC) or myriad tables for 
hereditary breast and ovarian cancer. In April 2007, the first risk prediction tool for pancreatic can-
cer, PancPRO, was released  [ 132 ] . 
 Although the genetic basis for most instances of aggregation of pancreatic cancer in families is 
unknown, the genes responsible for a small portion of familial pancreatic cancer are known (see 
Fig.  5.1 ). Germ line mutations in the  BRCA2 ,  CDKN2A/p16 ,  STK11 , and  PRSS1 genes have all been 
shown to increase the risk of pancreatic cancer  [ 133– 136 ] . In addition, some studies have described 
pancreatic cancers developing among individuals with HNPCC; however, the association between 
HNPCC syndromes and pancreatic cancer is not as well defined as it is for some of the other syn-
dromes  [ 137,  138 ] . While most patients with sporadic and familial pancreatic cancer have classic 
infiltrating ductal (tubular) adenocarcinoma, some inherited syndromes are associated with a spe-
cific histologic type. Although rare, these cases provide a unique opportunity to correlate genetics 
with histology. For example, many pancreatic cancers that develop in patients with HNPCC syn-
drome have a medullary phenotype  [ 139– 141 ] and individuals with the Peutz-Jeghers syndrome 
appear to be predisposed to IPMNs  [ 59,  142,  143 ] . These associations between phenotype and geno-
type are important because tumor phenotype can be used to identify at-risk families. 
 Hereditary Breast and Ovarian Cancer Syndrome 
 Hereditary breast and ovarian cancer syndrome is an autosomal, dominantly inherited disease 
characterized by early-onset breast and/or ovarian cancers. Germ line mutations in  BRCA1 and 
 BRCA2 are responsible for the breast and ovarian cancer syndrome in most families  [ 144 ] . Point 
mutations account for most germ line  BRCA1 and  BRCA2 mutations in these families, but germ 
line deletions of these genes also occur  [ 145– 147 ] . Germ line  BRCA2 mutations have been clearly 
associated with an increased risk of pancreatic cancer. Analysis of a large series of  BRCA2 
mutation- positive families, ascertained for young age at onset of breast and/or ovarian cancer, 
demonstrated a 3.5-fold increased risk of pancreatic cancer in mutation carriers. Furthermore, the 
probability that a patient with pancreatic cancer has a germ line mutation in  BRCA2 increases as 
the number of family members with pancreatic cancer increases. To date, mutations in the  BRCA2 
genes are considered the most common known genetic mutations associated with pancreatic can-
cer. Germ line  BRCA2 mutations do not appear to be associated with a specific type of pancreatic 
cancer  [ 148 ] as most pancreatic cancers that develop in  BRCA2 carriers are traditional ductal 
adenocarcinomas. There are, however, significant clinical differences between BRCA2-deficient 
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and BRCA2-intact pancreatic cancers. The BRCA2 functions in the repair of DNA interstrand 
cross-links and double-strand breaks. Pancreatic cancer cells with mutations in the BRCA2 path-
way are hypersensitive to DNA-interstrand cross-linking agents, such as mitomycin C, cisplatin, 
chlorambucil, and melphalan  [ 149 ] , as well as to inhibitors of poly (ADP-ribose) polymerase  [ 150, 
 151 ] . Therefore, the  BRCA2 gene could be a potential target for a genotype-based anticancer 
therapy. Large studies of  BRCA1 mutation-positive families, ascertained for young age of onset of 
breast and/or ovarian cancers, suggest that  BRCA1 gene mutation carriers have a twofold increased 
risk of pancreatic cancer  [ 152,  153 ] .  BRCA1 gene mutations, however, appear to be substantially 
less common in families with pancreatic cancer without a significant breast cancer history  [ 154 ] 
so that the possibility that adenocarcinoma of the pancreas is an incidental finding in  BRCA1 muta-
tion carriers cannot be ruled out. 
 Peutz-Jeghers Syndrome 
 Peutz-Jeghers syndrome is an autosomal, dominantly inherited disease characterized by hamar-
tomatous polyps of the gastrointestinal tract and pigmented macules of the lips and buccal mucosa. 
A variety of cancers have been associated with Peutz-Jeghers syndrome, including gastrointestinal, 
gynecologic, lung, breast, and pancreatic cancer  [ 155– 158 ] . Inherited mutations in the  STK11/LKB1 
gene are responsible for most cases of Peutz-Jeghers syndrome, and as many as 80% of patients 
with Peutz-Jeghers syndrome have a germ line  STK11/LKB1 mutation. The hamartomatous polyps 
found in patients with Peutz-Jeghers syndrome most commonly occur in the small intestine; how-
ever, they can also involve the stomach, colon, and rectum. Patients with Peutz-Jeghers syndrome 
have a greater than 132-fold increased risk of developing pancreatic cancer  [ 133 ] . Interestingly, 
these cancers may progress through an IPMN precursor pathway. In addition,  STK11/LKB1 gene 
inactivation is more frequently seen in sporadic IPMNs than it is in conventional ductal adenocar-
cinoma  [ 142,  159 ] . The association of Peutz-Jeghers syndrome with IPMN precursor lesions has 
significant ramifications for screening because most IPMNs are detectable with currently available 
imaging technologies. 
 Hereditary Pancreatitis 
 Hereditary pancreatitis is a rare inherited form of chronic pancreatitis characterized by repeated 
attacks of acute pancreatitis, usually starting early in childhood, and leading to long-term exocrine 
and endocrine failure  [ 160 ] . It is now generally accepted that patients with chronic pancreatitis have 
a higher risk of developing adenocarcinoma of the pancreas  [ 135 ] , and more particularly if there is 
hereditary chronic pancreatitis  [ 161 ] . Chronic inflammation might cause DNA damage which accu-
mulates over time, as observed in PanINs. Several teams have described PanIN-like lesions in 
chronic pancreatitis tissue  [ 162,  163 ] . This could be highly significant for the well-known problem 
of the differential diagnosis between “tumor-like” chronic pancreatitis and cancer: despite the con-
tribution of endoscopic ultrasound, a definite diagnosis of adenocarcinoma is difficult to obtain. 
Furthermore, a negative specimen does not necessarily exclude a diagnosis of cancer in these 
patients  [ 164– 166 ] . The usefulness of searching for genetic anomalies in samples obtained from 
patients with chronic pancreatitis has already been explored: the search for the  KRAS oncogene 
mutation in tissue  [ 167 ] , serum  [ 168 ] , and endoscopic ultrasound-guided needle aspirations  [ 169 ] 
appears to be more useful than a search in pancreatic juice  [ 170,  171 ] . Nevertheless, there is no vali-
dated screening strategy to monitor patients with chronic pancreatitis. A better knowledge of the 
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genetic alterations and of the carcinogenesis of pancreatic tissue could be helpful in establishing 
earlier diagnosis of pancreatic cancer in these patients. Germ line mutations in the cationic trypsino-
gen gene ( PRSS1 ) have been associated with an autosomal dominant form of hereditary pancreatitis, 
while germ line mutations in the serine protease inhibitor gene ( SPINK1 ) have been associated with 
an autosomal recessive form of hereditary pancreatitis  [ 172 ] .  PRSS1 gene mutations in hereditary 
pancreatitis have been extensively studied. Multiple mutation sites have been identified, most of 
which cluster in the N-terminal half of the molecule encoded by exons 2 and 3. The most common 
mutations are R122H and N29I. Some  PRSS1 gene mutations appear to increase the stability of 
trypsin by eliminating a trypsin autodegradation site while other PRSS1 gene mutations appear to 
enhance trypsinogen autoactivation, both of which eventually result in chronic pancreatitis  [ 173–
 176 ] . Klöppel and colleagues  [ 177,  178 ] have carefully examined pancreatic specimens from 
patients with hereditary pancreatitis and they made the hypothesis that hereditary pancreatitis begins 
with necrosis of the duct-lining cells and periductal tissue, and gradually progresses to dilation of 
the involved ducts, periductal fibrosis, and in advanced cases, intralobular fibrosis. 
 Microscopically, in the early stages, the involved ducts are characterized by epithelial injury and/
or necrosis and inflammatory cell infiltration. Periductal fibrosis is more prominent than intralobu-
lar fibrosis and the pancreatic parenchyma away from the involved ducts is relatively well pre-
served. In the advanced stages of hereditary pancreatitis, there is extensive periductal as well as 
intralobular fibrosis, and the lobular parenchyma is eventually completely replaced by sclerotic tis-
sue containing metaplastic acini and aggregates of islets of Langerhans. The ducts can be dilated or 
very irregular in shape, and some ducts contain protein plugs and calculi. Individuals with heredi-
tary pancreatitis have an approximately 53-fold increased risk for pancreatic cancer after the age of 
50 years compared with the general population. Cumulative rates of pancreatic adenocarcinoma in 
patients with hereditary pancreatitis reach 30–40% by the age of 70 years  [ 179,  180 ] . Smoking, 
early onset of pancreatitis, and diabetes mellitus are associated risk factors for the development of 
pancreatic cancer in these patients  [ 161 ] and smokers tend to develop disease 20 years before non-
smokers  [ 180 ] . No specific histopathologic phenotype of pancreatic cancer has been associated with 
hereditary pancreatitis. Instead, most patients have a classic tubular type of infiltrating ductal 
adenocarcinoma. 
 Hereditary Nonpolyposis Colorectal Cancer Syndrome 
 Hereditary nonpolyposis colorectal cancer syndrome (HNPCC) is an autosomal dominant heredi-
tary disease characterized by early onset of colon cancer with a predilection for the right colon 
 [ 181 ] . Patients with HNPCC have germ line mutations in genes coding for proteins associated with 
DNA mismatch repair. These genes include  hMSH2 ,  hMLH1 ,  hPMS1 ,  hPMS2 , and  hMSH6/GTBP . 
Adenocarcinomas of the colon in patients with HNPCC show microsatellite instability (MSI+) and 
a distinct medullary histopathology. In addition, patients with HNPCC are at increased risk for a 
spectrum of extracolonic neoplasms, including carcinomas of the endometrium, ovary, stomach, 
bile duct, kidney, bladder, ureter, and skin  [ 181 ] . While some studies have suggested individuals 
with HNPCC may also have an increased risk for pancreatic cancer  [ 138,  182 ] , additional studies 
are needed to accurately quantify this risk. Lynch and colleagues  [ 182 ] first reported pancreatic 
carcinoma in kindreds with HNPCC. Further evidence linking HNPCC and pancreatic cancer comes 
from a study of medullary carcinomas of the pancreas by Wilentz and colleagues  [ 139 ] . The pan-
creatic cancers that arise in patients with HNPCC often have a distinctive medullary appearance. 
Medullary carcinoma of the pancreas is a rare variant of pancreatic adenocarcinoma. As with med-
ullary carcinoma of the colon, it is associated with a better prognosis than conventional ductal 
adenocarcinoma  [ 138,  139 ] . The morphology of pancreatic medullary carcinoma is very similar to 
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that of medullary carcinoma of the colon. Unlike conventional ductal adenocarcinoma of the 
 pancreas, most medullary carcinomas do not harbor  KRAS2 gene mutations. Instead, medullary 
carcinomas of the pancreas often harbor  BRAF gene mutations and are MSI+  [ 139,  141,  183 ] . 
As one would expect in a neoplasm with genetic inactivation of a DNA mismatch repair gene, med-
ullary carcinomas of the pancreas often show loss of expression of one of the DNA mismatch repair 
proteins (Mlh1 and Msh2) as recently reported for a patient with HNPCC due to a mutation of the 
hMSH2 mismatch repair gene  [ 140 ] . The presence of medullary phenotype in a pancreatic cancer 
may suggest inherited susceptibility to HNPCC. 
 Familial Atypical Multiple Mole Melanoma 
 Familial atypical multiple mole melanoma (FAMMM) is an autosomal dominant inherited syn-
drome with incomplete penetrance. It is characterized by greater than normal numbers of melano-
cytic nevi, multiple atypical melanocytic nevi, and an increased risk of cutaneous malignant 
melanoma  [ 184,  185 ] . Germ line mutations in the  CDKN2A/p16 gene are responsible for a portion 
of FAMMM cases  [ 134,  185,  186 ] . A variety of cancers, other than melanoma, have been docu-
mented in kindreds with familial melanoma, including carcinoma of the lung, pancreas, and breast 
as well as sarcoma. A subset of FAMMMs is associated with pancreatic cancer. Kindreds with 
FAMMM have a 13- to 22-fold increased risk for pancreatic cancer  [ 187 ] and the risk for pancreatic 
cancer among mutation carriers is 38-fold higher than that of the general population. Lynch and 
colleagues  [ 188 ] studied 159 families with familial pancreatic carcinoma and identified 19 families 
with FAMMM. DNA testing revealed a germ line  CDKN2A/p16 gene mutation in every case. 
 Familial Adenomatous Polyposis 
 Familial adenomatous polyposis (FAP) is an autosomal, dominantly inherited disorder characterized 
by the development of hundreds to thousands of colonic adenomatous polyps at an early age. Some 
of the adenomas can progress to invasive adenocarcinoma, and, if untreated, invasive adenocarci-
noma of the colon will develop in almost all patients by the age of 40 years  [ 181 ] . Germ line muta-
tions in adenomatous polyposis coli ( APC ) gene, a tumor suppressor gene, are responsible for the 
development of FAP  [ 189,  190 ] . Patients with FAP are at increased risk for other neoplasms, includ-
ing thyroid tumors, gastric, duodenal, and ampullary adenocarcinoma. Although the association of 
pancreatic cancer and FAP is not as strong as the association of FAP with other cancer types, several 
lines of evidence suggest that patients with FAP are also at increased risk for the development of 
pancreatic neoplasms. Pancreatic adenocarinoma has been described in individuals with germ line 
 APC gene mutations, and patients with FAP may have a fourfold increase in risk for pancreatic 
adenocarcinoma  [ 191 ] . Furthermore, in a report of a patient with FAP and an IPMN with high-grade 
dysplasia, it was noted that the IPMN showed biallelic inactivation of the  APC gene, a fact that 
supports the genetic link between FAP and IPMN for this patient  [ 192 ] . In addition to the associa-
tion of FAP with pancreatic adenocarcinoma, Abraham and colleagues  [ 137 ] reported a rare pancre-
atic neoplasm, pancreatoblastoma, arising in a patient with FAP. Pancreatoblastoma is a malignant 
epithelial neoplasm with acinar differentiation and squamoid nests. In contrast to conventional duc-
tal adenocarcinoma of the pancreas, both sporadic and FAP-associated pancreatoblastomas lack 
KRAS2 and TP53 gene mutations. Instead, most cases harbor alterations in the APC/beta-catenin 
pathway  [ 137 ] . 
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 Germ line DNA Mutations that Increase Susceptibility 
to Develop Pancreatic Adenocarcinoma 
 Most pancreatic cancers are sporadic. In sporadic forms, association with polymorphic somatic 
mutations, spontaneous or generated by environmental factors is of paramount importance. It is well 
known that sporadic forms of cancers result from the accumulation of genetic modifications or 
mutations (see above). Besides particular syndromes whose association with pancreatic cancer is 
well known, a lot of work remains to identify genetic variations associated with cancer predisposi-
tion. Recent advances in large-scale genotyping (SNP chips) increased considerably the number of 
markers that can be simultaneously genotyped. As a consequence, haplotype blocks can be deter-
mined much more precisely than with microsatellite markers. These methodologies allowed recent 
studies of associations covering all intragenic regions of the whole human genome, these studies 
being called “genome wide association studies” (GWAS). Several GWAS led to the identification 
of susceptibility markers of several types of cancers (review in New England Journal of Medicine 
in 2010)  [ 193 ] . More than 700 GWAS are presently registered ( http://gwas.nih.gov/index.html ) 
 [ 194 ] ; among them, only four concern pancreatic cancer  [ 195– 198 ] . 
 Two GWAS for pancreatic cancer  [ 196,  197 ] , have been conducted within the framework of the 
“Pancreatic Cancer Cohort Consortium,” or PCCC, an international consortium comprising Centers 
from Europe, China, and North America. In these studies, 12 cohorts representing more than 3,800 
cases of cancer and 3,900 controls allowed detection of four new genes associated with pancreatic 
cancer. The first locus, harboring several SNPs strongly associated with cancer occurrence, was 
localized on chromosome 9q34 and contains the first intron of the  ABO gene. That gene encodes 
the glycosyl-transferase which catalyzes the transfer of sugars to antigen H (Histo-blood group 
ABO system transferase). By this mechanism, antigen H becomes antigen A or B, depending on the 
nature of the sugar transferred by the ABO enzyme. In individuals from group O, the gene is 
mutated and generates a nonfunctional protein. Association of the ABO gene with pancreatic cancer 
has already been suggested 50 years ago in studies showing a higher frequency of pancreatic or 
gastric cancer in individuals from groups A, B, or AB than from group O  [ 199,  200 ] . That gene is 
also found altered in primary tumors and metastases of pancreatic cancer  [ 201 ] . More recently, the 
PCCC added three other regions strongly associated with cancer  [ 196 ] . The first one is an intergenic 
region of 600 kb in chromosome 13q22.1, located between genes  KLF5 and  KLF12 . These two 
members of the Kruppel transcription factor family are involved in regulating cell growth and trans-
formation  [ 202,  203 ] . The same region has already been found deleted in other cancers  [ 204,  205 ] , 
or associated with an increase in breast cancer susceptibility in families at risk for that cancer 
because of high incidence in relatives but negative for  BRCA1 and  BRCA2 mutations  [ 206 ] . The 
second region is located on 1q32.1. That region harbors gene nuclear receptor subfamily 5 group A 
member 2 ( NR5A2 ), at 91 kb upstream of the gene. The receptor encoded by gene  NR5A2 is present, 
in adults, in the exocrine pancreas, liver, gut, and ovaries. Its function is not completely understood. 
In liver, it would be a key regulator of CYP7A, an enzyme involved in the homeostasis of choles-
terol and bile salts, and in steroidogenesis (reviewed in Frontier Bioscience in 2008)  [ 207 ] . Also, 
HBV could use it to enhance the expression of its genome  [ 208 ] . In the pancreas, NR5A2 would 
contribute to the regulation of the expression of several genes  [ 209 ] . Finally, the importance of 
NR5A2 in embryogenesis was demonstrated in mice by showing that its knock-out results in embry-
onic lethality  [ 210 ] . The last locus identified by this consortium is localized at 5p15.33. SNP mark-
ers that border this locus are within intron 13 of the  CLPTM1L gene (cleft lip and palate 
transmembrane 1-like).  CLPTM1L is poorly described. It is overexpressed in cell lines resistant to 
cisplatin and could play a role in apoptosis  [ 211 ] . In the same locus rs401681 and only distant by 
23 kb is located the TERT gene, which encodes the catalytic subunit of telomerase, an enzyme 
required to maintain the telomeres with a correct size. TERT activity is almost undetectable in normal 
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cells but is increased in 90% of cancers  [ 212 ] . However, a more recent study has shown that association 
of that marker (i.e., C–T shift at locus rs401681) with the increase risk of cancer occurrence is not 
due to a decrease in TERT activity  [ 213 ] . 
 One of the critical factors in the interpretation of GWAS is the ethnicity of the studied group. 
PCCC studies mentioned above have been conducted on Caucasian populations and do not neces-
sarily reflect risk factors for other ethnic groups. In fact, a GWAS conducted by Biobank Japan (BJJ) 
has evidenced a different set of markers of pancreatic cancer  [ 195 ] . Among loci strongly associated 
with the disease, three are specific to the Japanese population. The first one, in 6p25.3, is a 75 bp 
linkage disequilibrium block containing the  FOXQ1 gene (Forkhead-box (Fox) Q1), one of the 43 
members of the Fox transcription factor family.  FOXQ1 had already been associated with pancreatic 
cancer  [ 214 ] and colorectal cancer  [ 215 ] . Finding this new marker 25 kb upstream from the begin-
ning of the  FOXQ1 gene suggests a change in its promoter region that could alter its expression 
 [ 195 ] . The second SNP showing significant association is located within gene Bicaudal-D homolog 
1 (BICD1 ). The BICD1 protein is involved in vacuolar trafficking and associated with a shortening 
of telomeres  [ 216 ] . Telomere shortening has been associated with pancreatic cancer  [ 37,  217,  218 ] , 
which makes BICD1 an excellent candidate to explain these findings. The last locus with a high 
odds ratio (OR = 3.73) corresponds to several SNPs that fall in the first intron of the  DPP6 gene. 
That gene encodes dipeptidyl-peptidase 6, a member of the DPP family devoid of the catalytic resi-
dues required for enzymatic activity but which acts through protein–protein interactions. The major 
activity known for that protein is the modulation of the activity of voltage- dependent potassium 
KCND2 channels in the CNS (reviewed by the Federation of European Biochemical Societies 
Journal in 2010)  [ 219 ] . However, that gene also appears in one of the 12 pathways and metabolic 
processes identified by Jones et al.  [ 66 ] In this study, DPP6, which is involved in the regulation of 
tumor invasion, shows somatic mutations in 3 of 24 pancreatic cancers. 
 The enormous wealth of information generated by the successive GWAS and by the other high-
throughput studies provides the first opportunity to study at the genomic scale the genetic anomalies 
associated with pancreatic cancer. Their contribution to the understanding of cancer genetics, to risk 
prediction, and to the monitoring of cancer evolution opens-up new ways toward individualized 
treatments and, hopefully, cancer prevention. The major challenges of GWAS lie mostly in the 
management of studies, toward a standardization of results allowing easier interpretation of results. 
Analyses will have to take into account disease heterogeneity and ethnic factors (effect of stratifica-
tion of probation) and the complex interactions between multiple genetic and environmental factors. 
Another limiting factor of GWAS is cost. There is a correlation between the number of samples 
required to establish an association and the degree of penetrance of a gene or the frequency of 
involved alleles  [ 193 ] . For instance, to detect with a reasonable statistical significance a single locus 
with a moderate risk (odds ratio between 1.5 and 5), at least 1,000 cases and 1,000 controls are 
required. If the risk is lower (OR < 1.3), 10 times more cases and controls will be necessary, which 
requires multicenter international collaborations. 
 Two studies have extended the results obtained by analyzing tumor exome, including a study com-
paring the exomes of the primary tumor and corresponding metastases  [ 220,  221 ] . In the first one, 
Yachida and colleagues  [ 220 ] gathered data on the exomes of seven tumors previously characterized 
by Jones and colleagues  [ 66 ] and compared them to data on the exomes of the corresponding metas-
tases. The second study was conducted on 13 tumors and corresponding metastases  [ 221 ] . Information 
produced by these studies allowed to fill in a high resolution framework of the various modifications 
and rearrangements that occur in the DNA of metastases, of the various underlying mechanisms, on 
the genes potentially involved in the metastatic process and finally on the time between the appearance 
of the cancerous cell and the occurrence of a clone with a metastatic profile. 
 Genomic instability is apparently the main characteristic of pancreatic cancer  [ 221 ] . DNA 
sequencing in tumors and in cells at different stages of progression toward metastases revealed that 
the major chromosomal rearrangement is a duplication of fragments and their insertion in opposite 
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directions, a phenomenon called “fold-back inversions” by the authors. The origin of fold-back 
inversions is not known. A possible hypothesis is that early in tumor progression telomerase activity 
is altered or inhibited  [ 42 ] generating a progressive shortening of telomeres and successive cycles 
of breaking and abnormal fusion of chromatides by a mechanism called “breakage-fusion-bridge” 
 [ 222 ] . These rearrangements will determine the gain or loss of DNA and, as consequence, genomic 
instability. Interestingly, these results suggest that fold-back inversions arise early in tumor evolution 
and would trigger progression toward metastasis  [ 221 ] . These results have shown unequivocally, for 
 Fig. 5.2  Development of the pancreatic cancer. Development of sporadic pancreas cancer results from the combination 
of a genetic background of susceptibility, which remain largely to be characterized, with the protumoral environmental 
factors. In the familial forms of pancreas cancer, mutations on specific genes are responsible for the accumulation of 
genetics alteration. The role of the environmental factors is not clearly demonstrated in these forms of pancreas can-
cer. Accumulation of genetic alterations results in direct cancer development or, more probably, through development 
of the precancerous lesions PanIN and/or IPMN. At  left , an estimated pancreatic cancer timescale associated with 
tumor progression. The  successive arrows represent the estimated times from a healthy asymptomatic state to tumor 
initiation, acquisition of metastatic capabilities, and to the production of metastasis and the patient death. Therapeutic 
window: Period of more than 10 years from the birth of the founding cell of the parental, nonmetastatic, subclone, 
and the acquisition for one of the subclones of the metastatic profile 
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the first time, that the pancreatic tumor evolves from a first (parental) clone which generates 
progressively other subclones. Each subclone evolves independently by accumulating specific 
genetic modifications and, possibly, a tissue-specific metastatic affinity profile. Establishment of a 
phylogenetic correlation between genomic alterations of tumors and their metastases allowed draw-
ing a kinetic of tumor progression  [ 220 ] . Unexpectedly, the mean time between arising of the found-
ing cell and the occurrence of the first parent clone (nonmetastasis) is 11.8 years. Another 6.8 years 
will be required for one of the subclones to acquire the metastatic profile, which occurs about 
3 years before the patient dies. These findings, if confirmed, have major clinical consequences. 
They show that, if early detection of pancreatic cancer is possible, there is a large window of about 
10 years for therapeutic intervention. A diagram summarizing these data is represented in Fig.  5.2 . 
 Summary and Perspectives 
 The advent of genomic analysis, at both levels of gene expression and alternative splicing, as well 
as the increased in knowledge of the DNA structure with the detection of millions of SNPs and 
CNVs, or more recently, with the sequencing of the entire genome of coding regions using second 
generation sequencing techniques led us to rethink how the pathophysiology of pancreatic cancer 
must be analyzed and interpreted. 
 However, a really profitable use of all these genomic data still requires to standardize the differ-
ent types of protocols and platforms and to build consensus in quality control and methods to vali-
date the results. The interpretation of studies has been complicated by the lack of standards used for 
publications, the absence of a single gene annotation, and a delay in consolidation analysis. 
Furthermore, there is no fully established functional network allowing meta-analysis of high-
throughput data that can be considered to date as a “golden standard” and, as consequence, a lot of 
work remains to better characterize the affected pathways in pancreatic cancer. 
 In fact, obtaining a critical mass of data easily connected, followed by the optimization and 
standardization in the use and interpretation of data from the powerful informatics tools, and finally, 
the validation of their clinical interest using standardized protocols, will eventually give us powerful 
tools for diagnosis, prognosis, and personalized treatment of this terrible cancer. 
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 Introduction 
 Lung cancer is the primary cause of cancer mortality in developed countries. In the majority of 
cases, lung cancer is metastatic at the time of diagnosis. Although low-dose spiral computed tomog-
raphy (CT) has proven to be effective in the early detection of lung cancer, providing higher resect-
ability and higher long-term survival rates, the capacity of annual CT screening to reduce lung 
cancer mortality in heavy smokers has yet to be demonstrated. Numerous ongoing large-scale ran-
domized trials are under way in high-risk individuals, with different study designs. The initial 
results should be available in the next 2 years  [ 1 ] . Biomarker research in CT screening trials, com-
bining noninvasive genomic and proteomic analyses, could lead to a significant improvement in 
early detection, offering a potential contribution to diagnostic algorithms, assessment of individual 
risk, and management of CT-detected cancers  [ 1 ] . Surgical resection for early (stage I–II) non-small 
cell lung cancer (NSCLC) remains the only reliable treatment for cure. Patients with early disease 
who do not undergo surgery have a median survival of less than 1 year, while those who undergo 
appropriate surgery have a median survival of more than 4 years. A decision not to undergo surgery 
by patients with newly diagnosed early NSCLC has been associated with perceptions of communi-
cation and prognosis, older age, multiple comorbidities, and black race  [ 2 ] . Even in patients without 
lymph node involvement, tumor cells were found in bone marrow of 54% of the patients  [ 3 ] . 
MicroRNAs (miRNAs) are present in human plasma in a remarkably stable form that is protected 
from endogenous RNase activity. miRNAs could be an ideal class of blood-based biomarkers for 
cancer detection  [ 4 ] . Serum levels of four miRNAs (miR-486, miR-30d, miR-1, and miR-499) were 
significantly associated with survival in stage I–IIIA NSCLC patients who were resected and 
received adjuvant chemotherapy  [ 5 ] . Although intense efforts have been dedicated to the develop-
ment of useful biomarkers, many have not been established for diagnosis or decision-making in lung 
cancer. Blood-based biomarkers could have a great advantage because only a small tumor specimen 
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can be obtained by usual diagnostic modalities, such as fine-needle aspiration and transbronchial 
biopsy. Circulating tumor cell (CTC) count (using the CellSearch System, Veridex) was signifi-
cantly higher in NSCLC patients than in nonmalignant patients  [ 6 ] . However, the CTC test showed 
a moderate diagnostic performance. The CTC test has been approved by the US Food and Drug 
Administration (FDA) for monitoring of blood from metastatic breast and colon cancer patients  [ 6 ] . 
A microfluidic platform for detecting CTCs has also been developed, and CTCs were detected in 
all blood samples taken from NSCLC patients, permitting the identification of EGFR mutations in 
92% of the cases  [ 7 ] . Genomic assays for the prediction of clinical outcome are being used in breast 
cancer, including MammaPrint, and a 21-gene recurrence score (Oncotype DX)  [ 8 ] . 
 Prognosis in Early NSCLC: The Role of Gene Signatures 
 A recent meta-analysis based on individual data based on 11,107 resected NSCLC patients showed 
that the survival benefit of adjuvant chemotherapy was 4% at 5 years and the survival benefit of 
adjuvant chemotherapy plus radiotherapy was 5% at 5 years  [ 9 ] . Two new adjuvant chemotherapy 
trials with paclitaxel plus carboplatin have shown a trend toward improved survival in early NSCLC 
 [ 10,  11 ] . However, the benefit of adjuvant treatment remains suboptimal. In early resected NSCLC, 
there are three main issues to be resolved. Firstly, we must be able to distinguish two groups of 
patients: those who will not relapse (low-risk patients) – and who can thus be spared adjuvant treat-
ment – and those who will (high-risk patients). Secondly, we must personalize adjuvant treatment 
in the group of high-risk patients, since a majority of these patients will be resistant to cisplatin-
based chemotherapy or postoperative radiotherapy. Finally, we must predict the pattern of metasta-
ses, since this can help design-specific targeted treatments. In breast cancer patients, gene signatures 
predicting lung  [ 12 ] , bone  [ 13 ] or brain  [ 14 ] metastases have been reported. The gene expression 
analyses for predicting brain metastases include the cyclooxygenase (COX2), the epidermal growth 
factor receptor (EGFR) ligand HBEGF, and the  a 2,6-sialyltransferase ST6GALNAC5  [ 14 ] . A novel 
strategy will be the use of PCR-based quantitative analysis for personalized tumor monitoring of 
plasma samples. An almost universal feature of cancer is the widespread rearrangement of chromo-
somes as a result of chromosome instability. The consequences of chromosomal instability include 
copy number alterations (duplications, amplifications, deletions), inversions, insertions, and trans-
locations. Tumor-specific chromosomal rearrangements could be used as biomarkers for monitoring 
tumor response and detecting residual disease after surgery. A method called personalized analysis 
of rearranged ends can identify translocations in solid tumors. PCR with primers spanning the 
breakpoints was able to detect mutant DNA molecules present at levels lower than 0.001% and 
identified mutated circulating DNA in patient plasma samples  [ 15 ] . 
 A retrospective analysis of 787 patients, mainly early-stage NSCLC, performed at Duke 
University, identified low- and high-risk patients. In patients younger than 70 years, high-risk 
patients (with the shortest recurrence-free survival) had increased activation of the Src and tumor 
necrosis factor pathways compared to low-risk patients. High-risk patients older than 70 years dem-
onstrated increased activation of the wound healing and invasiveness pathways compared to low-
risk patients. In women, high-risk patients demonstrated increased activation of the invasiveness and 
STAT3 pathways, while high-risk men demonstrated increased activation of the STAT3, tumor 
necrosis factor, EGFR, and wound healing pathways  [ 16 ] . 
 Tumor growth encompasses many aspects of normal wound healing, and a wound response (WR) 
gene expression signature is reactivated in many types of human cancers, including breast and lung 
 [ 17 ] . The WR signature is composed of 512 genes that define the transcriptional response of fibro-
blasts to serum, the soluble fraction of clotted blood. In early breast cancer and lung adenocarcinoma, 
the WR signature provides prognostic risk stratification of metastasis development (Fig.  6.1 )  [ 17 ] . 
836 Diagnostic, Prognostic, and Therapeutic Value of Gene Signatures in Non-Small Cell Lung Cancer
 Several gene expression signatures, generally containing nonoverlapping genes, provide similar 
predictive information on clinical outcome, and a model combining several signatures did not per-
form better than did each of the signatures separately. These signatures may be largely different 
from one another as regards gene identity, but they occupy overlapping prognostic space  [ 8,  18 ] . 
The invasiveness gene signature (IGS), containing 186 genes, is prognostic not only in breast, but 
also in other tumors, including lung  [ 19 ] . The IGS includes genes involved in the nuclear factor- k B 
pathway, the RAS-mitogen-activated protein kinase pathway, and epigenetic control of gene expres-
sion  [ 19 ] . Of the 186 genes in the IGS, only six overlap with the WR signature  [ 19 ] . 
 Fig. 6.1  The wound response signature integrates 512 genes and is also defined as the fibroblast core serum 
response. Kaplan–Meier survival curves are shown for early breast, lung, and gastric cancer according to the activa-
tion of the wound response signature  [ 17 ] 
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 Gene Expression Signatures and Recurrence-Free Survival in Early NSCLC 
 Among completely resected NSCLC patients, 40% of stage I, 66% of stage II, and 75% of stage 
IIIA patients die within 5 years of resection  [ 20 ] , mainly due to the development of distant metas-
tases. In some clinical trials, the benefit of adjuvant chemotherapy has been negligible in stage IB 
 [ 21,  22 ] , although a recent meta-analysis has identified a moderate benefit  [ 23 ] . Although at present 
there are no reliable clinical predictors of relapse after surgery in early-stage NSCLC, transcrip-
tional analysis of primary tumors has identified gene expression profiles strongly related to disease 
recurrence in adenocarcinoma  [ 24– 30 ] and, to a lesser extent, in squamous cell carcinoma (SCC) 
 [ 27– 30 ] . The lung metagene model is a gene expression profile that predicts recurrence in early 
NSCLC (including stage IA) with an overall accuracy of 72%  [ 30 ] . A meta-analysis  [ 29 ] of data 
sets from seven microarray studies  [ 24,  26,  31,  32 ] identified a 64-gene-expression signature that 
predicted survival with 85% accuracy. However, the use of these gene signatures has not been 
implemented due to practical difficulties. Importantly, the simultaneous coactivation of two genes 
(TTF1 and NKX2–8)  [ 33 ] provides the same prognostic information of short recurrence-free sur-
vival in stage I patients, similar to the metagene model  [ 30 ] , the 64-gene-expression signature  [ 29 ] , 
and the 50-gene signature (Fig.  6.2 )  [ 26 ] . The coupled overexpression of TTF1 and NKX2–8 is 
associated with resistance to cisplatin, taxanes, gemcitabine, and vinorelbine but is positively 
correlated with response to pemetrexed  [ 33 ] . However, the majority of predictive models are 
hampered by the difficulty of reproducing them. A recent example demonstrated the lack of value 
of the lung metagene model  [ 30 ,  101 ] . 
 The quantitative PCR (QPCR) assay is convenient in terms of laboratory work-load and appli-
cable for large-scale routine use, making it a viable alternative to more complex microarrays. QPCR 
also allows for accurate and reproducible RNA quantification. The expression pattern of eight genes 
determined by QPCR correlated with survival in lung adenocarcinoma  [ 34 ] . Similarly, QPCR-based 
three-  [ 35 ] , four-  [ 36 ] , and five-  [ 37 ] gene signatures and a five-miRNA signature  [ 38 ] correlated 
with metastasis-free survival and overall survival in early NSCLC. A three-gene prognostic model 
 [ 39 ] includes a key gene, hypoxia-inducible factor 1 a (HIF1 a ). The construction of the small gene 
signatures developed with QPCR is based on the prognostic value of each gene as determined in a 
multivariate analysis. Each gene that is significant according to the multivariate analysis is then 
included in a risk score model, generated by adding the  z -scores of the expression levels of each 
of the genes multiplied by its corresponding coefficient. The risk score is used to classify patients 
into high or low risk of metastasis and death  [ 37 ] . The five-gene signature  [ 37 ] comprises dual- 
specificity phosphatase 6 (DUSP6), monocyte-to-macrophage differentiation-associated protein 
(MMD), signal transducer and activator of transcription 1 (STAT1), HER3/neu receptor tyrosine 
kinase (ERBB3), and lymphocyte-specific protein tyrosine kinase (LCK). 
 Intriguingly, special AT-rich binding protein 1 (SATB1), originally identified as a protein that 
recognized double-stranded DNA with a high degree of base-unpairing  [ 40 ] , is a genome organizer 
that upregulates metastasis-associated genes, including genes involved in EGF signaling, such as 
ERBB1, ERBB2, ERBB3, and ERBB4  [ 41 ] . In addition, SATB1 upregulates multiple other genes 
that stimulate invasion and mediate angiogenesis and bone metastasis, such as connective tissue 
growth factor. SATB1 nuclear staining significantly correlates with survival in 985 patients with 
ductal breast carcinoma stratified by SATB1 expression level  [ 41 ] . Importantly, since SATB1 tethers 
multiple genomic loci and regulates chromatin structure and gene expression  [ 42 ] , the analysis of 
SATB1 mRNA or protein expression could provide important prognostic information that merits 
testing in NSCLC in the clinical setting. Fibronectin is also upregulated by SATB1  [ 41 ] and has 
been identified in a six-gene expression signature that predicted survival in diffuse large-B-cell 
lymphoma  [ 43 ] . Fibronectin, an extracellular matrix glycoprotein, is highly expressed in tobacco-
related lung disease and stimulates lung cancer growth  [ 44 ] . In our experience, median survival of 
resected SCC patients with low levels of fibronectin mRNA was not reached while it was 31 months 
for those with high levels ( P = 0.002)  [ 35 ] . 
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 miRNAs are attractive candidates as upstream regulators of metastatic progression because miRNAs 
can posttranscriptionally regulate entire sets of genes. Quantitative stem-loop PCR of five miRNAs 
showed that patients with high-risk scores in their miRNA signatures had poor overall and disease-
free survival compared to patients with low-risk scores  [ 38 ] . The five-miRNA signature includes 
two protective miRNAs (let-7a and miR-221) and three miRNAs indicative of poor survival (miR-
137, miR-372, and miR-182)  [ 38 ] . Interestingly, miR-335 regulates a set of metastasis genes and 
has been shown to predict bone and lung metastases in breast cancer  [ 45 ] . 
 The WR signature predicts survival in several tumors, including NSCLC (Fig.  6.1 )  [ 17 ] . It is 
important to know that the coordinate amplification of CSN5 (also known as JAB1 or COPS5, resid-
ing on 8q13) and MYC (8q24) regulate WR signature activation in breast cancer. Coexpression of 
CSN5 with MYC is sufficient to induce the WR signature  [ 46 ] . A high expression level of both 
CSN5 and MYC was a significant predictor of poor patient survival in breast tumors, with efficacy 
equivalent to that observed for the WR signature  [ 46 ] . 
 The induction of a proteasome signature was associated with an activated WR signature. 
MCF10A cells with the activated WR signature were more susceptible to death by drugs that inhibit 
 Fig. 6.2  Kaplan–Meier survival curves for early resected NSCLC according to different gene signatures: ( a ) 64 
genes  [ 29 ] ( b ) 50 genes  [ 26 ] ( c ) the two-gene signature of TTF1 and NKX2-8  [ 33 ] and ( d ) the metagene signature 
 [ 30 ,  101 ] . (Fig.  6.2 c reprinted with permission, Copyright 2009 National Academy of Sciences, USA); (Fig.  6.2 d 
reprinted with permission, Copyright Massachusetts Medical Society 2006) 
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the ubiquitin–proteasome pathway. MCF10A cells expressing MYC or MYC plus CSN5 induced the 
proteasome signature  [ 47 ] . CSN5 encodes the catalytic subunit of the COP9 signalosome, a protein 
complex that regulates cell proliferation, response to extracellular stimuli, cell migration, and DNA 
damage checkpoints. The main function of COP9 is to maintain the activity of the multisubunit ubiq-
uitin ligase SCF (SKP1, CUL1, and F-box). CNS5 enhances the cotranscriptional ubiquitination of 
MYC that activates the transcriptional activity of MYC on a set of target genes promoting cell prolif-
eration, invasion, and angiogenesis. Monomeric CSN5 protein can bind to and modulate the activity 
of multiple transcription factors and signaling proteins, including interactions with HIF1- a , leading to 
HIF-1 a protein stabilization and increased angiogenic activity  [ 48 ] . F-box and WD repeat domain-
containing 7 (FBW7, also known as FBXW7, CDC4, AGO, and SEL10) is a component of SCF 
ubiquitin ligases. FBW7 mediates the ubiquitin-dependent proteolysis of several oncoproteins, includ-
ing cyclin E, MYC, JUN, and Notch  [ 49 ] . Importantly from the clinical perspective, the SV40 large T 
antigen oncoprotein binds to and functionally inactivates two major tumor suppressor genes, p53 and 
retinoblastoma (Rb), that are often inactivated in NSCLC. Large T contains a decoy phospho-degron 
that inhibits FBW7 function, thus repressing its role in cyclin E, MYC, JUN, and Notch  [ 50 ] . 
 An integrated gene signature, composed of approximately 150 genes, from multiple transgenic 
models of epithelial cancers intrinsic to the functions of the Simian virus 40 T/t antigens, has been 
associated with biological behavior and prognosis. This genetic signature is activated primarily in 
tumors with aberrant p53, Rb, or BRCA1 expression. Human breast, lung, and prostate tumors 
expressing this set of genes represent subsets of tumors with the most aggressive phenotype and 
with poor prognosis  [ 51 ] . It was observed that small-cell lung cancer, SCC, and a subset of lung 
adenocarcinoma harbor the intrinsic T/t-antigen signature  [ 51 ] . Analysis of the SV40 T/t-antigen 
signature revealed that BRCA1 is overexpressed in conjunction with a network of genes related to 
BRCA1 function in breast, lung, and prostate cancers. Furthermore, the T/t-antigen proliferation 
cluster includes RRM1, which is also a potential target for customizing chemotherapy  [ 52– 54 ] and 
for developing drug therapies targeting RRM1  [ 51 ] . In addition to repressing the expression of 
RRM1 and RRM2, let-7 also inhibits BRCA1 expression  [ 55 ] . 
 Prognostic and Predictive Roles of BRCA1 
 We performed QPCR in frozen lung cancer tissue specimens from 126 early NSCLC patients who 
had undergone surgical resection and evaluated the association between survival and expression 
levels of nine genes involved in DNA repair pathways and in invasion and metastasis. For valida-
tion, we used paraffin-embedded specimens from 58 other NSCLC patients. A strong intergene 
correlation was observed between expression levels of all nine genes except nuclear factor of acti-
vated T cells (NFAT), for example, between ERCC1, RRM1, and BRCA1. Along with disease stage 
(stage I vs II vs III), BRCA1 mRNA expression significantly correlated with overall survival (HR, 
1.98;  P = 0.02). In the independent cohort of 58 patients, BRCA1 mRNA expression also signifi-
cantly correlated with survival (HR, 2.4;  P = 0.04)  [ 56 ] . When only stage I patients were examined, 
median survival was significantly different according to expression levels of ERCC1, MZF1, Twist, 
and BRCA1  [ 56 ] . Our findings indicate that although BRCA1 is closely related to ERCC1, RRM1, 
and other genes like MZF1, it stands out as the most significant prognostic marker of relapse. 
Patients whose tumors had high BRCA1 expression had significantly worse survival and should be 
candidates for adjuvant chemotherapy. Intriguingly, in vitro studies have shown that BRCA1 can 
regulate differential sensitivity to different classes of chemotherapy agents  [ 57,  58 ] . The absence of 
BRCA1 results in high sensitivity to cisplatin, whereas its presence increases sensitivity to antimi-
crotubule agents  [ 57,  58 ] . Therefore, it is plausible that patients with the highest expression levels 
would receive more benefit from antimicrotubule, nonplatinum-based chemotherapy. 
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 The fact that high levels of ERCC1 or RRM1 transcripts conferred a higher risk of relapse  [ 56 ] 
provides further evidence for the role of the loss of let-7 in upregulation of ERCC1 and RRM1, as 
well as BRCA1  [ 55 ] and for the upregulation of BRCA1 and RRM1 in the SV40 T/t-antigen signa-
ture  [ 51 ] . Paradoxically, contradictory findings  [ 59,  60 ] , leading to opposed strategies of customizing 
adjuvant chemotherapy, have reported that the lack of ERCC1 protein implies a higher risk of relapse 
and a greater sensitivity to cisplatin-based chemotherapy  [ 59 ] . Nevertheless, the clinical evidence 
that overexpression of ERCC1, RRM1, and especially BRCA1 confers poor survival in early NSCLC 
patients indicates the high risk involved in adjuvant chemotherapy. Against the current standard of 
cisplatin-based chemotherapy, noncisplatin-based chemotherapy, including antimicrotubule drugs, 
may be the proper treatment for the majority of patients with a high risk of relapse (Fig.  6.3 )  [ 56 ] . 
 It has been further demonstrated that genes belonging to DNA repair (including BRCA1) and 
replication pathways are overexpressed in resected NSCLC patients and associated with a more 
aggressive phenotype  [ 61 ] . 
 BRCA1: A Potential Biomarker for Cisplatin-Based Chemotherapy 
 Experimental findings suggest that both DNA double-strand breaks (DSBs) and a DNA damage 
response (DDR) can be induced by ionizing radiation  [ 62 ] , hypoxia  [ 63 ] , DNA-damaging agents, 
and activated oncogenes  [ 64 ] . In precancerous lesions, p53 binding protein 1 (53BP1) localized at 
foci, and histone H2AX, ataxia telangiectasia (ATM), and checkpoint kinase 2 (Chk2) were phos-
phorylated, suggesting the presence of DNA DSBs  [ 65,  66 ] . In lung cancer, there is evidence for the 
presence of DSBs when phosphorylated histone H2AX and 53BP1 foci are present with a high 
proliferation index but low levels of apoptosis  [ 64,  65 ] . More than 50% of surgically resected lung 
cancers show phosphorylation of Chk2  [ 66 ] . Many proteins, including ATM,  g -H2AX, mediator of 
DNA damage checkpoint protein (MDC1), BRCA1, Chk1, and Chk2, are involved in the ionizing 
radiation-induced DDR pathway  [ 62 ] . Under nonirradiated normoxic conditions,  g -H2AX and 
53BP1 are not activated; however, under nonirradiated anoxic conditions,  g -H2AX can be induced 
 Fig. 6.3  The BRCA1 model shows the potential prognostic and predictive relevance in resected NSCLC. Low levels 
of BRCA1 mRNA have a lower risk of disease recurrence. These tumors could be sensitive to platinum combinations. 
In contrast, patients with high levels of BRCA1 mRNA have a higher risk of relapse and could be more resistant to 
platinum combinations. Alternatively, these tumors could be sensitive to tubulin-binding agents, such as taxanes  [ 56 ] 
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through the chromatin  [ 63 ] . At the core of DDR signaling, ATM is central, activating  g -H2AX. 
A large-scale proteomic analysis of proteins phosphorylated in DDR identified multiple super- complexes, 
including BRCA1, the COP9 signalosome, and the AKT-insulin pathway  [ 67 ] . 
 A proposed model for DDR to irradiation involves the formation of a BRCA1 complex  [ 68,  69 ] . 
In DDR, ATM and ATR phosphorylate H2AX on Ser-139  [ 70 ] , which serves to recruit the MDC1 
protein to chromatin, where it is also phosphorylated. RNF8/UBC13 complexes go to sites of DNA 
damage through their forkhead domain and initiate the synthesis of K63 polyubiquitin chains on 
chromatin that recruit the BRCA1 complex through the ubiquitin-interacting motif domains (UIM) 
of RAP80 (Fig.  6.4 )  [ 71,  72 ] . RAP80 targets a complex containing Abraxas, BRCA1–BARD1 
(BRCA1-associated ring domain protein 1) and BRCC36  [ 68,  69 ] . BRCC36 is frequently overex-
pressed in breast cancer, and its depletion disrupts irradiation-induced phosphorylation of BRCA1, 
thereby sensitizing breast cancer cells to irradiation-induced apoptosis  [ 73 ] . Cells lacking MDC1 
are also sensitive to ionizing irradiation  [ 74 ] . 
 The Potential Relevance of BRCA1 Sumoylation 
 The limited efficacy of current chemotherapy approaches is epitomized in metastatic (stage IV) 
NSCLC, where median survival is only 10–11 months with either noncustomized platinum-based 
chemotherapy  [ 75,  76 ] or customized cisplatin-based chemotherapy based on ERCC1 mRNA 
expression  [ 77 ] , and the 2-year survival rate is only 14–21%  [ 75– 77 ] . 
 Receptor-associated protein 80 (RAP80) or ubiquitin-interacting motif containing 1 (UIMC1) is a 
nuclear protein containing two functional UIMs at its amino terminus. It has been shown that RAP80 
plays a critical role in DDR signaling  [ 68,  69,  78,  79 ] . These studies report that RAP80 translocates 
 Fig. 6.4  In response to DNA 
DSBs induced by irradiation 
or chemotherapy, the ATM/
ATR-dependent phosphoryla-
tion of H2AX creates 
 g H2AX, the initial signal for 
subsequent accumulation of 
signaling and repair proteins 
to DNA breaks to form the 
so-called ionizing radiation-
induced foci. Binding of the 
mediator of DNA damage 
checkpoint 1 (Mdc1) protein 
to the phosphorylated tail of 
H2AX at sites of DNA 
breakage recruits the 
ubiquitin ligase RNF8, which 
generates ubiquitin chains 
bound by RAP80 and 
Abraxas, which in turn recruit 
BRCA1  [ 71 ] (Copyright 2007 
National Academy of 
Sciences, USA) 
 
896 Diagnostic, Prognostic, and Therapeutic Value of Gene Signatures in Non-Small Cell Lung Cancer
to ionizing radiation (IR)-induced foci (IRIF) after IR and that the UIMs are essential for relocalization. 
It was further found that RAP80 forms a complex with BRCA1 and that this association is dependent 
on the BRCA1 COOH-terminal (BRCT) repeats of BRCA1. BRCA1 plays a critical role in DNA 
repair and activation of cell cycle checkpoints. RAP80 depletion disrupts the translocation of BRCA1 
to IRIF and causes defects in G2-M checkpoint activation after IR  [ 68,  69,  78 ] . In addition, knock-
down of RAP80 expression by small interfering RNA reduces DSB-induced homology-directed 
recombination and increases the sensitivity of cells to IR-induced cytotoxicity  [ 68,  79 ] . 
 Abraxas binds BRCA1 to the mutual exclusion of BRCA1-associated C-terminal helicase 
(BACH)/BRCA1-interacting protein (Brip1) and CtBP-interacting protein (CTIP) through the 
pSer–X–X–Phe motif. The BRCA1–RAP80–Abraxas complex (Fig.  6.5 ) is clearly involved in 
DDR  [ 68 ] . It is likely that different BRCA1 complexes play redundant roles or promote multiple 
distinct steps in DDR. For example, the three complexes (Fig.  6.5 ) are required for homologous 
recombination repair  [ 68 ] . Furthermore, both the BRCA1–RAP80–Abraxas complex and the 
BRCA1–RAP80–CTIP complex are required for the G2-M checkpoint. These two complexes are 
also involved in transcription, through their association with RAP80 (Fig.  6.5 )  [ 68 ] . It is also inter-
esting to note that RAP80 binds the estrogen receptor, suggesting that the BRCA1–RAP80 com-
plexes might mediate the BRCA1 role in estrogen signaling in breast cancer  [ 80 ] . Similar to our 
findings of poor prognosis in NSCLC patients with elevated BRCA1 expression  [ 56 ] , high BACH1/
Brip1 transcript levels found in more aggressive breast cancers with an estrogen receptor-negative, 
progesterone receptor-negative or HER-2-positive status  [ 81 ] seem to contradict their function as 
tumor suppressors. 
 In addition to BRCA1, RAP 80 and Abraxas, a deubiquitinating enzyme – BRCC36 – has also 
been shown to be present in the RAP80–BRCA1 complex  [ 69 ] . Interestingly, BRCC36 is also aber-
rantly expressed in many breast cancers. Along the same lines, downregulation of BRCC36 expres-
sion impairs the DNA repair pathway activated in response to IR by inhibiting BRCA1 activation, 
 Fig. 6.5  RAP80 interacts with BRCA1 through binding to Abraxas. The RAP80–BRCA1 interaction decreases 
when Abraxas – but not BACH1 or CtIP – is depleted  [ 68 ] (Reprinted with permission from American Association 
for the Advancement of Science) 
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thereby sensitizing breast cancer cells to IR-induced apoptosis  [ 73 ] . BRCC36 displays sequence 
homology to CSN5 (the fifth subunit of the COP9 signasolome), including a conserved JAMM 
motif (reviewed in Yan and Jetten  [ 82 ] ). How the BRCA1/BARD1–RAP80–Abraxas–BRCC36 
complex localizes to sites of DNA damage has been actively investigated. The two UIM motifs of 
RAP80 are required for foci formation of BRCA1 and Abraxas  [ 68,  78 ] . It has been also shown that 
the UIM domains of RAP80 bind to ubiquitin chains assembled through K63 linkages  [ 69 ] . In addi-
tion, RNF8 transduces the DNA-damage signal via histone ubiquitylation and checkpoint protein 
assembly  [ 71,  83,  84 ] . RNF8 ubiquitylates histones at DNA DSBs and promotes assembly of repair 
proteins. A model has been proposed for IRIF formation of the BRCA1/BARD1–RAP80–Abraxas–
BRCC36 complex. In response to DNA damage, ATM and ATR phosphorylates H2AX on Ser-139, 
which serves to recruit the mediator of DNA damage checkpoint protein 1 (MDC1) protein to chro-
matin, where it is also phosphorylated  [ 74 ] . In an H2AX-and MDC1-dependent manner, RNF8–
Ubc13 complexes go to sites of DNA damage through their FHA domain and initiate the synthesis 
of K63 polyubiquitin chains on chromatin, which recruits the BRCA1/BARD1–RAP80–Abraxas–
BRCC36 complex through the UIM domains of RAP80. 
 Protein complexes formed at DNA damage sites have to be removed after the damage is repaired. 
Although little is understood about this process, it likely involves dephosphorylation of gamma-
H2AX and other proteins, K63-liked deubiquitination, and ubiquitination–proteasome-dependent 
degradation. It is therefore intriguing that BRCA1/BARD1, which functions as an E3 ligase, is 
associated with the deubiquitinase BRCC36  [ 69,  85 ] . It can be speculated that the deubiquitinase 
activity of BRCC36 might play a role in terminating the DNA repair signaling at a later stage of 
DDR  [ 82 ] . 
 In addition, the SUMO pathways components (UBC9-protein inhibitor of activated STAT 
(PIAS)4 and UBC9–PIAS1) also accumulate at DSBs, where they catalyze the SUMOylation of 
BRCA1  [ 86,  87 ] . SUMOylation stimulates BRCA1 E3 ubiquitin ligase activity, leading to ubiquitylation 
of target proteins at DSBs, including the H2AX. Depletion of PIAS1 and PIAS4 impaired recruit-
ment of BRCA1 to DSBs, significantly impaired ubiquitylation at DSBs, and reduced ubiquitylation 
of H2AX. PIAS SUMO ligases are required for homologous recombination and nonhomologous 
end-joining. PIAS1 and PIAS4 depletion resulted in ionizing radiation hypersensitivity  [ 86,  87 ] . 
Therefore, these could be essential components – together with BRCA1 – for predicting response 
to radiotherapy and cisplatin-based chemotherapy. 
 BRCA1 as a Differential Modulator of Chemosensitivity 
 A growing body of evidence indicates that BRCA1 confers sensitivity to apoptosis induced by 
antimicrotubule drugs (paclitaxel and vincristine) but induces resistance to DNA-damaging agents 
(cisplatin and etoposide) and radiotherapy  [ 88– 91 ] . These preclinical findings are supported by a 
variety of experimental models in breast and ovarian cancer cells: inducible expression of BRCA1-
enhanced paclitaxel sensitivity  [ 92 ] ; a short interfering RNA-mediated inactivation of endogenous 
BRCA1 led to paclitaxel and docetaxel resistance  [ 57,  58,  93 ] , and reconstitution of BRCA1-
deficient cells with wild-type BRCA1 enhanced sensitivity to paclitaxel and vinorelbine  [ 57 ] . This 
differential modulating effect of BRCA1 mRNA expression was also observed in tumor cells iso-
lated from malignant effusions of NSCLC and gastric cancer patients, where BRCA1 mRNA levels 
correlated negatively with cisplatin sensitivity and positively with docetaxel sensitivity  [ 94 ] . Five 
retrospective studies – in NSCLC  [ 95,  96 ] , ovarian  [ 58,  97 ] and bladder  [ 98 ] cancer patients – found 
that low or intermediate BRCA1 mRNA levels correlated with a significantly longer survival fol-
lowing platinum-based chemotherapy  [ 58,  95 ] while survival in patients with higher BRCA1 
expression increased following taxane-based chemotherapy  [ 58,  96 ] . 
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 NSCLC with EGFR Mutations 
 We evaluated the feasibility of large-scale screening for EGFR mutations in advanced NSCLC 
patients and the impact of EGFR mutations on clinical outcome to customized erlotinib  [ 99 ] . EGFR 
mutations were found in 350 of 2,105 patients (16.6%). Mutations were found more frequently in 
women (69.7%;  P < 0.001), in never-smokers (66.6%;  P < 0.001), and in adenocarcinomas (80.9%; 
 P < 0.001). Deletions in exon 19 were found in 62.3% and L858R mutations in 37.8% of patients. 
Metastatic NSCLC patients with EGFR mutations were eligible for erlotinib treatment. Median 
progression-free and overall survival for 217 patients receiving erlotinib was 14 months and 
27 months, respectively. Large-scale screening of patients for EGFR mutations, with subsequent 
customization of erlotinib, is feasible and leads to impressive outcomes and is becoming standard 
practice  [ 99 ] . 
 However, the treatment approach in early resected NSCLC patients with EGFR mutations is still 
unclear although the majority of cases display favorable outcomes  [ 100 ] . Other genetic alterations, 
such as activation of complementary signaling pathways, could influence outcome in patients with 
EGFR mutations and should be kept in mind for targeted therapy approaches. 
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 Introduction 
 Although the incidence and mortality of gastric cancer (GC) have fallen over the past 70 years, GC 
continues to be the second leading cause of cancer death and the fourth most common malignant 
neoplasia across the world  [ 1 ] . GC still represents a major clinical challenge because it has a poor 
prognosis and limited treatment options due to its relative resistance to radiotherapy and chemo-
therapy. At present, tumour stage provides the major prognostic variables used in clinical manage-
ment of GC patients. However, GC with similar morphology may display different biological 
aggressiveness, prognosis and response to therapy. 
 It is now widely accepted that GC develops through the accumulation of genetic and epigenetic 
alterations affecting oncogenes and tumour suppressor genes and that alterations in mechanisms that 
control genomic instability lay at the base of this process  [ 2 ] . Current knowledge on the molecular 
mechanisms underlying gastric carcinogenesis indicate that two major genomic instability pathways 
are involved in the pathogenesis of GC, microsatellite instability (MSI) and chromosome instability 
(CIN)  [ 3,  4 ] . From a molecular standpoint, there is evidence that gastric carcinogenesis is a long-
term multistep process associated with alteration in genomic stability and accumulation of multiple 
gene abnormalities. According to a metaplasia–adenoma–carcinoma progression model  [ 5 ] , a 
sequence of molecular changes related to MSI and CIN phenotypes may be observed in gastric 
carcinogenesis. 
 Several attempts to classify GC have been made over the past decades. Most successful, and 
widely used, is the classification by Lauren, which, by microscopic morphology alone, distinguishes 
two main cancer phenotypes, diffuse and intestinal subtypes, which appear clearly as dissimilar 
clinical and epidemiological entities. Although most of the genetic alterations that have been 
reported are observed in both intestinal and diffuse GCs, it has become apparent that these two 
tumour types result from different genetic pathways  [ 2,  6 ] . 
 MSI,  p53 mutation, reduced p27 expression, cyclin E overexpression and c-met 6.0-kb 
transcripts are involved in malignant transformation from precancerous lesions to intestinal-type 
GC. In addition,  DCC loss,  APC mutations, 1q loss of heterozygosity (LOH), p27 loss, reduced 
expression of transforming growth factor (TGF)-beta type I receptor and  HER2 gene amplification 
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are frequently associated with an advanced stage of intestinal-type gastric carcinomas. In com-
parison, LOH at chromosome 17p (p53) and mutation or loss of  E-cadherin are more often impli-
cated in the development of diffuse-type GC, while gene amplification of  k-sam and  c-met , and loss 
of  p27 lead to disease progression and metastatic spread. The two types of gastric carcinoma orga-
nize different patterns of interplay between neoplastic and stromal cells through the growth factor/
cytokine receptor system that has a critical role in cell growth, apoptosis, morphogenesis, angio-
genesis and metastasis. 
 In addition to genetic alterations, epigenetic alterations are also involved in carcinogenesis. In 
particular in gastric carcinogenesis, the CpG islands methylator phenotype (CIMP), characterized 
by abnormal degree of hypermethylation in the context of CpG islands localized in gene promoters, 
may lead to the transcriptional silencing of various genes including  E-cadherin ,  p16 ,  p15 and 
 hMLH1  [ 7 ] . Interestingly, GC hypermethylation of gene promoters progressively increases with 
histopathology progression from chronic gastritis, intestinal metaplasia and adenoma to carcinoma 
 [ 8 ] . Thus, CIMP may represent a distinct pathway in GC, although there is evidence of a high fre-
quency of CIMP phenotype in GC displaying MSI phenotype. 
 Recently, the role of micro-RNA (miRNA) deregulation in gastric carcinogenesis has been 
pointed out. Micro-RNAs are involved in many important biological processes of cell growth con-
trol and proliferation, and alterations in these patterns are possibly crucial to cancer initiation, 
progression and treatment outcome. 
 Overall, a complete knowledge about GC molecular signatures may provide an accurate bio-
logical rationale for predicting clinical behaviour and to establish more appropriate therapeutic 
interventions. Here, we will focus on the role of genomic instability, genetic variations and miRNA 
expression in GC development and progression and their possible clinical relevance. 
 Genomic Instability 
 Loss of genomic stability represents a key molecular step in GC development and progression. 
Genomic instability occurs early in the carcinogenesis process and creates a permissive environment 
for the accumulation of genetic and epigenetic alterations in tumour suppressor genes and oncogenes. 
Two main phenotypes of genomic instability, including MSI and CIN, are recognized in GC. MSI, 
characterized by high frequency of mutations in simple repetitive sequences (microsatellite), is 
responsible for a well-defined subset of GCs. CIN, characterized by high frequency of allelic losses 
(LOHs), gene deletions/amplifications and aneuploidy, comprises heterogeneous subsets of GC. 
 In addition to MSI and CIN, the CIMP plays an important role in gastric carcinogenesis. CIMP, 
characterized by abnormal degree of hypermethylation in the context of CpG islands within gene 
promoters, may lead to the transcriptional silencing of various genes involved in GC development 
and progression. Evidence suggests that although MSI, CIN and CIMP phenotypes can be distin-
guished from one another, there might be some degree of overlap  [ 2 ] . 
 MSI 
 MSI is a common feature of GC due to a deficit in the DNA mismatch repair system (MMR) and 
derives from the presence of spontaneous DNA replication errors in simple repetitive sequences  [ 4 ] . 
During cell replication, MMR recognizes base-pair mismatches which occur by addition or deletion 
of one base. A standard panel of microsatellite markers, including mononucleotide ( BAT25 and 
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 BAT26 ) and dinucleotide ( D2S123 ,  D5S346 and  D17S250 ) repeats, has been recommended and 
guidelines for MSI testing (Bethesda Guidelines) have been drawn up  [ 9 ] . Using the reference 
panel, three levels of MSI can be identified: high-level MSI (MSI-H), low-level MSI (MSI-L) and 
microsatellite stable (MSS). Recently, it has been established that mononucleotide repeats are 
instrumental in detecting MSI-H tumours because of their high sensitivity and specificity, and 
MSI-L has been defined as instability limited to dinucleotide loci  [ 10 ] . After the adoption of the 
Bethesda panel, MSI-H phenotype was reported in a range of 5–50% of all gastric carcinomas with 
significant differences in various ethnic groups. 
 MSI-H appears to be a phenotypical marker of an underlying cellular defect involving MMR. 
Functional inactivation of MMR genes (including  hMLH1 and  hMSH2 ) by mutations or epigenetic 
mechanisms is responsible for the MSI-H phenotype in GC. Abnormal loss of protein expression of 
either hMLH1 or hMSH2 has been observed in MSI-H gastric carcinomas  [ 11 ] . In particular, altered 
expression of hMLH1 has been associated with gene inactivation by promoter hypermethylation. 
 MSI-H GCs follow a molecular pathway of tumour progression characterized by the presence of 
multiple frameshift mutations affecting mononucleotide tracts within genes involved in cancer-
related molecular networks, which control cellular homeostasis at different levels. MSI-related 
mutations occur in many genes at variable frequencies. Genes regulating cell cycle and apoptotic 
signalling are frequently targeted in MSI-H gastric carcinomas and include  TGF b RII ,  IGFIIR , 
 TCF4 ,  RIZ ,  BAX ,  CASPASE5 ,  FAS ,  BCL10 and  APAF1  [ 12 ] . Moreover, genes involved in genomic 
integrity maintenance, i.e.  hMSH6 ,  hMSH3 ,  MED1 ,  RAD50 ,  BLM ,  ATR and  MRE11 , are also fre-
quently altered in MSI-H tumours  [ 13,  14 ] . Several studies indicate that, in most MSI-H GCs, 
multiple target genes are simultaneously mutated and multiple hits impact on different genes in the 
same pathway  [ 15 ] . The occurrence of mutations in specific sets of cancer-related genes may confer 
distinctive clinico-pathological features to MSI-H gastric carcinomas, which tend to occur as 
expanding tumours of the distal stomach, usually displaying an intestinal histotype with prominent 
lymphoid cell infiltration, and do not often give rise to lymph node metastasis, regardless of the 
extent of wall invasion  [ 15– 19 ] . Moreover, MSI-H tumours generally show improved survival com-
pared to MSS/MSI-L cases  [ 15 ] . 
 MSI genotyping may allow the identification of discrete molecular GC subtypes and MSI seems 
to represent one of the most promising molecular markers with prognostic but also predictive value 
for chemosensitivity. In fact, MSI testing could also result in more patients being assigned to proper 
treatment based on their disease profile. Since, an intact MMR system is a determinant of sensitivity 
to a variety of chemotherapeutic agents, including 5-fluorouracil (5-FU), it is therefore reasonable 
to consider MSI-H tumours as a separate entity when determining response to chemotherapy. At 
present, data regarding the relevance of MSI for predicting the prognosis and benefits of 5-FU-based 
chemotherapy in GC are scarce to draw conclusions  [ 20,  21 ] . In colon cancer, MSI status is regarded 
as a predictive factor since a significant improved prognosis for MSS patients treated with 
5-FU-based chemotherapy is observed compared to MSI-positive cases  [ 22,  23 ] . 
 CIN 
 CIN is the most common type of genomic instability observed in human cancers and it has been 
reported in at least the 60% of gastrointestinal tumours  [ 4 ] . CIN is characterized by changes in 
chromosome copy number (aneuploidy) and alterations in chromosomal regions, including LOHs, 
gene deletions and/or amplifications  [ 24 ] . All these alterations may lead to oncogene activation and/
or tumour suppressor gene inactivation. The identification of specific patterns of chromosome 
gains/losses occurring during the progression from adenoma to carcinoma and the observation that 
CIN is an early event in tumour formation and increases with tumour progression are consistent 
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with the idea that CIN is a relevant pathogenic process in GC. The allelotype of gastric carcinoma 
is similar to that of colorectal and oesophageal cancers, suggesting the presence of a common 
genetic pathway for tumour development. Some of these chromosomal segments include genes, 
which are strongly implicated in carcinogenesis, such as the  p53 gene on chromosome 17,  DCC , 
 DPC4 and  SMAD2 genes on chromosome 18, and  APC and  MCC genes on chromosome 5  [ 25,  26 ] . 
 By contrast with MSI, the mechanism underlying CIN is largely unknown. Mitotic chromosomal 
mis-aggregation and errors in the mitotic spindle checkpoint have been implicated.  APC is one of 
the major genes involved in the regulation of chromosome segregation; cells carrying  APC muta-
tions may acquire structural alterations in chromosomes and aneuploidy  [ 27 ] .  APC mutations have 
been observed in about 10% of GC  [ 28 ] .  p53 is one of the most important genes involved in the 
regulation of the mitotic checkpoint  [ 29 ] .  p53 point mutations are observed in 30–50% of GCs and 
 p53 locus is targeted by LOH in 60% of GCs  [ 28 ] . Inactivation of proteins involved in DNA damage 
checkpoints, chromosome metabolism and centrosome function, cell proliferation, apoptosis, cell 
adhesion and in neoangiogenesis has been shown also to be involved in CIN pathway  [ 29 ] . 
The progression of CIN positive (CIN+) GC is characterized by frequent LOH at the  APC locus 
(30–40%) and, at lower level (3–20%), by  K-ras activating point mutations, specifically at codons 
12, 13, 59 e 61  [ 30,  31 ] . 
 CIN has been demonstrated to be a valuable prognostic factor and tumour stage indicator in GC. 
As with other tumours, aneuploidy is generally considered an unfavourable prognostic factor  [ 32– 35 ] , 
though contrasting results have been reported  [ 36– 39 ] . High CIN levels have also been associated 
with a shorter survival in GC patients  [ 40 ] and several studies have found that tumours with LOH at 
chromosome 5q, 18q or 17p had a poorer prognosis than tumours that did not show LOH at these sites 
 [ 25,  26 ] . High LOH frequencies have been also identified at several chromosome arms, including 1p, 
3p, 4p, 7p, 8p, 8q, 9p, 12p, 13q, 20q and 22q  [ 41,  42 ] thus supporting the hypothesis that, in GC, 
tumour progression, and consequently survival, correlates with the accumulation of genomic insta-
bility. A few studies have shown an association between high CIN levels with a good response to 
cisplatin-based chemotherapy and poor survival  [ 43– 55 ] . 
 CIMP 
 Epigenetic changes, such as aberrant methylation of CpG islands in promoter regions are commonly 
detected in human cancers and can permanently inactivate tumour-suppressor genes and affect 
important pathways of cell cycle regulation and proliferation. The methylation of CpG islands may 
be considered a third molecular phenotype of GC and the tumour-related genes more commonly 
methylated are  APC, E-cadherin, MHL1, CDKN2A, CDKN2B and  RUNX3 . It has also been widely 
reported that  CDKN2A, E-cadherin and  MLH1 are more frequently inactivated by promoter methy-
lation rather than by mutations  [ 56 ] . Hypermethylation of gene promoters progressively increases 
with histopathological progression from chronic gastritis, intestinal metaplasia, adenoma and carci-
noma, suggesting a distinct pathway in gastric carcinogenesis and progression  [ 48,  57 ] . 
 A series of individual methylated genes has been related to prognosis in GC. Methylation of 
tumour-suppressor genes, such as  E-cadherin  [ 58 ] ,  DKK3  [ 59 ] ,  PTEN  [ 60 ] and  MGMT  [ 61 ] of puta-
tive tumour-suppressor genes, such as  TFPI2  [ 7 ] and  CACNA2D3  [ 62 ] , and of other tumour-related 
genes, such as  PCDH10  [ 63 ] and  SOX2  [ 64 ] , has been associated with shorter disease-free and/or 
overall survival. The combined use of  APC and  E-cadherin methylation markers has identified a 
subgroup of patients with a worse prognosis  [ 43 ] . Conversely, methylation of single genes has been 
associated with a better prognosis in some cases. Patients showing methylation of  APC  [ 44 ] , the M1 
region of  MAL promoter  [ 65 ] and cyclooxygenase-2 ( COX2 )  [ 46 ] showed prolonged survival, com-
pared to patients without methylation of these genes. 
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 In order to define CIMP tumours as a group characterized by distinct genetic, morphological 
or clinical characteristics compared to tumours with other predominant forms of genomic insta-
bility the definition of CIMP-positive as been suggested to be quantitative and a low CIMP level 
(CIMP-L) and high CIMP level (CIMP-H) can be identified if less than 50% and more than 50% 
of genes/loci are respectively methylated. CIMP status is associated with clinically useful infor-
mation and patients with CIMP-negative phenotype have significantly shorter survival than those 
with high CIMP levels  [ 48,  50 ] . Intriguingly, concurrent hypermethylation of gene promoters is 
associated with MSI-H phenotype in GC and concordant methylation of multiple genes/loci 
(CIMP-H) is associated with better survival but is not an independent predictor of prognosis in 
GC  [ 48 ] . Overall, much overlap of MSI and CIMP has been noted in GC, suggesting that MSI is 
a confounding factor. 
 Irrespective of CIMP being a separate pathway in gastric carcinogenesis, the presence of hyper-
methylation of important genes could be clinically relevant, because methylation can be reverted by 
DNA methyltransferase inhibitors reactivating genes, thus CIMP is emerging as interesting candi-
date for the development of  ad hoc therapeutic strategies  [ 66 ] . 
 Molecular Pathways in GC 
 Genetic and genomic variations occurring in genes and molecules that participate in proliferation, 
invasion and metastasis (e.g. growth factors and their receptors, signal transducers, cell cycle and 
apoptosis regulators, cell adhesion molecules, DNA repair genes and matrix metalloproteinases) are 
involved in GC development and progression and may influence the prognosis of patients with GC. 
In particular, deregulation of oncogenic and tumour suppressor pathways such as  HER2 ,  K-ras, p53, 
p21, MYC and  Wnt/ b -catenin are known to occur with varying frequencies in GC  [ 67 ] indicating 
that GC is a molecularly heterogeneous disease. Indeed, experimental evidence indicates that most 
cancer phenotypes (uncontrolled growth, resistance to apoptosis, cell invasion, metastasis and 
angiogenesis) are largely controlled by complex interactions between multiple pro- and anti-onco-
genic signalling circuits  [ 68 ] , suggesting that pathway interactions may play an important role in 
influencing disease behaviour. 
 Cell Growth and Proliferation 
 HER2 (HER2/neu or ErbB-2), a glycoprotein with tyrosine kinase activity, is a member of the ErbB 
family of receptors. HER2 is codified by a gene located on chromosome 17q21 and does not bind 
to any known ligand. Some studies demonstrated that overexpression of HER2 is selectively found 
in intestinal tumours and may serve as a prognostic marker for tumour invasion and lymph node 
metastasis. Overexpression of HER2 protein in GC has been reported to range from 7.4% to 38% 
 [ 68– 70 ] . The prognostic value of HER2 expression and/or amplification has been widely investi-
gated with controversial findings. Although most available studies indicate that the HER2 overex-
pression is an independent prognostic factor associated with a shorter disease-free  [ 71 ] and overall 
survival  [ 72,  73 ] , some studies failed to confirm its prognostic role on multivariate analysis  [ 53 ] or 
to find a correlation between HER2 overexpression and survival parameters  [ 70– 73 ] . Also associ-
ated with poor survival is the presence of HER2 amplification  [ 74,  75 ] . 
 The epidermal growth factor receptor (EGFR or ErbB-1), also a member of the ErbB family of 
receptors, is a trans-membrane protein that homo- or heterodimerizes with other  EGFR family 
members at the cell membrane. Receptor dimerization causes activation of the intrinsic cytoplasmic 
kinase domain, resulting in the phosphorylation of several tyrosine residues  [ 76 ] . The active  EGFR 
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stimulates the  MAPK cascade and  PI3K survival pathways  [ 77 ] .  EGFR is overexpressed in a maximum 
frequency of 38% of GC  [ 78– 80 ] and very few cases were reported to harbour gene structural altera-
tions like gene amplification or mutations  [ 81– 83 ] . EGFR mutations have been identified as predic-
tors of response to EGFR tyrosine kinase inhibitors (TKIs), thus, a small subset of gastric 
adenocarcinoma patients may respond to EGFR TKIs  [ 84 ] . 
 The  K-ras oncogene encodes a membrane-associated protein, p21 RAS , with intrinsic GTPase activ-
ity involved in cellular signal transduction. Point mutations at codons 12, 13 and 61 of  K-ras result 
in a shift of  K-ras protein toward the activated state, which constitutively activates the mitogenic 
signal transduction pathway. In GC, the  K-ras gene mutation frequency varies between 3 and 8% and, 
whenever present,  K-ras mutations normally cluster in the MSI subset (30% of MSI cases)  [ 85 ] . 
 The oncogene  c-met , encoding for the hepatocyte growth factor receptor, is preferentially ampli-
fied in diffuse-type tumours and has been described to be well correlated with stage and prognosis 
 [ 53 ] . Overexpression of c-met has also shown to be associated with lower survival probability  [ 55 ] . 
 k-sam oncogene, a member of the fibroblast growth factor receptor family, is more frequently acti-
vated in diffuse-type tumours. Overexpression of k-sam occurs in approximately 32% of diffuse-type 
GCs, and the prognosis of k-sam positive patients is poorer than that of k-sam negative patients  [ 86 ] . 
 Cell Cycle and Apoptosis 
 The p53 protein plays a fundamental role in cell cycle control. Mutations of  p53 are present in about 
40% of early and advanced well-differentiated GC  [ 87 ] . A lower incidence of  p53 mutations has 
been shown in young patients compared to older patients  [ 88 ] . p53 can be investigated by immuno-
histochemical techniques, bearing in mind that the half-life of the p53 mutant protein is prolonged. 
Cells carrying the p53 mutant protein can be stained with antibodies against p53, whereas cells car-
rying normal p53 are negative. Sequencing of the gene after screening can also be performed in 
order to determine the mutation location within the gene  [ 89 ] . Overexpression of p53 often occurs 
in the early stages of intestinal-type tumours, and there is no significant difference between early 
and advanced cancers. In contrast, p53 abnormalities are not often seen in the early stages of dif-
fuse-type tumours, but tend to occur as the disease progresses  [ 90 ] . 
 p53 cell cycle regulatory function is mediated by different effectors. One of these is a cyclin-
dependant kinase inhibitor (CDK I), the p21 protein. The cell cycle checkpoints are controlled by a 
cascade of phosphorylation. Protein kinases such as cyclin-dependent kinases are activated by 
cyclins and inhibited by CDK I, although p21 is up-regulated not only through a p53 pathway, but 
through a TGF b RII pathway, as well. Levels of p21 expression could indicate the absence of a 
functional p53 protein in neoplastic cells. It has been reported that the survival of GC patients with 
p21-positive tumours is significantly longer than that of patients with p21-negative tumours  [ 91 ] . 
The expression of p21 is usually assessed in combination with p53 status and contributes in predict-
ing the clinical outcome of GC patients  [ 92,  93 ] . 
 It has been suggested that the cyclin-dependent inhibitor p27, which controls the transition from 
G1 to S in the cell cycle, has prognostic relevance in GC. Reduced p27 expression is detected in 
approximately 40–50% of GCs  [ 42 ] . Some studies have shown that tumours with a low expression 
of p27 protein are poorly differentiated and at an advanced stage  [ 94,  95 ] . However, some authors 
have found no difference in overall survival of GC patients whether with high or low p27 expression 
 [ 96 ] . p53, p21 and p27 have also been analysed in combination, confirming their role as prognostic 
markers  [ 90 ] . 
 c-myc encodes a multifunctional, nuclear phosphoprotein that plays a role in cell cycle progression, 
apoptosis and cellular transformation. It functions as a transcription factor that regulates transcription 
of specific target genes. The c-myc protein has been shown to have a significantly enhanced expression 
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in well-differentiated GC and to be associated with a poor prognosis  [ 97,  98 ] . Although c-myc is a 
short-lived protein in normal cells, its stability is increased in transformed cells through several mecha-
nisms. One of these has recently been identified in the overexpression of a human oncoprotein, the 
cancerous inhibitor of protein phosphate 2A (CIP2A) that stabilizes c-myc  [ 99 ] . Interestingly, the 
expression of CIP2A has been associated with reduced overall survival in GC patients  [ 100 ] . 
 A fundamental negative regulator of the cell cycle is  pRb, a protein encoded by the tumour suppressor 
gene  RB . Poor prognosis of GC patients with low levels of pRb expression has been reported  [ 101 ] . 
 BCL2 and  p53 are closely linked in the regulation of apoptosis. LOH at the  BCL2 locus is fre-
quently observed in GC. The overexpression of BCL2 may have a role in the development of GCs. 
It has been shown that BCL2 overexpression reduces cellular proliferative activity and correlates 
with a less aggressive biological behaviour of the tumour. The prognostic role of BCL2 on its own 
or in association with p53 has not yet been elucidated  [ 102 ] . 
 BAX gene encodes a protein belonging to the BCL family members. Negative BAX protein 
expression has been associated with de-differentiation, lymph node metastasis and shorter survival, 
suggesting that BAX status may play a role in the development and differentiation of GC and 
tumour progression  [ 103 ] . 
 Invasion and Metastasis 
 Invasion and metastasis are complex processes that require multiple genetic alterations and, more 
importantly, their coordinated interactions. Among the metastasis-associated factors, the Wnt-
frizzled- b -catenin signalling pathway is frequently activated in GC leading to poor differentiation 
and increased tumour invasiveness. Activation of Wnt signalling pathway leads to inhibition of 
GSK-3 b activity, resulting in deregulated accumulation of cytoplasmic  b -catenin that can shift to 
nucleus and activates transcription of a series of genes. In addition to Wnt activation, mutational 
events targeting APC, Axin or  b -catenin itself also result in  b -catenin deregulation  [ 104 ] . However, 
the incidences of APC mutation are from 4 to 20% in intestinal GCs and only 0–5% in diffuse GCs 
 [ 28,  105 ] . To date, no Axin gene mutation has been reported in adenocarcinomas of the stomach, 
and frequent loss of Axin locus found in other cancer systems does not lead to imbalanced  b -catenin 
distribution  [ 106 ] . The data of  b -catenin mutations in the hotspot codons of exon 3 are highly vari-
able from 0 to 26% in GCs. On the other hand, more frequent  b -catenin nuclear translocalization 
was found in 26–42% of GCs from different ethnic populations  [ 107 ] . Overall, Wnt/ b -catenin sig-
nalling pathway is activated in most of the GCs, and since it plays essential roles in cancer dissemi-
nation has potential value in prospecting the metastasis risk of GC patients. 
 E-cadherin, is a trasmembrane glycoprotein and is located at the adherens junctions. Its cytoplas-
mic tail binds either  b -catenin or  g -catenin, which in turn mediates interaction with the actin 
cytoskeleton via  a -catenin as a linker. The intact function of E-cadherin is crucial for the establish-
ment and maintenance of epithelial tissue polarity and structural integrity. Around 25–40% of 
hereditary diffuse GCs are caused by heterozygous E-cadherin. The inactivation of the second allele 
occurs by mutation and methylation events, and this results in the complete inactivation of the pro-
tein  [ 108 ] . Reduced expression of E-cadherin correlates with infiltrative and metastatic ability in 
GC  [ 58 ] . Patients with E-cadherin positive GCs showed statistically significant prolonged 3- and 
5-year survival rates, compared to patients with E-cadherin negative tumours  [ 109 ] . It has been 
shown that serum soluble E-cadherin is increased in several non-neoplastic diseases and also in 
various cancers including gastric tumours  [ 110 ] . E-cadherin may be a potentially useful prognostic 
marker, and high levels of soluble E-cadherin correlate with the depth of tumour invasion, as well 
as inoperability  [ 111 ] . In addition, levels higher than 10,000 ng/mL predict a survival of less than 
3 years in more than 90% of patients  [ 112 ] . 
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 Mucins (MUC) are high-molecular weight glycoproteins containing oligosaccharides. These 
glycoproteins constitute the major components of the mucus that protects the gastric epithelium. 
Overexpression of MUC1 has been linked to poor prognosis in GC patients  [ 113 ] . It has been 
reported that MUC1 may accelerate tumour invasion by the impairment of E-cadherin  [ 114 ] . The 
combined expression of MUC1 and E-cadherin shows that survival for GC patients with abnor-
mal E-cadherin/MUC-positive expression was shorter than for patients with other expression 
patterns  [ 110 ] . 
 Overexpression of cyclin E, a member of the cyclin family required for the transition from G1 
to S phase, correlates with invasiveness and proliferation and may be a marker of tumour aggres-
siveness. Although somatic mutations of the cell cycle inhibitor  p16  MTSI  are rare, its reduced 
expression is associated with depth of invasion and metastatic potential in both diffuse- and intesti-
nal-type gastric carcinomas. However, recent data show that the survival of GC patients with cyclin 
E positive tumours is not significantly shorter than that of negative patients  [ 91 ] . 
 Tumour-associated proteases and their inhibitors play a central role in tumour invasion and 
metastasis. The positive correlation of histological data with the urokinase-type plasminogen activa-
tor (uPA) and the plasminogen activator inhibitor type I (PAI-1) has been reported. Moreover, the 
independent prognostic impact of both uPA and PAI-1 on the survival of GC patients has been 
demonstrated. Elevated uPA and PAI-1 levels have been shown to be associated with shorter sur-
vival  [ 115 ] . A trend towards poor prognosis has also been observed in patients with high expression 
of the u-PA receptor (u-PAR)  [ 116 ] and the uPA system may therefore be a target for novel thera-
peutic agents. The prognostic role of some uPA genotypes has recently been investigated and an 
association between the exon 6 C/T polymorphism with invasive phenotype, but not with suscepti-
bility or survival, was demonstrated  [ 117 ] . 
 Angiogenesis 
 Vascular endothelial growth factor (VEGF) is a pro-angiogenic factor, frequently overexpressed in 
tumours. Mutations of  p53 , which under physiological conditions downregulates VEGF, may be 
responsible for its overexpression. A correlation of the expression of VEGF with lymph node and 
liver metastasis has been described  [ 118 ] and patients with VEGF-positive tumours have a rather 
worse prognosis than those with VEGF-negative tumours  [ 119,  120 ] . 
 RUNX3 , a gene that codifies for a member of the runt domain-containing family of transcription 
factors, frequently shows loss of expression due to hemizygous deletion and hypermethylation in 
GC. This gene, generally expressed in 45–50% of GC patients  [ 121 ] positively regulates the expres-
sion of the proapoptotic protein BIM and p21, and negatively regulates VEGF, thus affecting apop-
tosis, cell growth arrest and angiogenesis  [ 122 ] . The loss or substantial decrease of RUNX3 protein 
expression in GC has been significantly associated with shorter survival  [ 123 ] . 
 The hypoxia inducible factor, HIF-1 a , is a transcription factor that plays an essential role in cel-
lular and systemic homeostatic responses to hypoxia. Its upregulation (high HIF-1 a mRNA levels) 
has been found to be positively correlated with VEGF protein expression in GC patients and overall 
survival of patients with high mRNA levels of HIF-1 a and VEGF was shorter compared to patients 
with different features  [ 124– 126 ] . 
 Signal transducers and activators of transcription (STAT) behave as signal transducers in the cyto-
plasm and as transcription factors in the nucleus. Thus, an aberrant activation of STATs, especially 
STAT3, is often associated with cell survival, proliferation, and transformation. Dysregulated STAT3 
activation has been linked to the development and progression of gastric adenocarcinoma via induc-
tion of VEGF overexpression leading to an elevated angiogenic phenotype  [ 127 ] . STAT3 may be 
used as a molecular staging biomarker predicting poor prognosis of GC  [ 128 ] . Several reports indi-
cate that constitutively activated STAT3 is a target for antitumour drug discovery  [ 129 ] . 
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 The secreted protein acidic and rich in cysteine (SPARC) or osteonectin is a member of a family 
of matricellular proteins that modulates cell–matrix interactions and cell function without partici-
pating in the structural scaffolding of the extracellular matrix. Since SPARC alters membrane per-
meability, cell shape, proliferation, migration and attachment, it may play a role in angiogenesis. 
It has been reported that its overexpression correlates with poor prognosis  [ 130 ] . 
 Micro-RNA and GC 
 Micro-RNAs are regulatory RNAs involved in the pathogenesis of many types of cancer  [ 131– 136 ] , 
including GC  [ 137 ] . miRNA carries out its biological functions by repressing the expression of its 
target genes, which often belong to the same metabolic or signalling pathway, through base-pairing 
with endogenous mRNAs. Partial or perfect base-pairing allows translational repression and mRNA 
degradation, respectively. It is estimated that up to 30% of genes in the human genome are regulated 
by miRNA  [ 138 ] . miRNA transcription is similar to that of protein-coding genes, suggesting that the 
regulation of miRNA expression could also be controlled by transcriptional factors  [ 139 ] . Moreover, 
the majority of miRNAs is located within introns and their expression is linked to the regulation of 
their host genes  [ 140 ] . Alteration of genes involved in miRNA processing could also contribute to 
miRNA deregulation  [ 141 ] . Finally, epigenetic alteration of DNA, such as DNA promoter hyperm-
ethylation and histone modification, may have critical roles in miRNA deregulation  [ 142 ] . 
 The biogenesis and the function of miRNA may be likely altered in GC. Cytogenetic and molec-
ular analyses have revealed frequent chromosomal abnormalities in GC including gains at 20q, 8q, 
20p, 7q, 17q, 5p and 13q and deletions at 19p, 18q, 5q, 21q, 4p, 4q, 15q and 17p  [ 143 ] . Several 
miRNAs are hosted in these regions, currently investigated in GC, suggesting a role of chromo-
somal abnormality in miRNA deregulation  [ 144 ] . 
 Molecular Pathways and miRNA in GC 
 miRNAs are involved in important biological processes related to proliferation, apoptosis, differen-
tiation, metastasis, angiogenesis and immune response, deregulation of which is possibly crucial to 
cancer initiation, progression and treatment outcome  [ 145– 149 ] . 
 Aberrant miRNA expression may enhance cell cycle progression through downregulating the 
expression of CDK inhibitors in GC. For example, TGFb is known to suppress GC cell proliferation 
through transcriptional upregulation of p21  [ 150 ] . In this respect, miR-106b and miR-93, both of 
which are upregulated in GC and are downstream targets of the oncogenic transcription factor E2F-
1, directly target p21 and thus impair the tumour-suppressive activity of TGFb  [ 139 ] . The miRNAs 
in two clusters (miR-106b-93-25 and miR-222-221) have also been reported to suppress the p21 
family of CDK inhibitors and, consistently with their biological roles, both clusters are upregulated 
in GC  [ 151 ] . In addition to direct targeting of CDK inhibitors, miRNA has been shown to affect the 
expression of a CDK inhibitor-interacting protein known as anion exchanger-1 (AE1), which is 
expressed in GC cells. AE1 sequesters p16 in the cytoplasm and thus promotes cell proliferation 
 [ 152 ] . The expression of AE1 is modulated by miR-24, and transfection of miR-24 leads the return 
of AE1-sequestered p16 to the nucleus and the inhibition of cell proliferation  [ 153 ] . 
 Regarding apoptosis control, miRNA deregulation alters the expression of Bcl-2 family members 
in GC. For instance, TGFb is known to induce RUNX3, which interacts with FoxO3a/FKHRL1 to 
activate the proapoptotic protein BIM and induce apoptosis in GC cells  [ 154,  155 ] . In this regard, 
miR-106b and miR-93 impair TGFb-induced apoptosis in GC cells by inhibiting Bim expression 
 [ 139 ] . Overexpression of miR-130b has also been reported to suppress TGFb-induced Bim expression 
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and apoptosis by targeting RUNX3 in GC cells  [ 156 ] . Moreover, several miRNAs, including miR-15b, 
miR-16, miR-34 and miR-181b, have been shown to target directly the antiapoptotic protein Bcl-2 
and positively regulate apoptosis  [ 157,  158 ] . miR-34 is a downstream target of p53  [ 159 ] . 
Overexpression of miR-34 increases caspase-3 activation and impairs growth in p53-mutant GC 
cells  [ 160 ] . 
 Macrophage migration inhibitory factor (MIF) is a lymphokine whose expression is increased in 
 H. pylori -infected mucosa and GC  [ 161 ] . MIF may bind to CD74 to reduce apoptosis in gastric 
epithelial cells by downregulating p53 phosphorylation and stimulating Bcl-2 expression  [ 162 ] . 
MIF also promotes gastric epithelial cell proliferation through transactivation of epidermal growth 
factor receptor and the PI3K/Akt pathway  [ 163,  164 ] . MIF expression may be reduced by miR-451, 
whose expression is correspondently reduced in GC. Restoration of miR-451 expression decreases 
expression of MIF target genes in GC cells, leading to cell proliferation reduction and cell death 
enhancement in response to irradiation. Moreover, there is a significant inverse correlation between 
miR-451 and MIF expression in GC biopsies, suggesting that miR-451 functions as a tumour sup-
pressor by repressing MIF  [ 165 ] . 
 miRNA deregulation has been demonstrated to alter apoptosis by regulating pro-survival signal-
ling: the PI3K/Akt pathway and NF-kB signalling. miR-375 suppresses the activity of PI3K/Akt 
pathway through direct targeting PDK1, a kinase that phosphorylates Akt. miR-375 is one of the 
most downregulated miRNAs in GC in which ectopic expression of miR-375 substantially reduces 
cell viability through induction of caspase-dependent apoptotic pathway  [ 166 ] . 
 NF-kB signalling inhibits apoptosis and, importantly, is induced during  H. pylori -associated 
gastritis and is constitutively active in GC  [ 167,  168 ] . miR-218 induces apoptosis in GC by targeting 
a positive regulator of NF-kB transcriptional activity and also by inhibiting NF-kB-regulated pro-
liferative and anti-apoptotic genes, such as cyclooxygenase-2  [ 169 ] . NF-kB can be directly targeted 
by other miRNAs in GC like miR-9  [ 170 ] . 
 miRNA deregulation may contribute to GC cell invasiveness. Enforced expression of miR-21 
increases the invasiveness of cultured GC cells by directly targeting RECK a tumour-suppressor 
gene, which inhibits tumour metastasis and angiogenesis by modulating MMPs, including MMP9, 
MMP2 and MMP14  [ 171 ] . Activation of PI3K/Akt pathway by miR-21 may also confer the ability 
to avoid detachment-induced anoikis to GC cells. In addition, miR-21 may target PDCD4, a 
tumour suppressor. Low levels of PDCD4 mRNA are correlated with lymph node metastasis and 
venous invasion in GC  [ 171,  172 ] . Similarly, the oncogenic miRNA miR-106a is upregulated and 
its expression correlates with invasion as well as lymphatic and distant metastasis  [ 173 ] . 
Downregulation of miR-218 is also implicated in GC metastasis by activation of Slit/Robo1 signal-
ling pathway  [ 174 ] . 
 miRNA deregulation seems to modulate transcription through alteration of chromatin architec-
ture in GC. In particular, the high mobility group A2 (HMGA2) is a non-histone chromosomal 
protein, which can promote the assembly of regulatory protein complexes at sites of transcription 
 [ 175 ] . This gene is expressed abundantly during early development, but at very low levels in adult 
tissues. HMGA2 overexpression is a hallmark of various benign and malignant tumours including 
GC, in which it is associated with serosal invasion and is evaluated as an independent prognostic 
factor for poor clinical outcome. The let-7 miRNA family has been demonstrated to negatively regu-
late HMGA2 and an inverse relationship between the expression of let-7 and HMGA2 has been 
observed in GC  [ 176 ] . These findings suggest that the loss of inhibition by let-7 contributes to 
HMGA2 overexpression and probably enhances transcription in GC. Alterations of miRNA expres-
sion may affect transcriptional activities of various oncogenic/tumour-suppressing transcription 
factors by regulating the expression of prohibition  [ 177 ] . This transcriptional co-regulator has been 
reported to enhance the transcriptional activity of p53, but have opposite effects on E2F-1 and 
NF-kB  [ 178– 180 ] . MiR-27a, an miRNA upregulated in GC, directly binds to prohibitin mRNA, 
thus switching off protein expression. Suppression of miR-27a also impairs GC cell proliferation, 
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suggesting that miR-27a may act as an oncogene by targeting prohibitin  [ 177 ] . miRNA deregulation 
has been reported to alter the expression of MeCP2, a methyl-CpG-binding protein involved in gene 
silencing by promoter hypermethylation. MeCP2 has been identified as the direct target of miR-212, 
an miRNA frequently downregulated in GC, and the restoration of MeCP2 expression by downregu-
lation of miR-212 may promote carcinogenesis by enhancing epigenetic silencing of tumour-sup-
pressor genes  [ 181 ] . 
 miRNA and Clinical Implication in GC 
 The development of sensitive and specific biomarkers may improve current management of GC, 
including cancer early detection, differentiation, progression and recurrence monitoring and treat-
ment response evaluation. miRNAs have the following advantages as biomarkers (a) miRNAs are 
involved in tumorigenesis; (b) miRNAs are tissue, tumour, or even pathology specific; and (c) some 
miRNAs are related to treatment response or patients’ survival  [ 149 ] . 
 Some recent studies suggest that polymorphisms in the miRNA genes may serve as novel risk 
predictors for GC. A polymorphism of miR-27a genome region is associated with a higher risk for 
the development of gastric mucosal atrophy in Japanese men  [ 182 ] . An association of miRNA-
196a-2 gene polymorphism with GC risk has been reported in a Chinese population  [ 183 ] . 
Circulating miRNA profiling has been suggested as useful tool for non-invasive early diagnosis of 
GC. Plasma concentrations of various miRNAs, such as miR-17-5p, miR-21, miR-106a, miR-106b, 
are higher whereas let-7a is lower in GC patients compared to healthy people  [ 184 ] . High levels of 
miR-17 and miR-106a in peripheral blood of GC patients have also been confirmed in another study 
 [ 185 ] . Probably, the inclusion of miRNAs into the panels of biomarkers may enhance the sensitivity 
and specificity of diagnostic tests for GC. 
 Prognosis of GC patients is heterogeneous, with overall 5-year survival rates of about 20% 
 [ 186 ] . Efforts have been put forth to predict disease outcome and response to treatment. For 
example, a seven-miRNA signature (miR-10b, miR-21, miR-223, miR-338, let-7a, miR-30a-5p 
and miR-126) is closely associated with relapse-free and overall survival among GC patients 
 [ 187 ] . High expression levels of miR-20b or miR-150  [ 188 ] or downregulation of miR-451  [ 165 ] 
or miR-218  [ 174 ] are also associated with poor survival, whereas there is a correlation between 
miR-27a and lymph node metastasis  [ 188 ] . In addition, miR-125b, miR-199a and miR-100 may 
represent a progression-related signature, whereas low expression of let-7 g and high expression 
of miR-214 are associated with shorter overall survival, independently of depth of invasion, lymph 
node metastasis and stage  [ 137 ] . These prognostic miRNAs could be applicable to future decisions 
concerning treatment. 
 The association of miRNA deregulation with malignant diseases indicates the great potential of 
miRNAs as therapeutic targets. The basic strategy of current miRNA-based treatment studies is 
either to antagonize the expression of target miRNAs with antisense technology, to restore or else 
to strengthen the function of given miRNAs in order to inhibit the expression of specific protein-
coding genes. There are several types of modifications for anti-miRNA antisense oligoribonucle-
otides (AMOs), locked nucleic acid, phosphorothioate backbone and cholesterol conjugation, which 
show difference in stability to nuclease degradation and in affinity and specificity to target miRNAs 
 [ 189 ] . Several studies have evaluated the effects of reducing or knocking down the expression of 
overexpressed miRNAs with AMOs in GCs. For example, knockdown of miR-21 by AMOs caused 
a significant reduction in cell proliferation and a significant increase in apoptosis  [ 171 ] . Loss-of-
function of miR-27a inhibits GC cell growth in vitro  [ 190 ] . Conversely, the induction of tumour 
suppressor miRNA with viral or liposomal delivery of miRNA mimics may taper the growth of 
GCs. Functional restoration of miR-34 by miR-34 mimics or lentiviral miR-34a could impair cell 
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growth, accumulate the cells in G1 phase and increase caspase-3 activation in p53-mutant GC cells 
 [ 160 ] . Chemotherapy resistance remains one of the major problems in improving overall survival 
and quality of life in GC patients. miRNAs-based therapy could be used to modulate the response 
of cancer cells to chemotherapy. For instance, miR-15b and miR-16 were downregulated in the 
multi-drug resistant GC cell line SGC7901/VCR and an enforced overexpression of miR-15b or 
miR-16 could sensitize these GC cells to apoptosis induced by vincristine  [ 157 ] . The chemotherapy 
sensitizing effect of the miRNAs was partly mediated by modulation of apoptosis via targeting BCL2. 
 Summary 
 Gastric carcinomas are histologically and genetically heterogeneous and are influenced by gene–
environment interactions resulting in the activation of multiple molecular pathways. The evidence 
of different patterns of genomic instability in GC may allow the identification of specific GC sub-
sets characterized by peculiar molecular alterations and clinico-pathological features and this infor-
mation may indicate improved management for patients care. In this respect, MSI is a promising 
tool. Indeed, MSI-H GCs identify a well-defined subset of GC characterized by unique clinico-
pathological characteristics and, importantly, MSI-H GC cases show a relatively improved long-
term survival compared to MSS/MSI-L counterparts. Thus, a role for MSI as prognostic marker is 
currently being evaluated. MSI can be also used as a marker for early diagnosis of GC considering 
that it can be detected in both gastric adenoma and intestinal metaplasia, which are precancerous 
lesions associated with well-differentiated GC. In this regard, it is noteworthy that the presence and 
the extent of MSI, but also CIN phenotype, assessed in endoscopic biopsy specimens from GC 
patients, was shown to provide valuable information for making a preoperative genetic diagnosis of 
GC  [ 54 ] . 
 Since GC is a heterogeneous disease, it may be amenable to different therapeutic treatment 
depending upon tumour mutational profiles, particularly whether they display MSI, CIN or 
CIMP phenotype. Currently, there is no consensus whether adjuvant therapy is differentially 
beneficial for patients with MSI + or MSI-GC. However, in vitro data suggest that MSI + and 
CIN + cancers differ in their response to therapy-induced DNA damage, and MSI + cancers are 
relatively insensitive to 5-fluorouracil. From a clinical standpoint, DNA methylation changes 
in GC represent an attractive therapeutic target, as epigenetic alterations are, in theory, revers-
ible by using DNA methylation inhibitors, which have been demonstrated to restore gene 
expression and to exert antitumour effects in vitro and in vivo laboratory models. Similarly, 
the development of novel in vivo RNA delivery systems may enhance the importance of 
miRNA as cancer therapeutic drugs. 
 Recently, it has become apparent that gene expression profile may provide an accurate biologic 
rationale for predicting clinical behaviour and outcome  [ 189,  190 ] . By comparing gene expres-
sion in normal and abnormal gastric cells, sets of genes have been identified as putative markers. 
In addition, comparison of expression profiles between malignant gastric histological subtypes 
has allowed the identification of additional genes that may represent a distinct molecular gene 
expression signature. The identification of genes with differential expression in specific gastric 
tumours may provide insight into the initiating mechanisms predicting progression and facilitate 
precise diagnosis. 
 At present, a complete understanding of the basis of genomic instability, aberrant methylation of 
cancer genome, miRNAs and gene expression profiling has to be achieved in GC but the translation 
of molecular genetics to new diagnostic, prognostic and therapeutic modalities has already shown 
its relevant role in GC patients’ management. 
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 Introduction 
 The Tumor Node Metastasis (TNM) staging system from the American Joint Committee on 
Cancer and the “Union Internationale Contre le Cancer” (AJCC/UICC) remains the most reliable 
prognostic indicator for patients with colorectal cancer  [ 1 ] . Overall 5-year survival rates are 
reported at 65% and correspond closely to disease progression; patients with stage I disease have 
more favorable prognoses with 5-year survival rates exceeding 80–90%. In contrast, patients with 
stage II, III and IV disease experience progressively worse outcomes with varying 5-year survival 
rates of 70–85%, 44–80% and <10%, respectively  [ 2 ] . The role of accurate staging has in recent 
years been expanded to include the selection of patients for more individualized treatment regi-
mens. In particular, patients with lymph node positive, nonmetastatic (TNM stage III, AJCC 6th 
edition) colorectal cancers are considered for adjuvant therapies, patients with pT3-4 or lymph 
node (TNM stage IIB or stage III, AJCC 6th edition) positive rectal cancers may be suitable for 
preoperative neoadjuvant therapy while patients with TNM stage IV (AJCC 6th edition), and thus 
metastatic diseases are currently offered anti-EGFR therapies based on molecular analysis of 
 K-RAS gene mutations. According to changes in treatment and improvements in surgery, therapy, 
overall and disease-specific survival, newly outlined and updated tumor staging for patients with 
colorectal cancer is warranted. In November 2009, the AJCC published the 7th edition of the 
Cancer Staging Manual where several important changes in colorectal cancer staging have been 
made; for example, T classification now includes T4a (tumor penetrates the surface of the perito-
neum) and T4b (tumor directly invades or is histologically adherent to other organs or structures) 
 [ 3 ] . This change has consequently led to modifications in stage II, III and IV with the aim of 
improving prognostication and tailoring therapy. 
 Lessons from previous TNM staging systems have demonstrated that despite having identically 
staged tumors, not all patients within the same TNM stage neither experience similar clinical out-
comes nor rates of recurrence or responses to therapy. For this reason, highly relevant and promising 
prognostic and predictive features are currently being explored including a range of tumor- and 
host-related histomorphological, protein and molecular factors. 
 Although many studies have proposed novel prognostic and predictive markers in colorectal 
cancer, their implementation into daily diagnostic work has until now not been performed for 
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several reasons, such as lack of standardized scoring systems, missing inter- and intraobserver and 
laboratory variability studies and concise validation in prospective patient cohorts. The recently 
published REMARK guidelines aim towards standardization of the approach used to investigate 
novel prognostic and predictive biomarkers and increase the likelihood of their inclusion as part of 
pre- or postoperative management of colorectal cancer patients  [ 4 ] . 
 In the last years a considerable progress has been made in the field of gene signatures proposing 
prognostic and predictive biomarkers based on Affymetrix, Oligonucleotide, cDNA and miRNA 
arrays. The aim of this chapter is to give the reader a general overview on prognostic and predictive 
factors in colorectal cancer on various cellular/molecular levels including DNA, RNA, miRNA and 
protein. 
 Prognostic and Predictive Role of Histomorphological, Protein 
and Molecular Markers in Colorectal Cancer: Current Perspectives 
 Tumor-Related Histomorphological Markers 
 According to the UICC, the most pertinent and prognostically relevant histomorphological factors 
after TNM staging recommended for routine pathological diagnosis include venous and lymphatic 
invasion (Fig.  8.1 )  [ 5 ] . Tumor grade, histological subtype, perineural invasion, tumor border con-
figuration and tumor budding are considered “additional” prognostic factors. Indeed, tumor budding 
defined as single cells or clusters of up to five cells at the invasive front, has consistently been shown 
to have adverse effects on clinical outcome and recurrence, with strong associations with lymph 
node positivity and the presence of distant metastatic spread  [ 6– 12 ] . Problems with standardization 
in the reporting of tumor budding constitute the most important limiting factor for this feature and 
therefore studies focusing on a simple and reproducible tumor budding score are still missing. In 
contrast, the tumor border in colorectal cancer is clearly defined and includes the infiltrating, push-
ing and mixed pattern  [ 13 ] . In a recent study, the addition of tumor border configuration to TNM 
stage (AJCC 6th edition) was found to improve the prognostic classification of colorectal cancer 
patients by almost 20%  [ 14 ] . 
 Host-Related Histomorphological Markers 
 The presence of conspicuous peritumoral lymphocytic (PTL) inflammation, viewed as a distinctive 
“encapsulating” connective tissue mantle cap at the invasive front of colorectal cancer, is inversely 
correlated with the presence of tumor budding and positively associated with improved survival. 
Jass demonstrated that PTL infiltration in rectal cancer decreased with more advanced Dukes’ stage 
to 53%, 28% and 13% with Dukes’ A, B and C cases respectively  [ 15 ] . In addition, the significantly 
worsened prognosis in patients lacking PTL inflammation at the tumor border was highlighted, 
while patients with moderate or pronounced infiltration performed significantly better indepen-
dently of disease stage. The results have also been confirmed by other study groups. However, the 
presence of PTL inflammation at the invasive front does not appear to be an independent prognostic 
factor in patients with this disease  [ 14 ] . Nonetheless, PTL inflammation seems to be intimately 
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linked with abundant CD8+ tumor infiltrating T-lymphocytes, further implicating tumor immunity 
in the defense against colorectal cancer. 
 Tumor-Related Molecular and Protein Markers 
 In 2007, a molecular classification of colorectal cancer including the  K-RAS ,  B-RAF , microsatellite 
instability (MSI), methylation of O 6 -methylguanine-DNA methyltransferase ( MGMT ) and the CpG 
Island Methylator Phenotype (CIMP) status was proposed  [ 16 ] . 
 K-RAS and B-RAF Status 
 The pathogenesis and oncogenic behavior of colorectal cancer is in large part regulated by the RAS/
MAP kinase signaling pathway  [ 17 ] . In fact, several key components of this pathway, including 
epidermal growth factor receptor (EGFR),  K-RAS and  B-RAF are being intensively investigated for 
their potential predictive value in patients with metastatic disease treated with anti-EGFR monoclo-
nal antibodies  [ 18 ] . The EGFR is a tyrosine kinase receptor, which upon ligand binding, dimerizes, 
is autophosphorylated and activates downstream signaling molecules. Initial efforts to uncover the 
 prognostic value of EGFR in both unselected and metastatic patients focused on the immunohisto-
chemical detection of the protein in colorectal cancers. The use of over ten different definitions to 
 Fig. 8.1  The most important prognostic and predictive factors in colorectal cancer. ( a ) Two major pathways involved 
in colorectal cancer progression. Up-regulation of WNT pathway signaling, as a consequence of APC mutation, leads 
to translocation of beta-catenin to the nucleus. RAS/MAPK signaling is up-regulated as a consequence of EGFR 
over-expression,  K-RAS mutation and  B-RAF mutation. ( b ) Strength of evidence supporting the most important 
features as prognostic and predictive factors 
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characterize EGFR over-expression has led to conflicting reports in the literature regarding the 
pro g nostic value of this protein, although the majority of reports suggest a more adverse clinical 
outcome in patients with “over-expression” of EGFR  [ 19 ] . This evidence was considered the basis 
for the development of monoclonal antibodies such as Cetuximab and Panitumumab, now approved 
for the treatment of patients with metastatic colorectal cancer. In fact, immunohistochemical detec-
tion of EGFR was used as a selection criterion for patients considering entry into anti-EGFR mono-
clonal antibody clinical trials. However, it was soon noted that not all patients expressing EGFR 
experienced an objective response to treatment although anti-EGFR therapies did indeed seem to 
improve the overall survival rates of patients randomized to therapy in comparison to those 
receiving best supportive care  [ 20 ] . In response to these negative findings, researchers turned their 
focus toward EGFR gene amplification or increased EGFR gene copy number as possible prog-
nostic or predictive markers  [ 21 ] . The few reports evaluating the use of FISH to detect increased 
gene copy numbers in colorectal cancer have shown either a positive association or no correlation 
with response or clinical outcome in metastatic patients treated with anti-EGFR agents. Current 
technical advances have led to the development of EGFR mutation-specific antibodies which can be 
used for immunohistochemistry on paraffin-embedded material. This novel area of investigation 
may also have an impact on the identification of patients with poor clinical outcome, although no 
studies to date have been performed to investigate this hypothesis. 
 The lack of predictive value of EGFR for identifying potential metastatic colorectal cancer 
patients responsive to anti-EGFR therapy has recently promoted the investigation of downstream 
RAS/MAPK signaling molecules and their potential predictive value. Mutations of  K-RAS occur in 
approximately 30–40% of all colorectal cancer patients. Although the majority of studies indicate 
that mutations in  K-RAS have a negative effect on prognosis, these findings have not been unani-
mously described. The largest meta-analysis to date performed by Andreyev and colleagues in 1998 
and again in 2001 seems to suggest that the overall increase in the relative risk of death in patients 
with mutation of  K-RAS is only 1.3 times greater than those patients without  K-RAS mutation  [ 22, 
 23 ] . A possible explanation for these relatively weak findings may be due to the possible differential 
prognostic effects of specific point mutations in the  K-RAS gene. In particular, three mutations 
(codon 12 Gly → Asp (G12D); codon 12 Gly → Val (G12V) and codon 13 Gly → Asp (G13D)) 
occur with a relative increased frequency compared to all other mutations, namely in 14%, 8.5% 
and 7.3% of cases, respectively  [ 24 ] . Works by Finkelstein and colleagues have demonstrated the 
significantly different clinical behaviors of tumors bearing each of these three mutations in addition 
to patients with wild-type tumors  [ 25,  26 ] . The most aggressive form of  K-RAS appears to be muta-
tion in G12D followed by tumors with wild-type  K-RAS . More indolent than the wild-type tumors 
were those with G12V mutation and finally the least aggressive of all were tumors with mutations 
in G13D. Therefore, the proportion of patients with specific point mutations may to some extent 
influence the overall relative risks of death attributed to  K-RAS mutation. Despite this controversy, 
a clear association of  K-RAS gene mutation and lack of response to anti-EGFR therapies has been 
consistently described, to the point where now  K-RAS mutational investigations are routinely 
performed in molecular pathology laboratories  [ 27 ] . However, not all patients with  K-RAS wild-
type tumors respond to monoclonal antibodies targeting EGFR and conversely not all responders 
are those with  K-RAS wild-type tumors. 
 Downstream of  K-RAS in RAS/MAP kinase signaling lays  B-RAF , a gene that is mutated in approxi-
mately 10–15% of CRCs  [ 17 ] . Interestingly,  K-RAS and  B-RAF mutations appear to occur as mutually 
exclusive events. On a clinico-pathological level,  B-RAF mutations have been described as occurring 
more frequently in colon versus rectal cancers and often found in proximal compared to distal tumors. 
Moreover, mutation in  B-RAF seems to be specific for sporadic disease, with mutation status suggested as 
an exclusion criterion for suspected Lynch syndrome-associated/hereditary nonpolyposis CRC 
(HNPCC)  [ 28 ] . Molecularly,  B-RAF mutations have been linked to high levels of MSI (MSI-H), MLH1 
1198 Gene Signatures in Colorectal Cancer
hypermethylation as well as CIMP-high status  [ 29 ] . On a protein level, down-regulation of  B-RAF in 
cell lines has been shown to significantly decrease ERK1/2 phosphorylation and Cyclin D1 expression 
as well as increase expression of p27, results which have been confirmed using tissue from CRC 
patients  [ 30– 33 ] . Additional differences between  B-RAF mutated and wild-type CRCs seem to include 
decreased expression of CDX2, loss of p16, positivity for DNA methyltransferase-3B, a marker of de 
novo CpG island methylation or SIRT1 histone deacetylase expression  [ 31,  34,  35 ] . 
 Only recently have a hand-full of large studies confirmed the poorer outcome in patients with 
 B-RAF mutation. Ogino et al. report a significant adverse effect of  B-RAF mutation in a large cohort 
of more than 600 CRC patients  [ 29 ] . French et al. investigated combinations of  B-RAF mutation and 
MSI status and found that those with MSI cancers and  B-RAF wild-type gene status had a signifi-
cantly improved outcome  [ 36 ] . In MSS cases, Kakar and colleagues report a significantly poorer 
outcome with  B-RAF mutation and a significant association with chromosomal instability  [ 37 ] . The 
recent results from the PETACC-3 study also show significantly worse overall survival with  B-RAF 
mutation in patients with MSI-low or MSS CRCs  [ 38 ] . Richman and colleagues reporting the find-
ings of MRC FOCUS Trial find as well a poorer prognostic effect in patients with  B-RAF mutation 
compared to those with wild-type gene status  [ 39 ] . In the metastatic setting, patients with  B-RAF 
mutation are found to be nonresponsive to anti-EGFR therapies. However, the role of  B-RAF muta-
tion as a general prognostic or specifically as a predictive factor in metastatic patients requires 
further assessment in large randomized trials. 
 Microsatellite Instability Status 
 Microsatellite instability is a term used to characterize changes occurring in the number of micro-
satellite loci, a phenomenon observed in certain tumor types such as colorectal cancer, endometrial 
and gastric carcinomas. The importance of MSI status in colorectal cancer was first recognized 
through investigations on HNPCC, or Lynch syndrome, a familial form of colorectal cancer affect-
ing approximately 3–5% of patients with this disease. HNPCC cancers exhibit a high degree of MSI 
(MSI-H) manifested by germline mutations in one or more of the genes associated with DNA mis-
match repair (MMR)  [ 40 ] . Colorectal cancers arising in the setting of HNPCC are distinct from 
sporadic tumors in that patients are generally younger, seem to have an improved survival and have 
a decreased risk of metachronous tumor development compared to their sporadic counterparts. 
Importantly, MSI-H status is found in approximately 15% of sporadic colorectal cancers caused by 
biallelic hypermethylation of the promoter region of MLH1 leading to inactivation of MMR genes 
 [ 41 ] . MSI-H status can be established by analyzing mutations in a panel of five MSI markers which 
include mono- and dinucleotide markers, namely BAT25, BAT26, D2S123, D5S346 and D17S250 
which can also be supplemented by the more complex repeat MYCL1  [ 42 ] . Sporadic MSI-H tumors 
appear to originate from the serrated pathway (i.e., arising through serrated adenomas), tend to 
occur more often in female patients and are located on the right side of the colon  [ 43 ] . 
 Histomorphologically, they appear frequently as poorly differentiated tumors, with pushing/
expanding tumor borders with little tumor budding, and with a significant PTL infiltration 
(or Crohn’s-like reaction) at the invasive tumor front  [ 44,  45 ] . Additionally, these MSI-H tumors 
tend to have abundant CD8+ tumour infiltrating lymphocytes (TILs) suggesting an inherent immu-
nogenicity not seen in tumors with no instability at any of the five MSI loci. Sporadic MSI-H col-
orectal cancers seem to have a favorable prognosis despite being less responsive to chemotherapeutic 
agents such as 5-FU  [ 41 ] but these findings have recently been challenged  [ 46 ] . The remaining 85% 
of colorectal cancer cases are thought to follow to a large extent the classical adenoma–carcinoma 
sequence first proposed by Volgelstein and Fearon and are microsatellite stable (MSS). The adenoma–
carcinoma sequence proposes that colorectal cancers may arise through a linear accumulation of 
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genetic mutations occurring at various stages of adenoma and carcinoma progression including 
mutations in APC,  K-RAS and p53  [ 47 ] . Mutations in the p53 gene, particularly in patients with 
rectal cancer seem to have a considerable negative effect on clinical outcome and local recurrence 
rates  [ 48 ] . Although mutation in p53 may occur in up to 50% of cases, only 10% of all colorectal 
cancers seem to harbor mutations in APC,  K-RAS and p53 simultaneously. Loss of heterozygosity 
(LOH) at 18q is also being proposed as a prognostic factor for patients with MSS, or chromosomal 
instable tumors, but no consensus has been reached  [ 49,  50 ] . Interestingly, an intermediate subset 
of colorectal cancers has been hypothesized based on the number of low-level MSI, or MSI-L col-
orectal cancers, which are defined, although ambiguously, as instable in <30–40% of microsatellite 
loci  [ 51– 53 ] . Although anecdotal evidence suggests that MSI-L cancers lead to a highly adverse 
outcome, the definition of MSI-L status is equivocal since the larger the number of MSI markers 
evaluated, the larger is the probability of finding instability in at least one of them. Several groups 
have evaluated either 5-panel markers, according to the recommended Bethesda guidelines, while 
others assess 10-panel markers or have evaluated only the more complex MYCL1 in order to estab-
lish MSI-L status. For this reason, the frequency of MSI-L in the literature is difficult to ascertain, 
ranging from 5 to 35% in certain reports. MSI-L colorectal cancers, if they truly exist, have yet to 
be characterized. 
 CIMP Status 
 MSI-H is linked to high-level CIMP. CpG islands are short sequences rich in the CpG dinucleotide 
and can be found in the 5 ¢ region of about half of all human genes  [ 54 ] . Methylation of cytosine within 
5 ¢ CpG islands is linked to transcriptional gene silencing, and occurs in approximately 40% of col-
orectal cancers. This process described as a nonrandom event, is usually associated with absence of 
coding region mutations suggesting that CpG island methylation is a highly relevant mechanism for 
gene inactivation. In fact, CIMP status plays a fundamental role in the current model of colorectal 
tumorigenesis and is currently thought to predispose tumors to MSI. CIMP-High/CIMP-positive 
(CIMP-H/CIMP+) colorectal cancers are often right-sided, more frequent in older female patients, are 
commonly of high tumor grade, and mucinous histology  [ 55 ] . At the molecular level, CIMP-H cancers 
are often associated with  B-RAF mutation, are less common in  K-RAS mutated cases and are most 
often, but not exclusively, MSI-H. Despite the more “favorable” prognosis typically associated with 
MSI-H tumors, outcome in patients with CIMP-H colorectal cancers may be dependent on MSI status 
and/or  B-RAF mutation  [ 29,  55– 57 ] . Older female individuals compose a recognized group of patients 
poorly responsive to 5-FU-based therapies and are reportedly at greater risk of developing CIMP-H 
colorectal cancers as suggested by their higher rates of hypermethylation in normal adjacent colonic 
mucosa compared to males and younger individuals. In 2003, Van Rijnsoever and colleagues investi-
gated two groups of 103 matched stage III patients receiving either surgery or surgery plus 5-FU/
leucovorin and found that CIMP + patients had a significant survival benefit from 5-FU compared to 
CIMP-negative patients  [ 58 ] . Jover and colleagues have recently shown the opposite  [ 59 ] . 
 MGMT Status 
 CIMP has itself been linked with methylation of  MGMT  [ 60 ] .  MGMT acts as a DNA repair enzyme, 
which works to removes alkyl groups that have been added to guanine residues, often occurring as 
a result of chemotherapy. Over-expression of  MGMT has been shown, in patients with glioblastoma, 
to lead to tumor cell resistance  [ 61 ] . In contrast, methylation of  MGMT leads to down-regulation of 
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the gene and decreased expression has been linked to improved therapeutic success. In fact, methylation 
of  MGMT is currently incorporated into diagnostic molecular pathology laboratories to help with 
clinical decision making for patients with gliomas. In colorectal cancer, it is currently being pro-
posed that methylation of  MGMT in the precancerous state (termed field cancerization) produces a 
selective pressure for the subsequent development of MSI. If  MGMT is impaired, the MMR system 
is itself unable to repair lesions caused by the addition of methyl adducts thus leading to double-
strand breaks and apoptosis, while MMR defects would lead to “methylation tolerance”  [ 62 ] . Only 
a handful of studies have investigated the clinical impact of  MGMT and its relationship with molec-
ular features. Loss of  MGMT expression may be linked to Temozolomide response in patients with 
metastatic colorectal cancer  [ 63 ] while Ogino and colleagues have shown no effect of  MGMT 
methylation status on prognosis  [ 60 ] .  MGMT methylation has never been evaluated in the context 
of tumor budding. 
 Molecular and Protein Biomarkers of the PIK3CA/PTEN Signaling Pathway 
 The PIK3CA gene appears to be mutated in 20% of colorectal cancers. PIK3CA mutations occur-
ring in the “hotspots” located in exon 9 (E542K, E545K) and exon 20 (H1047R) are oncogenic in 
colorectal cancer cellular models. The PIK3CA gene encodes for a lipid kinase that regulates, 
alongside with  K-RAS , signaling pathways downstream of EGFR. Moreover, the p110a subunit of 
PI3K, encoded by PIK3CA, can be activated by interaction with RAS proteins. PI3K-initiated sig-
naling is normally inhibited by phosphatase and tensin homologue deleted on chromosome ten 
(PTEN). Recent evidence suggests that both mutation of PIK3CA and negative immunohistochemi-
cal expression of PTEN leads to a lack of response in metastatic colorectal cancer patients treated 
with anti-EGFR therapies  [ 64,  65 ] . 
 Host-Related Molecular and Protein Markers 
 Most studies to date confirm that a high rate of TILs, in particular those located intraepithelially 
characterized by CD4+ and CD8+ tumor-associated antigens are beneficial for patient outcome. An 
abundant TIL count appears to be linked to earlier Dukes’ stage, decreased local recurrence rate 
following curative surgery and improved overall and disease-free survival time both in nonmeta-
static and metastatic patients undergoing hepatic resection. Galon et al . evaluated by gene expres-
sion profiling and immunohistochemistry, the type, density and location (whether at the invasive 
margin or the tumor center) of TILs in a large number of cases. They evaluated CD3, CD8, gran-
zyme B and memory CD45RO T cells and demonstrated a significant independent and positive 
effect of TILs on both recurrence and survival  [ 66 ] . Pages et al. performed a comprehensive analysis 
of TILs focusing on early metastatic invasion  [ 67 ] . They found, by RT-PCR on 75 cases that mRNA 
levels of CD8, granzyme B and granulysin were significantly greater in patients without vascular 
emboli, lymphatic and perineural invasion (collectively known as VELIPI) compared to those with 
these features and that CD45RO+ cells had independent prognostic value  [ 67 ] . New evidence sug-
gest that TIA-1 may be a marker for an activated cytotoxic phenotype and helps to further stratify 
the prognostic effect associated with high levels of CD8+ T-cells  [ 67 ] . Increased numbers of 
interepithelial CD3, CD4, CD8, CD20 and CD16 have been reported to significantly improve over-
all outcome  [ 68,  69 ] . Moreover, regulatory T-cells expressing FOXP3+ and IL-17-expressing cells 
have been shown to correlate with improved outcome independently of TNM stage  [ 70,  71 ] . 
However, evidence suggests that the prognostic value of inflammatory and immunological biomark-
ers is surely confounded by MSI status. 
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 Gene Signatures of Relapse and Prognosis 
 An estimated 102,900 and 39,670 new cases of colon and rectal cancer, respectively, were  diagnosed 
in the United States in 2010  [ 72 ] . Colorectal cancer remains the third most important cancer-related 
killer in Western countries with patient prognosis closely linked to TNM stage of disease. Five-year 
survival rates are stage I: more than 90%, stage IIA and IIB: 60–85%, stage IIIA: 55–60%, stage 
IIIB: 35–42%, stage IIIC: 25–27% and finally stage IV: 5–7%  [ 2,  73 ] . In addition to TNM stage, 
other prognostic factors have been linked to poor survival including fewer than 12 lymph nodes 
examined, poor differentiated histology, lymphovascular invasion, perineural invasion, bowel 
obstruction, or perforation and tumor involvement of surgical resection margins  [ 73 ] . At diagnosis, 
more than 75% of patients undergo curative resection, but up to 40% of patients present at first 
diagnosis with distant metastases. Postoperative adjuvant therapy has had a major positive impact 
on the treatment of patients with colorectal cancer, which is primarily limited to stage III disease. 
Randomized trials support 6 months of postoperative fluorouracil, leucovorin and oxaliplatin and 
may be beneficial to both younger and older patients  [ 74 ] . Interestingly, patients with stage II dis-
ease represent a subgroup of colorectal cancer patients that may differ widely in terms of prognosis. 
In fact, one of the most interesting areas of colorectal cancer research today is the study of prognos-
tic or predictive biomarkers in stage II patients that could identify those who may derive a benefit 
from adjuvant chemotherapy. Additional histomorphological prognostic factors, such as the pres-
ence of tumor budding and infiltrating tumor border configuration with absence of PTL inflamma-
tion and low numbers of CD8+ TILs and possibly other immunological cell types have all been 
shown, mostly in retrospective studies to stratify stage II patients into high- and low-risk groups 
 [ 75– 78 ] . The potential for gene signatures to help complement TNM stage and identify patients 
with lymph node-negative disease who may be at risk of local recurrence and distant metastasis 
would lead to the identification of high-risk patients who may benefit from additional adjuvant, or 
even neo-adjuvant, therapies (Table  8.1 ). 
 Using cDNA or oligonucleotide arrays, Wang and colleagues describe a 23-gene signature to 
predict cancer recurrence in Dukes’ B (node-negative) patients, which led to a 78% accuracy in a 
validation group of 36 independent patients  [ 98 ] . Moreover, recurrence-free survival time differ-
ences between high- and low-risk groups had independent prognostic value when adjusting for age, 
T stage, grade, and tumor size in multivariate analysis. Of the 23 genes included in their signature, 
several are involved in cell proliferation, cell signaling and immune response. Bandres and col-
leagues, using two different statistical methods, found eight genes, five of which were validated by 
real-time PCR, to predict high-risk of recurrence  [ 80 ] .  They show that down-regulation of  CHD2 
(Chromodomain helicase DNA binding protein 2),  RPS5 (Ribosomoal protein S5),  ZNF148 
(Zinc-finger protein 148),  BRI3 (Brain protein I3) and MGC23401 (a hypothetical protein with 
unknown function) discriminate between patients with and without relapse. Arango and 
 colleagues made use of a unique subset of Dukes’ C patients only treated by surgery to investigate 
high- and low-risk groups within this stage of disease  [ 79 ] . They performed gene expression 
analysis first on fresh-frozen material from these adjuvantly nontreated patients and identified, 
among the 218 distinct genes differentially expressed between tumors leading to “good” and “bad” 
prognosis, the gene  RHOA , a Ras homologue. Using an independent set of more than 100 patients, 
they performed immunohistochemistry for RHOA and survival analysis, which seemed to confirm 
that down-regulation of this gene had a considerable negative prognostic effect. Eschrich and 
 colleagues identify a 43-gene signature to discriminate between prognostic groups of patients with 
Dukes B and C cancers. Of these genes, two, namely  osteopontin (a ligand for CD44) and  neuregulin 
(a ligand for ERBB) were singled out as having possibly important biological significance  [ 88 ] . 
Barrier and colleagues identified a 30-gene prognostic predictor in a training set of stage II patients, 
which yielded an 80% prognostic accuracy in the validation set. These 30 genes included many 
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ribosomal proteins, calreticulin, and insulin-like growth factor binding protein 1, among others  [ 82 ] . 
In a second study, the same group investigated a prognostic predictor for stage II patients using 
nonneoplastic mucosa gene expression profiles and identify a 70-gene signature leading to 81.8% 
accuracy  [ 81 ] . 
 These studies highlight the fact that despite investigating colorectal cancers from a relatively 
“homogeneous” histological background, the number of genes included in particular signatures, the 
biological functions of such genes and the prognostic accuracies of gene signatures vary widely. 
 Prognostic Gene Signatures Available on the Market 
 There are several commercial prognostic gene signatures either already available on the market or 
in the last phases of development. The ChipDx ® Colon Cancer module offers a 163-gene prognostic 
gene expression signature to predict risk of recurrence in patients with stage II or III colon cancer 
 [ 102 ] . The Onco type Dx ® Colon Cancer Assay is a quantitative multigene real-time PCR assay, 
which offers a 7-gene relapse-free prognostic gene signature to yield a prognostic recurrence score 
for patients with stage II disease  [ 100 ] . The genes included in the assay are:  BGN (biglycan),  MYC , 
 FAP (fibroblast activating protein),  GADD45B (growth arrest and DNA-damage-inducible, beta), 
 INHBA (inhibin, beta A),  MK167 (antigen Ki67) and  MYBL2 (v-myb myeloblastosis viral oncogene 
homolog (avian)-like 2) and five reference normalization genes. These are associated with activated 
stroma ( BGN ,  INHBA and  FAP ), represent cell cycle ( MK167 ,  MYBL2 , and  MYC ) and genotoxic 
stress pathways ( GADD45B ). 
 ColoPrint ® is a prognostic gene expression profile to predict the risk of recurrence in stage 
II and III colon cancer patients  [ 96 ] . It is based on an 18-gene signature, which when classify-
ing patients into low- and high-risk groups seems to have independent prognostic impact as 
shown by multivariate analysis for relapse free survival. Genes included in the ColoPrint ® assay 
are  MCTP1 (Multiple C2 domains, transmembrane 1),  LAMA3 (Laminin, alpha 3),  CTSC 
(Cathepsin C),  PYROXD1 (Pyridine nucleotide-disulphide oxidoreductase domain 1; unknown 
function),  EDEM1 (ER degradation enhancer, mannosidase alpha-like 1),  IL2RB (Interleukin2 
receptor beta),  ZNF697 (Zinc finger 697; unknown function),  SLC6A11 (Solute carrier family 
6 (neurotransmitter transporter, GABA), member 11),  IL2RA (Interleukin 2 receptor alpha), 
 CYFIP2 (Cytoplasmic FMR1 interacting protein 2),  PIM3 (Pim-3 oncogene),  LIF (Leukemia 
inhibitory factor) (cholinergic differentiation factor),  PLIN3 (Mannose-6-phosphate receptor 
binding protein 1),  HSD3B1 (Hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid 
delta-isomerase 1),  ZBED4 (Zinc finger, BED-type containing 4),  PPARA (Peroxisome 
proliferator- activated receptor alpha),  THNSL2 (Threonine synthase-like 2 [ Saccharomyces 
cerevisiae ]), and  CA4388O2 (function unknown). Interestingly, no genes proposed by either of 
these three commercial assays overlap. 
 Gene Signatures of Treatment Response 
 Over the last decade, considerable efforts have been initiated to identify biomarkers of treatment 
response to therapies with the hopes of identifying gene signatures leading to individualized and 
more tailored treatment regimens for patients with colorectal cancer. The focus has been on three 
areas: metastatic colorectal cancer patients and response to anti-EGFR-based therapies, stage II or III 
colorectal cancer patients and response to adjuvant chemotherapies and finally rectal cancer patients 
and response to preoperative radio/chemotherapies. Some examples are found in Table  8.2 . 
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 Treatment Response to Anti-EGFR Therapies 
 In 2004 and 2006, two monoclonal antibodies targeting EGFR received FDA approval for the 
 treatment of patients with EGFR-expressing, metastatic colorectal cancer with disease progression 
on or following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens: 
Cetuximab and Panitumumab. Cetuximab, in addition, has also been approved for use as a single 
agent in patients who are intolerant to irinotecan-based chemotherapy. It is now generally accepted 
that patients with  K-RAS mutated cancers respond little to anti-EGFR-based therapies  [ 18 ] . As a 
consequence, the ASCO recommends that metastatic patients who may be candidates for Cetuximab 
or Panitumumab be tested for  K-RAS codon 12 and 13 mutations, and this test is now available in 
many diagnostic molecular pathology laboratories  [ 131 ] . Interesting is, however, the relatively low 
clinical response rates, which range from 13 to 61% even in the  K-RAS wild-type setting  [ 27 ] . 
Although some of the lack of response in these patients may be explained by additional mutations 
in  B-RAF (and possibly mutations in other downstream effectors of the RAS/MAPK signaling path-
way), gene signatures that predict clinical responsiveness in the  K-RAS wild-type setting are sought 
after. The work by Oliveras-Ferraros and colleagues is of interest since it attempts to answer the 
question of response prediction among  K-RAS wild-type patients by evaluating different anti-EGFR 
therapies in vitro using Agilent whole genome arrays  [ 120 ] . They identify down-regulation of mark-
ers related to epithelial mesenchymal transition and up-regulation of E-cadherin as involved in 
Cetuximab response. Baker and colleagues and Khambata-Ford and colleagues could perform gene 
expression analysis using formalin-fixed paraffin-embedded material from metastatic colorectal 
cancer patients. They identify from an original probe set of 110 genes, a 4-gene classifier capable 
or predicting response and progression-free survival. Included in their classifier are epiregulin and 
amphiregulin, two ligands for EGFR  [ 105,  110 ] . In fact, expression of these two genes has been 
previously found to have an effect on patients receiving either monotherapy or cetuximab in com-
bination with chemotherapy  [ 110,  132 ] . 
 Although  K-RAS mutation has a negative effect on clinical response, several studies have none-
theless reported up to 30% response rates. Several questions have arisen. Although high rates of 
concordance between the primary colorectal cancer and the distant site of metastasis have been 
reported by several groups, should primary tumor or metastatic site be molecularly investigated? 
What is the effect of possible intratumoral heterogeneity of  K-RAS (and  B-RAF ) mutations? How 
many blocks or tissue samples should be evaluated? Gene expression studies and the identification 
of gene signatures predicting clinical response in metastatic colorectal cancer, particularly in the 
 K-RAS -wild type setting could have significant implications for patient management in the future. 
 Treatment Response to Preoperative Radiochemotherapy 
 About 1/3 of colorectal cancers are indeed located in the rectum. The clinical management of rectal 
cancers differs considerably from those located in the colon. Patients with clinically staged cT3-4 
or cN+ disease are considered for neoadjuvant radio/chemotherapy and relatively high rates of 
complete pathologic response are reported with various treatment protocols  [ 133 ] . The ability to 
predict from the pretreatment rectal cancer biopsy which patients are more or less likely to respond 
to various regimens would have an important impact on clinical decision making. To date, dozens 
of potential immunohistochemical biomarkers have been investigated for their predictive value, 
including Ki67, EGFR, p53, thymidylate synthase, p21, bax/bcl2 with mixed results  [ 134 ] . 
Predictive models based on immunohistochemistry would have many advantages: practicality, ease 
and cost-effectiveness. They are, however, not without their problems: fixation, staining protocols 
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and evaluation of “positive” staining are recognized as sources of variability making it difficult to 
standardize protein markers, despite their considerable potential as prognostic and predictive 
biomarkers. 
 Molecular investigations on rectal cancer biopsy material are significantly fewer and only a 
handful of research groups have performed gene expression profiling to identify gene signatures 
predictive of tumor response. Ghadimi and colleagues using cDNA microarrays analyzed 23 pre-
treatment rectal tumor biopsies and found 54 differentially expressed genes between responders and 
nonresponders  [ 108 ] . Using their algorithm, 78% of responders and 86% of nonresponders could be 
correctly predicted. A validation set confirmed differential expression of 39 out of the 54 genes and 
response for 6 out of 7 tumors was correctly predicted. Rimkus and colleagues analyzed 43 rectal 
cancer patients  [ 123 ] . With their 42-gene signature, 71% of responders and 86% nonresponders 
were correctly identified and led to a similar accuracy in a validation set of 5 patients. Interestingly, 
despite the nearly identical rates of discrimination in both studies, there was no overlap between 
differentially expressed genes. 
 Liersch and colleagues tested the prognostic value of a 54-gene signature previously established 
to discriminate between responsive and nonresponsive rectal cancer patients  [ 113 ] . Using two dif-
ferent platforms (cDNA and oligonucleotide arrays) and biopsies from 23 rectal cancer patients, 
they identify a 20-gene signature predicting tumor recurrence, with seven genes previously included 
in the original 54-gene signature. These included:  ZFP106 ,  KTN1 ( kinectin 1 ),  RBM25 S164 pro-
tein ,  AP3D1 ,  PAK1 p21/Cdc42/Rac1-activated kinase 1 ,  MLL myeloid/lymphoid or mixed-lineage 
leukemia ,  PPP1R10 protein phosphatase 1 ,  regulatory subunit 10 predict recurrence. Eschrich and 
coworkers used 48 different cancer cell lines to establish a predictive gene signature for rectal and 
esophageal cancer which could then be subsequently tested on human rectal cancer tissues. They 
describe a ten-gene profile including  androgen receptor ,  c-Jun ,  PKC ,  RelA ,  c-Abl ,  SUMO-1 , 
 HDAC1 ,  CDK1 ,  IRF1  [ 88 ] . 
 These studies distinctly show the wide variability in genes differentially expressed between dif-
ferent study groups. This problem is compounded with the issue of defining “tumor response” since 
at least five different methods are frequently used to assign patients into responsive/partially respon-
sive/nonresponsive subgroups  [ 135 ] . Even in cases where gene signatures have been established, 
accuracy of prediction is relatively low. The feasibility and clinical value of gene expression arrays 
on preoperative biopsy material from patients with rectal cancer remains to be proven. Nonetheless, 
this technology may be useful to identify candidate genes which should then be tested and validated 
on larger patient cohorts. 
 Treatment Response to Adjuvant Chemotherapy 
 Gene signatures identifying potentially responsive stage II and III patients to different adjuvant 
treatment regimens would be a significant stride forward toward more tailored treatment of these 
patients. Cancer cell lines grown in culture or mouse xenografts have been the major resources used 
to test drug sensitivity. In vitro studies have the advantage of being able to analyze a wide range of 
different chemotherapeutic agents and combine therapies prior to testing gene signatures on data 
from real patients. The group of McLeod and colleagues have investigated the changes in normal 
and tumor tissue from Dukes’ C patients treated with 5-FU and, in a second study, with irinotecan 
in order to identify molecular differences in relevant genes which may contribute to the variability 
in response  [ 136,  137 ] . Although their data was not related to clinical outcome, the evaluation of 
genes specifically targeting the metabolism of chemotherapeutic agents could provide important 
directions in which to focus future studies. 
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 MicroRNA and Methylation Profiling of Colorectal Cancer 
 MicroRNA Profiling 
 miRNAs are posttranscriptional regulators, only 18–25 nucleotides long, that bind to complementary 
sequences on target mRNA transcripts, usually resulting in translational repression and gene silencing. 
Several miRNAs have been linked to colorectal cancer and are found to be significantly over-
expressed in tumor compared to normal tissue including miR-20a, miR-21, miR-106a, miR-181b, 
and miR-203  [ 138 ] . miR-200 is proposed as an integral part of a regulatory feedback loop with 
Zinc-finger enhancer binding transcription factors (ZEB1 and ZEB2) to regulate EM  [ 139 ] . 
Investigations into miRNAs have provided researchers with insight into the fundamental differences 
between colon and rectal cancers and the possible interactions between miRNA and DNA methyla-
tion  [ 140 ] . Grady and colleagues found that transfection of miR-342 into colon cancer cell lines 
may lead to apoptosis which can be inhibited by methylation  [ 141,  142 ] . Others have found that 
miR-124a, let-7a-3, miR-10a and miR-342 may be silenced by DNA hypomethylation  [ 143 ] . miR-
155 and miR-146 have been associated with NFkB, suppressor of cytokine signaling 1 (SOCS1), 
interleukin 6 (IL6) and tumor necrosis factor-alpha (TNF-a). miR-21 may be important for IL6, 
signal transducer and activator of transcription 3 (STAT3), phosphatase and tensin homolog (PTEN), 
and Interleukin 12 (IL12) and others have been linked to SMAD4, COX2, PTGS2, VEGF and 
CCND1. 
 Upregulation of miR-21 has been related to shorter disease-free survival in patients with stage II 
colon cancers  [ 142 ] . miRNA profiling may also be useful to identify new targets for therapy. Ragusa 
and colleagues investigated 667 miRNAs in two human colorectal cancer cell lines, one resistant 
and the other sensitive to anti-EGFR monoclonal antibody Cetuximab using real-time PCR  [ 144 ] . 
They identify that upregulation of MiR-17 is a marker of Cetuximab resistance. Global network 
functional analysis (based on miRNA targets) showed a significant overrepresentation of cancer-
related biological processes and networks centered on critical nodes involved in EGFR internaliza-
tion and ubiquitin-mediated degradation. 
 Methylation Profiling 
 As mentioned previously, the current model of colorectal tumorigenesis encompasses to a signifi-
cant degree epigenetic aberrations in genes such as  MLH1 ,  MGMT and high-level CIMP. CpG 
islands are short sequences rich in the CpG dinucleotide and can be found in the 5 ¢ region of about 
half of all human genes  [ 54 ] . Methylation of cytosine within 5 ¢ CpG islands is linked to transcrip-
tional gene silencing, and occurs in approximately 40% of colorectal cancers. Not only could 
methylation profiling help to identify novel tumor suppressor genes, but the identification of com-
monly and aberrantly methylated genes could have significant diagnostic and therapeutic implica-
tions. Kim and colleagues  [ 145 ] analyzed the methylation profile of 27,578 CpG sites spanning 
more than 14,000 genes in CRC and in the adjacent normal mucosa with bead-chip array-based 
technology. They found that chromosomes 18 and 5 had the most frequently hypermethylated genes 
whereas chromosomes 22, 17 and 15 contained the most hypomethylated genes. Among the genes 
validated by pyrosequencing were ten hypermethylated genes  ADHFE1 (alcohol dehydrogenase, 
iron containing, 1),  BOLL ,  SLC6A15 (solute carrier family 6 (neutral amino acid transporter), mem-
ber 15),  ADAMTS5 (ADAM metallopeptidase with thrombospondin type 1 motif, 5),  TFPI2 (tissue 
factor pathway inhibitor 2),  EYA4 (yes absent homolog 4),  NPY (neuropeptide  Y ),  TWIST1 (twist 
homolog 1),  LAMA1 (laminin, alpha 1), and  GAS7 (growth arrest-specific 7). Interestingly, significant 
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overlap between methylated genes has been reported between different studies  [ 146,  147 ] . Ang and 
colleagues used the same technique to evaluated 1,505 CpG sites in 807 cancer-related genes using 
both normal colon and 91 colorectal cancer samples. Their methylation profile which included 202 
CpG sites differentially methylated between tumor and normal tissue showed distinct clinic- 
pathological and molecular features  [ 56 ] . Xu and coworkers performed methylation-specific PCR 
on 31 genes in colon cancer, normal mucosa and colorectal adenoma and identified changes in 
methylation in the early phases of colon cacrcinogenesis only  [ 148 ] . Intriguing is the reported lack 
of correlation between hypermethylation and changes in protein expression. 
 Summary 
 Our understanding of colorectal cancer progression is continuously changing. Although in 2007, a 
new molecular classification of colorectal cancer was proposed based on the  K-RAS ,  B-RAF , 
 MGMT , CIMP and the mismatch-repair status, the growing number of genes and proteins, which 
seems to be intimately involved in tumor progression will likely lead to further fine-tuning of the 
current proposal. Recent technological advances have opened many novel avenues of investigation, 
notably the extraction of good quality RNA from paraffin-embedded tissues, and are another step 
into the cellular micro-cosmos of colorectal cancer pathogenesis. Nonetheless, the goal of personal-
ized medicine is far from being reached since examples of molecular analysis helping to guide clini-
cal decision-making strategies are at this time limited to the metastatic setting. 
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 Why Epigenetics? 
 Malignant cells are characterised by global cancer-specific changes in gene expression patterns. 
cDNA abundance, analysed by microarray, has been successfully used to determine different types 
and subtypes of cancer cells  [ 1 ] . However, these approaches suffer from important limitations when 
aimed to distinguish groups among a same tumour type as the analysed specimens may display 
considerable heterogeneity. Conversely, even very similar gene expression pattern of groups of 
samples may be the outcome of fundamentally different underlying molecular mechanisms, which can 
be, in turn, cancer specific and associated with distinct clinical prognosis  [ 2 ] . These obstacles 
can, however, be overcome when combining transcriptomic approaches with epigenetic analyses 
of cancer specimens  [ 3 ] . A comprehensive analysis framework can lead, therefore, to a more sensi-
tive and discriminative cancer classification, and ultimately, to a better comprehension of funda-
mental mechanisms acting to establish malignant cell phenotype. Currently, much effort is being put 
in the dissection of the role of epigenetics in cancer development and maintenance  [ 4 ] . Aberrant 
epigenetic profiles of various loci are analysed in search of markers for cancer aggressiveness. 
Finally, the reversal of cancer phenotypes by means of a controlled epigenome modification(s) is 
envisioned in practise and the first clinical trials using the so-called “epidrugs” open new perspec-
tives in modern cancer treatment  [ 5 ] . In this chapter, we introduce fundamental notions in epigenetics 
and its association with cancer and discuss progress in the unbiased use of epigenomics as an additional 
tool in cancer therapy. 
 Fundamental Concepts in Epigenetics 
 Epigenetics can be viewed as “the structural adaptation of chromosomal regions so as to register, 
signal or perpetuate altered activity states”  [ 6 ] . At a molecular level, it is reflected by specific modi-
fications of the chromatin, which ensure proper function and activity of the genome and may act as 
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heritable determinants of cell-type-specific phenotypes  [ 7 ] . Various modifications of the chromatin 
fibre have been described, including post-translational modifications of histone proteins, DNA 
methylation and nucleosome displacement (Fig.  9.1 )  [ 8 ] . They are crucial to the regulation of 
nuclear processes, including gene and microRNA expression, DNA repair as well as replication, 
silencing of transposable elements, X-chromosome inactivation and gene imprinting  [ 7 ] . The 
fundamental role of epigenetics in normal development and physiology of the cell is highlighted by 
the observation that many diseases, including cancer, develop when chromatin is altered  [ 9 ] . 
 DNA Methylation 
 DNA methylation is probably the most extensively characterised epigenetic modification  [ 10,  11 ] . 
In mammals, the vast majority of DNA methylation occurs at position 5 of the cytosine pyrimidine 
ring (5mC) in the case of CpG dinucleotides. CpGs are underrepresented in the mammalian genome in 
 Fig. 9.1  Schematic view of the regulation of gene expression by epigenetic mechanisms. Acetylated chromatin 
(H3ac) at gene promoters is generally permissive to binding of transcriptional activators and recruitment of the RNA 
Polymerase II (Pol II). This conformation is favourable to transcription. Gene silencing can be mediated by either 
DNA methylation-dependent or polycomb Group (PcG)-mediated mechanisms. Hypermethylation of DNA inhibits 
the binding of transcriptional activators and is associated with methyl binding (MBD) proteins, which in turn recruit 
histone deacetylases (HDACs). Alternatively, PcG (formed by PRC1 and PRC2 complexes) methylates H3K27 via 
the PRC2 complex, which in turn allow the binding of PRC1 and establishment of a more compact chromatin, repressive 
towards transcription 
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comparison to other dinucleotide combinations  [ 10 ] . However, stretches of DNA with unexpectedly 
high content of CpGs are also found on the human genome and form the so-called CpG islands  [ 12,  13 ] . 
CpG islands are found in about 60% of gene promoters and are usually unmethylated in normal 
cells, although some CpG islands associated to tissue-specific genes might become methylated 
during cell differentiation  [ 10 ] . The majority of methylated DNA is thus found in regions display-
ing low CpG content. 
 DNA methylation is catalysed by specialised DNA methyl transferases (DNMTs), namely 
DNMT1, DNMT3a and DNMT3b  [ 10 ] . DNMT1, the so-called maintenance methyltransferase, is 
able to methylate DNA during replication based on the DNA methylation pattern of the mother 
strand. DNMT3a and DNMT3b insure de novo methylation of DNA. Whether a specific DNA 
demethylase exists in mammalian cell is still an open question; the removal of this mark is proposed 
to be mediated by DNA repair machineries  [ 14 ] . The recent discovery that the TET family of pro-
teins could catalyse conversion of 5mC to 5-hydroximethylcytosine (5hmC), raises the possibility 
that DNA demethylation might be achieved via TET-mediated hydroxylation  [ 15,  16 ] . Interestingly, 
TET1 is a frequent fusion partner of MLL in AML patients  [ 17 ] . 
 Initial studies using 5 ¢ aza-deoxycitidine, a drug which inhibits the enzymatic activity of DNMTs, 
showed a positive effect on gene expression, thus establishing CpG methylation as an epigenetic 
modification involved in gene silencing  [ 10 ] . Subsequently, DNA methylation has been linked to the 
regulation of tissue-specific gene expression throughout development  [ 11 ] . However, recent pieces 
of evidence point to a more complex interplay between DNA methylation and transcription; while 
DNA methylation in promoter regions anti-correlates with transcription, its presence in gene-bodies 
displays a positive correlation with gene expression level  [ 18,  19 ] . The repressive role of DNA 
methylation was furthermore associated with gene imprinting, which consists in parent-of-origin 
specific silencing of one of two alleles resulting in heterozygous gene expression  [ 20 ] . 
 DNA methylation at promoters can inhibit gene expression through various mechanisms  [ 11 ] , 
including (1) recruitment of methyl-CpG binding domains (MBDs) proteins, which in turn recruit 
histone modifying and chromatin-remodelling complexes to methylated DNA and induce a com-
pacted chromatin structure (Fig.  9.1 ); or (2) the inhibition of the binding of specific transcription 
factors (TFs) to their target sites. On the contrary, the absence of DNA methylation at promoter-
associated CpG islands generates a chromatin structure which favours gene expression  [ 21 ] . 
 Histone Post-translational Modifications 
 A nucleosome, the basic unit of chromatin, consists of an octameric histone core surrounded by 
genomic DNA  [ 22 ] . Post-translational modifications of histones occur mainly on the unstructured 
N-terminal tail of histone proteins protruding from the nucleosome surface. These modifications 
include: methylation, acetylation, phosphorylation, ADP ribosylation and sumoylation  [ 7 ] . The 
deposition of specific histone modifications are catalysed by the following dedicated enzymes: 
histone acetyl-transferases and deacetylases (HATs and HDACs, respectively), histone methyl 
transferases and demethylases (KMT and KDMs, respectively)  [ 8 ] . Plethora of possible combinato-
rial patterns of histone modifications at a given genomic position, along with the existence of dedi-
cated protein domains recognising distinct modifications, has led to the “histone code hypothesis” 
 [ 23 ] . According to this concept, distinct combinations of epigenetic modifications encode specific 
information. Indeed, histone modifications can serve as docking platforms for various factors, 
including components of the general transcription machinery and DNA repair enzymes, thus modu-
lating underlying nuclear processes, such as transcription and DNA repair. Protein domains able to 
recognise histone marks include, among others: bromodomains recognising acetylated histones, and 
PHD as well as chromodomains binding methylated histones  [ 8 ] . 
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 Distinct patterns of histone modifications positively or negatively correlate with gene expression. 
Transcriptionally active genes are enriched for histone 3 acetylation (H3ac) as well as trimethyl form 
of histone 3 lysine 4 (H3K4me3) established by the MLL family of HMTs, whereas the lack of his-
tone acetylation along with H3K9me3 and H3K27me3 deposited by Suv39h and the polycomb group 
(PcG) complex, respectively, is primarily associated with transcriptional repression  [ 7 ] . 
 The presence of specific chromatin modifications modulates the affinity of TFs to underlying 
DNA sequences, which results in a locus-specific transcriptional programme (Fig.  9.1 ). The marks 
H3K4me3 and H3ac stabilise the binding of the basic transcription machinery, thus promoting gene 
expression. In addition, these histone modifications favour nucleosome displacement resulting in a 
more “open” chromatin structure prone to TF binding, hence perpetuating active gene states. 
At inactive promoters, the lack of these modifications together with the deposition of H3K27me3 
and/or H3K9me2 and DNA methylation  [ 8 ] , induce a more condensed chromatin structure, less 
permissive to transcription. 
 Role of Epigenetic Alterations in Cancer: The Epimutation Concept 
 As mentioned earlier, epigenetic information can be transmitted mitotically  [ 6 ] . This leaves the 
possibility that an aberrant epigenetic pattern can, in turn, also be perpetuated through cell division. 
This assumption lays the basis of the epimutation concept  [ 24 ] , in which perpetuated alterations in 
the epigenetic state may cause heritable aberrant transcription pattern(s) observed in various human 
diseases, such as cancer (Fig.  9.2 ). As epimutations may occur at a much higher frequency than 
genetic mutations, they are likely to have a greater impact on a selection of subpopulations of cells 
during tumour progression or acquisition of resistance to anticancer drugs  [ 25 ] . Indeed, in addition 
to classic genetic mutations, cancer cells display a profoundly altered epigenetic landscape, charac-
terised by global changes in DNA methylation, histone modifications and expression of chromatin 
modifying enzymes  [ 9 ] . What could be at the origin of epigenetic aberrations found in cancer? 
Environmental factors (asbestos, tobacco, etc.) in conjunction with ageing have been shown to be 
significantly associated with epigenomic alterations (Fig.  9.2 ). Their already recognised oncogenic 
potential further points to a fundamental role of epimutations in common carcinogen-driven onco-
genesis  [ 26,  27 ] . Additional mechanisms include aberrant expression and/or function of chromatin-
modifying enzymes  [ 9 ] . As discussed in detail below, various chromatin-modifying enzymes 
display altered levels of expression in cancer, and the corresponding genes are often implicated in 
chromosomal translocations. 
 Methods for Assessing the Epigenetic Modifications 
at the Genome-Wide Scale 
 During the past two decades, considerable advances have been made in mapping and analysing 
epigenetic modifications  [ 28 ] . The completion of the human genome project, the advent and versa-
tility of array technologies and, more recently, next generation sequencing (NGS) technologies have 
led to a growing number of genome-wide studies assessing DNA methylation and histone post-
translational modifications in normal and cancer cells  [ 4,  29,  30 ] . 
 Various assays have been developed to analyse DNA methylation at a global scale, which mainly 
differ by the means used for isolation and detection of 5mC (Fig.  9.3 ). In restriction enzyme-based 
approaches, methylation sensitive and insensitive isoschizomers are used to generate restriction 
maps of the total genomic DNA, which directly reflects the genome-wide distribution of methylated 
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cytosines. The methylation pattern is further analysed by direct NGS or hybridisation to dedicated 
microarrays covering either the whole genome or chosen areas, such as gene promoters or CpG 
islands  [ 31,  32 ] . This technique enables the detection of hyper or hypomethylated regions with a 
moderate resolution depending on the restriction enzyme in use. Another approach consists in the 
affinity-based enrichment of methylated DNA by a 5mC-specific antibody (MeDIP)  [ 33 ] or a 
recombinant MBD protein (MethylCap)  [ 34 ] . MeDIP was originally combined with CpG or pro-
moter microarrays  [ 33,  35,  36 ] and subsequently adapted to NGS  [ 37,  38 ] . Limitations of these 
techniques include decreased affinity towards CpG-poor regions and potential bias against CG-rich 
regions  [ 35,  36,  39 ] . However, to improve the quantification efficiency, fully in vitro methylated 
DNA might be used as a control  [ 2,  39,  40 ] . Finally, in bisulfite-based methods, DNA is first treated 
with sodium bisulfite. This treatment converts all unmethylated cytosines to uracyl while methy-
lated cytosines remain unchanged. A bisulfite-based method has been adapted to microarrays in the 
 Fig. 9.2  Possible causes and consequences of epigenetic alterations in the development of cancer. Various environ-
mental clues may influence the epigenome of the cell. Alterations in the epigenome are reflected by aberrant changes 
in the level of DNA methylation and key histone post-translational modifications, which in turn induce genome 
instability and/or altered gene expression patterns. These aberrant epigenetic landscapes, along with other genetic 
events, might eventually lead to cancer 
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Infinium HumanMethylation27 assay developed by Illumina, Inc (California, USA)  [ 34 ] . Bisulfite-treated 
samples can also be used directly for high-throughput sequencing (BS-Seq) to precisely map the 
positions where 5mC is present in a genome-wide manner  [ 41 ] . Although to date, this technique 
enables the most accurate and unbiased localisation of methylated DNA, it still remains expensive, 
as it requires full genome sequencing  [ 30 ] . More affordable bisulfite-based sequencing methods 
have been developed, including “reduced representation bisulfite sequencing” (RRBS)  [ 42– 44 ] and 
bisulfite capture  [ 45 ] . A recent study provided a quantitative comparison of genome-wide DNA 
methylation mapping approaches applied to clinical samples  [ 46 ] . This study concluded that all 
tested methods allow for an efficient detection of differentially methylated regions between sam-
ples, but differ in terms of sensitivity and genomic coverage. 
 Histone post-translational modifications are commonly assessed by chromatin immunoprecipita-
tion (ChIP), which consists in immuno-enrichment of cross-linked and randomly sheared chromatin 
 Fig. 9.3  Genome-wide methods for studying histone post-translational modifications and DNA methylation. Chromatin 
immunoprecipitation (ChIP): Cross-linked and sonicated chromatin is immunoprecipitated with specific antibodies 
recognising distinct histone post-translational modifications. Methylation-dependent immunoprecipitation (MeDIP): 
Genomic DNA is first sonicated and an antibody specific to 5mC is used to recover methylated regions. Restriction 
enzyme: DNA methylation can be identified by a combination of restriction enzymes that differentially recognise 
methylated and unmethylated CpGs (Hpa II is shown as an example). Bisulfite treatment: the treatment of DNA with 
bisulfite changes all unmethylated cytosines into uracils, leaving methylated cytosines unchanged. Any of these methods 
can be combined with either microarray hybridisation or next generation sequencing (NGS). Alternatively, bisulfite-
treated samples can be enriched for regions of interest by using a capture approach before NGS 
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fragments using highly specific antibodies against a given chromatin modification (Fig.  9.3 )  [ 29 ] . 
To obtain a genome-wide view of histone modification patterns, ChIP samples are either hybridised 
onto tiling microarrays (ChIP-on-chip) or directly used for high-throughput sequencing (ChIP-Seq). 
This latter method provides genome-wide coverage and a less-biased analysis outcome, but gener-
ally requires a higher number of cells. Although ChIP-on-chip and ChIP-Seq procedures are clearly 
more technically demanding than DNA methylation approaches, it is possible to adapt it to large-
scale studies on primary blasts (see below). 
 General Alterations of DNA Methylation in Cancer 
 Aberrant DNA methylation events are believed to play a fundamental role in cancer development and 
maintenance  [ 47 ] . Global diminution of the level of DNA methylation in cancer measured by HPLC 
was the very first link between alteration in this epigenetic modification and cancer  [ 48,  49 ] . Global 
diminution of methylated DNA was further found to be molecularly associated with decreased genome 
stability via the activation of transposable elements and repetitive sequences  [ 50,  51 ] . The determining 
role of DNA hypomethylation in oncogenic processes was formally demonstrated later on by genetic 
disruption of the  DNMT1 gene in mouse, which resulted in global loss of DNA methylation and cor-
related with the occurrence of aggressive tumours and genomic instability  [ 52– 54 ] . 
 In addition to global loss of DNA methylation, cancer-specific DNA methylomes can also be 
characterised by site-specific hypo- and hypermethylation of CpG residues  [ 55 ] . Initial evidences 
of tumour type-specific epigenetic alterations have emerged from gene-by-gene analyses of pro-
moter DNA methylation. On the one hand, hypomethylation at specific promoters can activate the 
aberrant expression of oncogenes, such as  RAS  [ 56 ] ,  SERPINB5  [ 57 ] and  S100P  [ 58 ] .  L oss  O f gene 
 I mprinting (LOI) is a prominent example of DNA hypomethylation induced expression of growth 
promoting genes commonly observed in cancer  [ 59,  60 ] , such as  IGF2  [ 61 ] . Conversely, aberrant 
transcriptional down-regulation of various tumour suppressor genes, including  Rb ,  p53 ,  MGMT or 
 p16  INK4a  , was shown to involve abnormally frequent DNA methylation of their promoter regions; 
and was generally associated to a less favourable clinical prognosis  [ 55,  62– 65 ] . DNA hypermethy-
lation is also tightly linked to the so-called  L oss  O f  H eterozygosity (LOH) phenomenon, which 
consists in the complete silencing of imprinted loci and is commonly observed in cancer  [ 66,  67 ] . 
 Initial studies performing genome-wide profiling of DNA methylation of various cell lines, 
tumour samples and normal tissues, revealed both aberrantly methylated CpGs shared by distinct 
tumour types and tumour-specific signatures  [ 35,  68– 70 ] . Furthermore, in colon cancer and T-cell 
acute lymphoblastic leukaemia (T-ALL), some patients were shown to be more susceptible to aber-
rant DNA methylation of CpG-rich promoters of cancer suppressor genes  [ 71– 74 ] . This led to the 
“CpG Island Methylator Phenotype” (CIMP) hypothesis, whereby increased DNA methylation 
frequency and pronounced transcriptional down-regulation of surrounding genes are linked, together 
with a less favourable prognosis  [ 75 ] . Finally, even though most studies have focused on CpG 
islands located near promoters, recent findings revealed that most of the hypermethylated regions 
in cancer do not reside in CpG islands themselves but rather in CpG-rich flanking sequences termed 
“the CpG island shores”  [ 58,  76 ] . 
 DNA Methylation Signatures 
 The above described reports evidenced severe genome-wide alterations of DNA methylation profiles 
in cancer versus normal tissues. This point to the existence of a cancer-specific epigenome poten-
tially associated with distinct clinical outcomes  [ 77 ] . Several labs have performed promoter-wide 
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screens of DNA methylation profiles in collections of leukaemias  [ 74,  78– 83 ] and solid tumours 
 [ 69,  80,  84– 87 ] . Collectively, these studies suggest that DNA methylation distributes into specific 
patterns in cancer cells, and that these methylation profiles reflect critical biological differences 
with practical clinical and therapeutic implications. Furthermore, the study of epigenetic profiles of 
a cohort of two groups of acute myeloid leukaemia (AML) patients who shared a common gene 
expression profile, but differed in the way the  CEBPA locus was inactivated, revealed that these two 
groups could be readily segregated in an unsupervised fashion, based on their DNA methylation 
profiles alone  [ 81 ] . This latter study highlights the interest of performing integrative analyses com-
bining genomic, transcriptomic and epigenomic approaches. 
 However, in parallel with these outstanding discoveries, a substantial variability of DNA methy-
lation profiles has been observed, pointing to an increased biological noise in epigenetic profiles, 
which eventually hinders the intended analysis. Likely, epigenomic heterogeneity among distinct 
group of cancers is the rule and reflects their various ontogenic histories. For example, clustering of 
follicular lymphoma (FL) samples based on DNA methylation profiles distinguished well between 
FL and normal lymph node samples, but showed minor differences between subtypes of FL, sug-
gesting that the global epigenome is highly conserved among different FL subtypes  [ 79,  80 ] . This 
obstacle can probably be circumvented by using larger collection of samples. 
 To date, the most comprehensive study of the interplay between DNA methylome and clinical 
outcome was performed by Figueroa et al.  [ 82 ] . The DNA methylation signatures of a large cohort 
of 344 AML patients were analysed with methylation sensitive restriction enzyme recovery of 
methylated DNA, coupled with microarray detection  [ 82 ] . This study revealed the existence of 
distinct DNA methylation patterns in AML and identified novel, biologically and clinically relevant 
defined AML subgroups. Moreover, these authors described a “15 gene DNA methylation classi-
fier” capable of predicting overall survival in an independent cohort of patients. Thus, large-scale 
DNA methylation profiling demonstrates the potential benefit of using epigenetic markers, even 
with patients for whom clinical biomarkers are not currently available. 
 General Alteration of Histone Modifications in Cancer 
 Despite the fact that a plethora of histone-modifying enzymes has been shown to undergo mutation 
in cancer, the association between aberrant histone modifications and cancer is still not completely 
understood  [ 9,  88 ] . Pioneering quantification of global levels of histone modifications revealed a 
general loss of H3K16 acetylation and H4K20me3 modifications in various tumours, which were 
associated with diminished level of these modifications in repetitive sequences of the genome  [ 89 ] . 
In a parallel study, global levels of five histone post-translational modifications assessed by tissue 
microarray technology were also associated with clinical outcome of prostate cancer patients  [ 90 ] . 
Since then, several reports pointed to important alterations in the global level of various histone 
modifications, such as H3K27me3, and demonstrated their association with cancer prognosis 
(Table  9.1 )  [ 88 ] . Likewise, low levels of the histone variants macroH2A1.1 and macroH2A2 are 
poor-prognosis factors in prostate cancer  [ 100 ] . Although the genetic causes of global alteration in 
histone modifications are not clearly defined, they are likely due to aberrant expression of chroma-
tin-modifying enzymes. Indeed, histone modification profiles have been extensively studied in 
cancer models, where chromatin-modifying enzymes are directly implicated in the oncogenic 
process, due to defined genetic alterations involving notably RARa, MLL and NUP98 as fusion 
partners (Fig.  9.4 ). 
 Expression of the PML–RARa oncofusion protein is characteristic of a subset of acute promy-
elocytic leukaemia (APL). PML–RARa has been shown to recruit HDACs, PcG complexes and 
HMTs and to aberrantly silence genes in APL  [ 101 ] . Yet, recent genome-wide ChIP-Seq analyses 
1459 The Role of Epigenetics in Cancer: From Molecular Function to High-Throughput Assays
 Table 9.1  Alterations in global histone modifi cation levels associated with cancer 
 Modification  Cancer  Alteration  First author [Reference] 
 H3K4me1  Prostate  Decreased  Ellinger et al.  [ 91 ] 
 H3K4me2  kidney, breast, pancreatic adenocarcinoma  Decreased  Manuyakorn et al.  [ 92 ] 
 Elsheikh et al.  [ 93 ] 
 Prostate cancer  Increased  Ellinger et al.  [ 94 ] 
 Seligson et al.  [ 90 ] 
 Renal carcinoma  Increased  Bianco-Miotto et al.  [ 95 ] 
 Ellinger et al.  [ 91 ] 
 H3K4me3  Prostate  Increased  Ellinger et al.  [ 94 ] 
 H3K27me3  Breast, ovarian, pancreatic  Decreased  Wei et al.  [ 96 ] 
 H3K9me2  Pancreatic adenocarcinoma, prostate, kidney  Decreased  Manuyakorn et al.  [ 92 ] 
 Seligson et al.  [ 90 ] 
 H3K9me3  Gastric adenocarcinomas  Increased  Ellinger et al.  [ 94 ] 
 Prostate  Decreased  Ellinger et al.  [ 94 ] 
 H4K20me3  Various tumour cell lines, primary lymphomas 
and colorectal adenocarcinomas 
 Decreased  Fraga et al.  [ 89 ] 
 K3K79me3  Leukaemia  Decreased  Lin et al.  [ 124 ] 
 H2AK119ubq  Prostate cancer  Increased  Berezovska et al.  [ 97 ] 
 H3ac  Prostate  Decreased  Ellinger et al.  [ 94 ] 
 H4ac  Renal carcinoma  Decreased  Moshasvilli et al.  [ 98 ] 
 Prostate  Ellinger et al.  [ 94 ] 
 H4K16ac  Various tumour cell lines, primary lymphomas 
and colorectal adenocarcinomas, breast cancer 
 Decreased  Fraga et al.  [ 89 ] 
 Elsheikh et al.  [ 93 ] 
 H3K9ac  Renal carcinoma  Decreased  Moshasvilli et al.  [ 98 ] 
 H3K18ac  Renal carcinoma, pancreas  Decreased  Moshasvilli et al.  [ 98 ] 
 Prostate  Increased  Manuyakorn et al.  [ 92 ] 
 Bianco-Miotto et al.  [ 95 ] 
 H3K9ac  Esophagal squamous cell carcinoma  Distinct 
combinatorial 
pattern of 
modifications 
 I H et al.  [ 99 ] 
 H3K18ac 
 H4K12ac 
 H3K9me2 
 Fig. 9.4  Oncogenic 
processes directly involving 
chromatin-modifying 
enzymes and altered 
epigenetic profi les 
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revealed that alteration in histone acetylation is the essential epigenetic outcome associated with 
PML–RARa oncogenic function(s) (Fig.  9.4 )  [ 38 ] . Interestingly, PLZF–RARa, another oncofusion 
protein associated with APL, was shown to recruit the PcG complex and to induce H3K27 methyla-
tion of the silenced RAR target  RARb  [ 102 ] . It is therefore possible that depending on the RARa 
fusion partner, distinct epigenetic mechanisms may be involved in the leukaemogenic process. 
 Translocations of MLL histone methyltransferase are found within 10% of human leukaemias 
and involve some 50 different fusion partners  [ 103 ] . The resulting product is often devoid of the 
SET domain of MLL, and therefore loses its H3K4 methylation function. Interestingly, MLL often 
fuses to other chromatin-modifying enzymes, such as the HATs CBP and p300. Several MLL onco-
fusion partners, including AF4, AF9, AF10 and ENL TFs, have been reported to associates with the 
HMT DOT1L  [ 3 ] . DOT1L mediates H3K79 methylation, a histone mark associated with transcrip-
tional elongation. Ectopic recruitment of DOT1L to natural MLL targets, such as the  HOXA9 gene, 
resulted in increased level of H3K79me2 and gene activation. The best-characterised example of the 
interplay between MLL and DOT1L chromatin modifiers in leukaemia is provided by the oncofu-
sion protein MLL–AF4 (Fig.  9.4 )  [ 3 ] . Genome-wide mapping of MLL–AF4 targets revealed that 
regions bound by the fusion protein undergo widespread chromatin remodelling associated with 
enrichment in the H3K79me2 histone mark  [ 104 ] . In a parallel study, Krivtsov et al. also demon-
strated massive increases of H3K79me2 across MLL–AF4 targets in both murine and human cells 
 [ 105 ] . Whether other MLL oncofusion proteins that associate with DOT1L also induce a similar 
epigenotype still needs to be investigated. 
 Finally, translocation of the nucleoporin-98 ( NUP98 ) gene in AML often fuses NUP98 to either 
NSD1, which is an H3K36 histone methyltransferase, or to the PHD domain-containing proteins 
PHF23 and JARID1A  [ 106 ] . Conversely, NUP98–NSD1 binds genomic elements adjacent to 
 HoxA7 and  HoxA9 , maintains H3K36 methylation and histone acetylation, and prevents EZH2-
mediated transcriptional repression of the  Hox-A locus  [ 107 ] . NUP98–PHD fusions protein, how-
ever, binds to H3K4me2/3 via the PHD domain, thus preventing the repression of loci encoding 
lineage-specific TFs, such as the  HOX genes (Fig.  9.4 )  [ 108 ] . Hence, NUP98 fusions result in simi-
lar behaviour regarding gene expression but, depending on the fusion partner, differ in the target 
histone modification and hence in the intrinsic mechanism that may be in cause. 
 Histone Modification Signatures Associated with Cancer 
 For obvious reasons, including the technical complexity and variety of post-translational modifi-
cations, histone modifications profiles in primary cancer cells have thus far been less explored 
than DNA methylation  [ 4 ] . A proof-of-concept study investigated several cases of leukaemia by 
combining transcriptomic studies with genome-wide analysis of H3K9ac and DNA methylation 
 [ 109 ] . By combining gene expression and epigenetic analyses, the authors were able to identify 
additional aberrantly expressed genes that would have been missed in a less comprehensive 
analysis. Another example of the successful use of ChIP-on-chip technology in cancer patient 
classification and description of molecular bases of oncogene function was provided by the study 
of MLL-rearranged leukaemia, described earlier in this chapter  [ 105 ] . By comparing genome-
wide H3K79me2 profiles in leukaemia samples and normal B-cell precursors, a striking signature 
was observed. Based on these results, the authors were not only able to discriminate between 
ALL cells and their normal counterparts, but also between MLL-rearranged and not rearranged 
leukaemias  [ 105 ] . Of note, the H3K76me2 signature in MLL-rearranged ALL was mostly associ-
ated with gene activation, in contrast to the gene repression behaviour generally believed to be 
associated to epigenetics in cancer. 
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 Much attention has been put into the description of the role of the mark H3K27me3 in cancer 
cells as the overexpression of Ezh2 is associated with poor clinical outcome  [ 110 ] . A large-scale 
study addressing the question of H3K27me3 distribution in primary cancer cells has been conducted 
on gastric cancer specimens  [ 111 ] . The authors observed substantial differences in H3K27me3 
signal. Further insights into the relationship between distribution of this modification and oncogen-
esis have been gained by comparison of H3K27me3 ChIP-on-chip profiling between prostate cancer 
cell lines and normal prostate epithelial cells  [ 112– 115 ] . These studies demonstrated a strong fin-
gerprint of PcG-mediated transcriptional repression in metastatic prostate cancer. Interestingly, 
significant subsets of these genes are also targets of PcG in embryonic stem cells, highlighting the 
link between stem cell self-renewal and cancer  [ 110 ] . In addition, in prostate cancer, the mark 
H3K27me3 was associated with silencing of genes harbouring CpG-rich promoters, independently 
of DNA methylation, thus pointing to an alternative (DNA methylation independent) epigenetic 
mechanism of transcriptional down-regulation  [ 114 ] . However, other labs have reported that 
H3K27me3 targets loci for the novo DNA methylation in cancer cells  [ 116– 118 ] . Large-scale promoter 
profiling of H3K27me3 and methylated DNA marks in normal versus prostate cancer cell lines 
revealed frequent replacement of one mark by the other, without change in the expression level of 
the corresponding genes  [ 2 ] . This switch mechanism might serve as a modulator of epigenetic plas-
ticity potentially associated with the growth advantage of cancer cells. Thus, even though the link 
between aberrant DNA methylation and PcG/H3K27me3 chromatin signature in cancer is not clear 
yet (Fig.  9.1 ), it may provide important clues for the design of new therapeutic strategies targeting 
both DNA methylases and PcG components. 
 Summary and Future Directions 
 As discussed in this chapter, cancer cells can be described by altered profiles of epigenetic marks, 
including both DNA methylation and histone post-translational modifications  [ 9 ] . The alterations in 
these epigenetic modifications can thus be descriptive of a cancer-cell stage, as they occur gradually 
starting from the onset of the earliest malignant cells. In addition, they can constitute an additional 
source of information on the molecular determinants of the observed phenotype. Extensive mapping 
of epigenetic alterations in normal versus malignant cells can highlight molecular mechanisms 
guiding cancer formation and maintenance and, ultimately, can lead to the isolation of potential 
markers of cancer aggressiveness. In particular, the elevated stability of DNA molecules, in com-
parison to RNA molecules, and the development of highly sensitive DNA methylation assays render 
possible the epigenotyping of various tumour samples and early detection of cancer  [ 119 ] . The 
continuous decrease in the cost of genome-wide approaches will allow large-scale mapping of epi-
genetic profiles with growing number of cancer samples, including paraffin-embedded patient 
samples  [ 120 ] . Also the development of new sequencing technologies, such as single DNA mole-
cule sequencing, will allow, for instance, performing unbiased BS-Seq approaches in a cost-effec-
tive way  [ 30,  121 ] . Moreover, the reactivation of expression of tumour suppressor genes can be 
obtained by the use of drugs modulating the epigenetic profile of the cell. Such epidrugs are cur-
rently either already employed in cancer therapy or being tested in clinical trials  [ 5 ] . The successful 
development of epigenetic inhibitors for use in cancer therapy depends, however, on the precise 
understanding of epigenetic mechanisms involved. Examples of such knowledge-based approaches 
have recently been published  [ 122,  123 ] . In conclusion, it is the combination of comprehensive 
genotyping, gene expression pattern analyses, along with detailed epigenomic profiling of cancer 
cells that will eventually lead to a more profound understanding of cancer as a disease and ulti-
mately arm clinicians with more reliable and robust means of cancer classification and treatment. 
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 Origin, Pathogenesis, Morphology, Classification Immunomarkers 
 The World Health Organization (WHO) classification of ovarian tumors, which first appeared in 
1983 and since then has undergone a number of revisions ,  [ 1 ] is based on morphologic features as 
well as on the concept that each category of ovarian tumors develops from a specific ovarian cell. 
According to this histogenetic classification, all the epithelial ovarian neoplasms are derived from 
the ovarian surface epithelium and/or from ovarian inclusion cysts, which are lined by the above 
epithelial cells. 
 In recent years, a new approach to morphologic data, increasing presumptive evidence that the 
cell of origin of most, if not all, ovarian epithelial tumors may be extraovarian, especially from fal-
lopian tube and uterine endometrial cells, the recognition of precursor lesions, the emergence of 
certain key immunomarkers as well as molecular and genetic factors  [ 2– 4 ] have brought about a 
reevaluation of the traditional approach to these tumors. This has resulted in attempts of reclassifica-
tion or subclassification of ovarian epithelial neoplasms as well as new diagnostic criteria for these 
tumors  [ 5 ] . It should also be stressed that in most cases these new concepts correlate with the clini-
cal course of the disease and eventually may also have an impact on the therapeutic approach to 
these tumors. 
 Origin and Pathogenesis of Epithelial Ovarian Neoplasms 
 The long-standing classic theory that all types of ovarian epithelial neoplasm are derived from the 
ovarian surface epithelium (mesothelium) and/or from its stromal invaginations resulting in ovarian 
inclusion cysts has been challenged in recent years. Actually, the ovarian surface epithelium 
bears no resemblance to any of the different epithelial tumors, which involve the ovaries, and a 
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questionable metaplastic process has been suggested to explain the apparent transformation of 
these ovarian surface cells to serous, endometrioid, mucinous, clear cell, and other epithelial neoplasm. 
 In recent years, entirely new concepts concerning the origin and pathogenesis of ovarian epithelial 
tumors have been advanced and were recently summarized by Kurman and Shih  [ 4 ] . 
 According to this hypothesis, most ovarian epithelial neoplasms are considered to be of extrao-
varian origin. Thus, it has been suggested that serous carcinomas develop from the fimbriated por-
tion of the fallopian tube, endometrioid, and clear cell tumors from endometrial tissue passing 
through the fallopian tube resulting in endometriosis and mucinous as well as Brenner tumors arise 
from transitional-type epithelial nests at the tubal–mesothelial junction by a process of metaplasia. 
 Admittedly, much of the above still remains to be proven, but these preliminary data are of great 
interest and may find support in recent molecular and gene expression studies. 
 Serous Tumors 
 The vast majority of high-grade ovarian carcinomas are of the serous type. It is now being recognized 
that these tumors are morphologically very heterogenous which constitutes most likely an expression 
of their genetic heterogeneity  [ 3 ] . Most serous carcinomas not only demonstrate papillary features, 
but also glandular, cribriform and solid architecture. Squamous metaplasia has also been described 
in these neoplasms. Thus, it may be difficult in some of these cases to differentiate serous from other 
ovarian epithelial tumors, such as endometrioid, mucinous, or clear cell carcinoma, when adhering 
only to the WHO classification and to the traditional morphologic criteria of ovarian tumors  [ 3 ] . 
 Most useful in the differential diagnosis between ovarian high-grade serous carcinoma and other 
epithelial neoplasms especially endometrioid carcinoma is widespread WT 1 (Wilms tumor protein, 
a suppressor gene) expression  [ 6 ] as well as p53 (tumor suppressor gene) overexpression and muta-
tion which are characteristic for serous high-grade tumors and are absent in most other ovarian 
carcinomas (Fig.  10.1 )  [ 3,  7 ] . 
 Furthermore, precursor lesions, such as the coexistence of a serous ovarian borderline tumor with 
an epithelial malignant neoplasm favors the diagnosis of ovarian low-grade serous carcinoma in the 
latter  [ 8 ] while tubal intraepithelial carcinoma is characteristically associated with high-grade 
serous tumor (Fig.  10.2 )  [ 9 ] . 
 Mucinous Tumors 
 Less than 3% of ovarian mucinous carcinomas of the intestinal type are primary tumors. The vast 
majority are metastatic from the intestinal tract  [ 10 ] . 
 Fig. 10.1  ( a ) Ovarian high-grade serous carcinoma, ( b ) Positive WT1 and ( c ) Positive p53 
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 Most ovarian mucinous tumors are of the intestinal type. The so-called müllerian or seromuci-
nous (endocervical) type ovarian tumors are uncommon. They are sometimes included in the group 
of mixed epithelial ovarian tumors  [ 3 ] . 
 Since many mucinous tumors lack apical mucin, they may be erroneously diagnosed as other 
ovarian epithelial neoplasms, especially as endometrioid carcinoma. 
 Immunohistochemical staining of these tumors is crucial in reaching a correct diagnosis, since 
primary mucinous tumors show predominantly cytokeratin 7 with lesser expression of cytokeratin 
20. Most importantly, CDX2 is negative or occasionally only focally positive in primary mucinous 
ovarian tumors, while in metastatic carcinomas from the intestinal tract, CDX2 and cytokeratin 20 
are strongly and diffusely positive while cytokeratin 7 is absent or only focally positive (Fig.  10.3 ) 
 [ 11 ] . The precursor lesion of ovarian mucinous carcinoma is the mucinous borderline tumor 
(Fig.  10.4 ). 
 Endometrioid Tumors 
 According to Czernobilsky et al.  [ 12 ] , ovarian endometrioid carcinoma constituted about 23% of all 
ovarian primary carcinomas in 1970. 
 With the emergence of immunohistochemical markers, the recognition of precursor lesions and 
the change in our approach to classic morphologic features endometrioid carcinoma nowadays 
represents only about 10% of all ovarian carcinomas  [ 13 ] . Many of erroneously diagnosed endo-
metrioid carcinomas are indeed serous tumors. 
 Fig. 10.3  Ovarian mucinous carcinoma metastatic from colonic carcinoma. ( a ) Positive cytokeratin 20, ( b ) Negative 
cytokeratin 7, ( c ) Positive CDX2 
 Fig. 10.2  ( a ) Ovarian low-grade serous carcinoma. Precursor lesions: ( b ) Borderline serous tumor ( c ) Micropapillary 
serous tumor 
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 Thus, endometrioid carcinomas are commonly associated with endometriosis, endometrioid 
adenofibroma, endometrioid borderline tumors as well as synchronous endometrioid intrauterine 
carcinoma  [ 2,  3,  14 ] . These precursor lesions are absent in serous carcinomas (Fig.  10.5 ). Finally, 
endometrioid carcinomas in contrast to serous carcinomas, lack WT 1  [ 15 ] and p53 overexpression, 
and usually express estrogen and progesterone receptors  [ 3 ] . 
 Clear Cell Tumors 
 This tumor shows a papillary, tubulocystic, and solid architecture with typical hobnail type and clear 
cells. An oxyphilic cell type has also been described. A typical feature of these tumors is the large, 
highly atypical nuclei with large nucleoli. 
 Positive stainings for estrogen and progesterone receptors as well as WT 1 expression exclude a 
diagnosis of clear cell carcinoma  [ 16 ] . P53 may be evident but not in the diffuse, prominent way as 
it is seen in serous tumors  [ 17 ] . Hepatocyte nuclear factor (HNF) 1 b (1beta) has been recently 
described as a reliable immunomarker in ovarian clear cell tumors  [ 18,  19 ] . 
 Fig. 10.4  ( a ) Primary ovarian mucinous carcinoma. Precursor lesion: ( b ) Borderline mucinous tumor 
 Fig. 10.5  ( a ) Ovarian endometrioid carcinoma. Precursor lesions: ( b ) Endometrioid adenofibroma ( c ) Borderline 
endometrioid tumor 
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 Ovarian carcinomas composed of clear cell elements mixed with other cell types, such as endo-
metrioid or serous carcinoma should not be diagnosed as clear cell carcinoma but rather as serous 
carcinoma  [ 20 ] . In other words, the diagnosis of clear cell carcinoma should be reserved for tumors 
with a homogenous clear cell population and highly atypical nuclei  [ 21 ] . 
 Precursor lesions of clear cell carcinoma include endometriosis and clear cell adenofibromas 
(Fig.  10.6 )  [ 2 ] . 
 Transitional Cell Tumors 
 Most of the tumors classified as transitional cell carcinoma in the WHO classification  [ 1 ] are actu-
ally high-grade serous or high-grade endometrioid carcinomas and frequently express p53 and 
WT 1 , which are typical of serous carcinomas (Fig.  10.7 )  [ 22 ] . The only exception appears to be the 
benign Brenner tumor which is positive for uroplakin and may thus be of urothelial derivation 
(Fig.  10.8 )  [ 23 ] . 
 Fig. 10.6  ( a ) Ovarian clear cell carcinoma Precursor lesions: ( b ) Endometriosis with contiguous clear cell carcinoma 
( c ) Clear cell adenofibroma 
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 Mixed Epithelial Ovarian Tumors 
 These are tumors showing two or more distinctive types of neoplasms constituting at least 10% of 
the tumor. According to Soslow  [ 3 ] , the tumor elements in mixed epithelial tumors should be sepa-
rable and as such diagnosable as separate neoplasms. Notwithstanding the above definition of mixed 
epithelial tumors, most of these are considered to be high-grade serous carcinomas, which are supported 
by diffuse WT 1 staining  [ 3 ] . 
 Undifferentiated Carcinomas 
 Most of these tumors which are not histologically classifiable should also be diagnosed as high-
grade serous carcinomas especially if the tumor is WT 1 positive  [ 3 ] and other possibilities, such as 
metastases to the ovary are excluded (Fig.  10.9 ). Tables  10.1 – 10.3 summarize some of the above 
discussed data. 
 Fig. 10.7  Ovarian transi-
tional cell carcinoma 
morphologically resembling 
urothelial cancer but 
representing high-grade 
serous carcinoma 
 Fig. 10.8  Benign ovarian 
Brenner tumor 
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 Table 10.1  Proposed subclassifi cation of primary ovarian epithelial tumors  [ 5 ] 
 1. High-grade serous, high-grade endometrioid and undifferentiated carcinomas 
 2. Low-grade serous carcinomas and serous borderline tumors 
 3. Mucinous carcinomas and mucinous borderline tumors of intestinal type 
 4. Low-grade endometrioid carcinoma and endometrioid borderline tumors 
 5. Clear cell carcinomas 
 6. Transitional cell carcinomas 
 Table 10.3  ER, WT1, P53 in ovarian carcinomas 
 Ovarian carcinomas  ER  WT1  p53 
 Serous, high grade  –  +  + 
 Serous, low grade  +  –  – 
 Mucinous (intestinal type)  –  –  – 
 Endometrioid  +  –  – 
 Clear cell  –  –  + (variable) 
 Transitional cell (Brenner tumor excluded)  –  +  + 
 Undifferentiated a  –  +  + 
 Mixed b  –  +  + 
 ER Estrogen receptor 
 
a
 Usually represents high-grade serous carcinoma 
 
b
 Frequently shows a significant component of high-grade serous carcinoma 
 Table 10.2  Precursor lesions in ovarian carcinomas 
 Carcinoma  Precursor lesions 
 Serous (high grade)  Fallopian tube intraepithelial carcinoma 
 Serous (low grade)  Serous borderline tumor 
 Mucinous (intestinal type)  Mucinous borderline tumor 
 Endometrioid  Endometriosis 
 Endometrioid borderline tumor 
 Synchronous intrauterine endometrioid carcinoma 
 Clear cell  Endometriosis 
 Clear cell adenofibroma 
 Clear cell borderline tumor 
 Undifferentiated  Unknown 
 Mixed  Unknown 
 Fig. 10.9  ( a ) Ovarian undifferentiated carcinoma ( b ) Positive WT1 
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 Summary 
 The emergence of new data in recent years concerning the origin and pathogenesis of epithelial 
ovarian carcinomas culminating in a theory that the latter are of extraovarian origin, the morpho-
logic variability of hitherto well-defined ovarian tumors, the presence of precursor lesions, rela-
tively specific immunohistochemical markers as well as molecular and genetic features, require a 
reassessment of various aspects of ovarian epithelial tumors. 
 In addition, it has been proposed by Kurman et al.  [ 2,  4,  24 ] that ovarian epithelial tumors be 
divided in type I and type II tumors, similar to the already existing division of endometrial uterine 
carcinoma. 
 According to this proposal, type I tumors which are relatively genetically stable consist of micro-
papillary serous, mucinous, and endometrioid carcinomas. Type II tumors are genetically highly 
unstable aggressive neoplasms, such as high-grade serous carcinomas, carcinosarcomas, and undif-
ferentiated carcinoma. 
 The two groups vary in their histologic appearance, precursor lesions, and immunophenotype as 
well as by molecular and genetic features. The clinical course and prognosis also differ in these two 
groups. Since clear cell carcinomas show clinical morphological, immunohistochemical, and 
genetic features which are shared to some degree by both type I and type II ovarian tumors, they 
cannot at this time be definitely classified  [ 2 ] . 
 Finally, it is to be expected that a different therapeutic approach to patients with group I and II 
tumors, including screening and prevention may result in a more favorable response and improve 
prognosis especially in the patients with high-grade ovarian cancer. 
 Molecular Features and Gene Expression Studies 
 Despite the poor prognosis and the importance of early diagnosis, there are no reliable methods for 
detection of ovarian cancer in the early stages of disease. Since patients diagnosed with stage I 
epithelial ovarian cancers (EOCs) have a 90% survival rate, it is important to identify novel ovarian 
cancer biomarkers with potential utility in early stage screening. Little is known of the molecular 
genetic changes that are associated with the development of invasive ovarian cancer. Cytogenetic 
analyses of epithelial ovarian tumors have shown frequent structural aberrations of chromosomes 1, 
3, 6, and 11, suggesting that inactivation of genes located on these chromosomes may be important 
in ovarian tumorigenesis. A high frequency of allelic losses (LOH) was observed on 11p, 13q, and 
17p. The loss of tumor-suppressor genes on 13q and 17p may be involved in early events of ovarian 
tumorigenesis and changes on 11p in later events  [ 25 ] . 
 With regard to the application of new genomic technologies, the gene expression analysis has 
allowed to identify important differentially expressed genes and molecular pathways that may help 
to understand the evolution from normal ovarian tissue to ovarian cancer  [ 26 ] . Several studies have 
shown distinctive gene expression patterns that can differentiate between histological subtypes of 
ovarian carcinoma  [ 27– 31 ] or predict response to chemotherapy or survival  [ 32– 35 ] . The different 
histological subclasses and the clinical phenotypes displayed by EOCs are hypothesized to be 
driven by specific genes. Differentially expressed genes are included in pathways involved in chro-
mosomal instability, invasion cell, motility, proliferation, and gene silencing and provided new 
insights into the origin of this cancer  [ 36 ] . In addition, differences in gene expression patterns may 
help to characterize ovarian cancer and to identify potential targets for effective prevention and 
treatment of disease. Normal epithelial ovarian samples have been compared with tumor sam-
ples in gene expression profiling studies, generating very distinct groups in hierarchical clustering. 
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The choice of a normal control that can be compared to EOC samples in microarray analyses can 
strongly influence the identification of differentially expressed genes. Seventy-five gene expression 
profiles of EOC subhistotypes were compared by Zorn et al. to determine the similarities and dif-
ferences between all samples. The gene signature generated from Zorn et al. identified 166 genes 
that distinguished the samples into three subtypes: endometrioid, serous, and clear cell  [ 37 ] . Instead, 
Schwartz et al. found 158 differentially expressed genes histotype-specific for the endometrioid, 
serous, clear cell, and mucinous ovarian cancers. Of these 158 genes, 73 genes were clear cell 
histotype-specific, 64 genes were mucinous histotype-specific, 19 genes were specific for serous, 
and 2 genes were specific for endometrioid. These data showed that there are large expression dif-
ferences between the various histological types of ovarian cancer  [ 38 ] . There is a small set of 
upregulated genes related to ovarian clear cell tumors including  SOD2 (superoxide dismutase), 
 GPX3 (glutathione peroxidase 3),  RBP4 (retinol binding protein 4), UGT1A1 (UDP glycosyltrans-
ferase1family, polypeptideA1),  TFPI2 (tissue factor pathway inhibitor),  FXYD2 (FXYD domain 
containing ion transport regulator 2),  GLRX (Glutaredoxin), and  ANXA4 (Annexin). These genes 
overlap with genes identified by Zorn et al.  [ 29 ] . Two of these genes are associated with chemo-
therapy response:  UGT1A1 detoxifies the active metabolite of irinotecan, whereas  ANXA4 has been 
associated with paclitaxel resistance  [ 39,  40 ] .  SOD2 ,  GLRX , and  GPX3 are involved in oxidative 
stress response and particularly high levels of these in clear cell histotypes may make these tumors 
more resistant to chemotherapy  [ 38 ]  (Table  10.4 ). 
 A microarray analysis of 103 primary ovarian cancers has suggested the contributions of origin 
and histotype on the tumor gene expression profile  [ 41 ] . Sixty-two differentially expressed genes 
were observed between endometrioid versus serous histotypes. Of these 62 genes, endometrioid 
carcinomas often showed highly expressed  TFF3 (trefoil factor 3),  SFN (stratifin),  MSX1 (msh 
homeobox 1), and  CEACAM1b (carcinoembryonic antigen-related cell adhesion molecule) genes. 
Serous carcinomas often showed high expression of the following genes:  FOLR1 (folate receptor 
1),  PTGS1 (prostaglandin-endoperoxide synthase 1),  WT1 (Wilms tumor 1), and  GAS6 (growth 
arrest-specific 6). By an extensive Affymetrix microarray analysis, mucinous ovarian cancer was 
differentiated from the other subtypes of ovarian cancer, due to different gene expression profiles 
 [ 38,  42,  43 ] . In mucinos ovarian tumors, Wamunyokoli et al.  [ 42 ] identified specific differentially 
expressed genes involved in the following pathways: proliferation and cell cycle regulation ( ERBB3 , 
 CCND1 ,  TGF -a), transformation ( K-ras2 ,  c-JUN ,  YES1 ,  ECT2 ), signal transduction ( CAV-1 and 
 SPRY1 ), cytoskeleton rearrangement/signal transduction ( CDC42 ,  RAC1 ,  IQGAP2 ,  RALA , 
Cortactin), and drug resistance ( ABCC6 and  ABCC3 ). 
 In conclusion, clear cell, serous, endometrioid, and mucinous histotypes appear to show specific 
gene expression signatures. These differences in gene expression profiles could be useful in the 
treatment of the different histotypes. 
 Table 10.4  Gene signatures associated with epithelial ovarian cancers 
 Histological subtypes  Differentially expressed genes  References 
 Serous  FOLR1 ,  PTGS1 ,  WT1 ,  GAS6  [ 41 ] 
 Endometrioid  TFF3 ,  SFN ,  MSX1, CEACAM1b  [ 41 ] 
 Mucinous  ERBB3 ,  CCND1 ,  TGF -a  [ 42 ] 
 K-ras2, c-JUN, YES1, ECT2 
 CAV-1 ,  SPRY1 
 CDC42, RAC1, IQGAP2, RALA, Cortactin 
 ABCC6, ABCC3 
 Clear cell  SOD2 ,  GPX3 ,  RBP4 ,  UGT1A1 ,  TFPI2 ,  FXYD2 ,  GLRX , 
 ANXA4 
 [ 38 ] 
 [ 29 ] 
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 Using a Serial Analysis of Gene Expression (SAGE), David G. Peters et al.  [ 44 ] have identified 
several potentially novel biomarkers whose expression is elevated in ovarian cancer. These proteins 
include CD9, HMGA1, AHCY, GNAI2, CCT3, and TACC3. 
 Moreover, it has recently been demonstrated by some research groups that the gene expression 
signatures determined by microarray analysis may act as a prognostic factor in EOC  [ 45 ] . Several 
markers with prognostic value have been identified by specific molecular studies.  HER2/neu and 
 EGFR overexpression has been related to poor prognosis  [ 46– 48 ] . Clinical studies have shown that 
 TP53 overexpression is related with shorter survival in ovarian cancer  [ 49 ] and resistance to plati-
num-based chemotherapy  [ 50 ] . Other molecular studies by microarray identified several genes 
responsible for platinum resistance involved in the following pathways: proliferation ( FRA1 ,  ETV4 , 
 IGFBP3 ,  STAT1 ), cell-cycle control ( CDKN1A ,  CDKN1C ,  CDC25C ,  PLK3 ), apoptosis ( BAK ,  BAX , 
 STAT1 ,  c-JUN ,  TP53 ), DNA repair ( XRCC9 ,  PCNA ,  TP53 ,  DDB2 ,  GADD45B ,  POLH ), and energy 
regulation metabolism (STARD4 and FDXR)  [ 51 ] . Nevertheless, the  NAC-1 expression modulates 
taxol resistance in ovarian cancer and may provide an effective target for chemotherapeutic 
intervention in taxol-resistant tumors  [ 52 ] . The loss of protein p27 is an important prognostic 
marker for predicting disease recurrence in primary ovarian cancer  [ 53 ] . Moreover, the amplifica-
tion of oncogene  MYC and increased expression levels of cyclin E have been associated with poor 
prognosis  [ 54,  55 ] . In a recent work  [ 56 ] , the mammaglobin B ( MGB-2 ) gene expression was evalu-
ated in ovarian cancer tissues and in normal ovarian controls by quantitative real-time PCR and then 
by immunohistochemistry.  MGB-2 expression levels were found increased in EOC compared to 
normal ovarian controls, both at protein level and mRNA.  MGB-2 expressing tumors were related 
to clinicopathologic features of the less aggressive tumors. This finding suggest that  MGB-2 is an 
independent prognostic marker in EOC and its expression is correlated with reduced risk of disease 
recurrence  [ 56 ] . 
 Moreover, for the first time, the epithelial cell adhesion molecule (Ep-CAM) overexpression was 
associated with a decreased overall survival. Ep-CAM represents a novel independent prognostic 
marker for reduced survival of patient with EOC  [ 57 ] . 
 In conclusion, whole genome expression profiling has become a vital tool for identifying dif-
ferentially expressed genes in EOCs, in order to potentially prolong the survival of women diag-
nosed with this disease  [ 58 ] . 
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 Introduction 
 Thyroid cancer is the most common type of endocrine malignancy  [ 1 ] . The incidence of thyroid 
cancer has been steadily rising over the past three decades; since mortality remained unchanged, 
this increased incidence is more apparent than real and due to changes in diagnostic criteria and to 
the advent of a more sensitive diagnostic approach based on ultrasound (US) guided fine-needle 
aspiration (FNA)  [ 2 ] . Data from the survival, epidemiology, and end results database showed that 
this cancer constitutes approximately 1.5% of all newly diagnosed cancer cases in the USA  [ 3 ] , its 
incidence being two to three times higher among women than men and about twice higher in whites 
than in blacks  [ 1,  2 ] . 
 Histological Classification 
 Most of thyroid tumors are primary neoplasms originating from epithelial cells  [ 4 ] . Except from 
medullary carcinomas, that originate from thyroid C cells, the vast majority of thyroid neoplasms 
derives from follicular cells (Table  11.1 ), including both benign follicular adenoma and malignant 
neoplasms  [ 5 ] . These latter are most commonly well-differentiated carcinomas either of papillary 
or follicular histotype. Oncocytic (Hürthle cell) adenomas and carcinomas are considered as a vari-
ant of follicular tumors by the current (2004) WHO classification  [ 5 ] . Poorly differentiated and 
anaplastic carcinomas (ATC) also originate from follicular cells, often as the result of dedifferentia-
tion of preexisting papillary or follicular carcinomas  [ 5 ] . From a prognostic standpoint, well- 
differentiated papillary and follicular carcinomas have an indolent course, whereas ATC are almost 
always lethal  [ 5 ] . Poorly differentiated carcinoma (PDC) falls into a distinctly intermediate prog-
nostic category  [ 6 ] . Placement into separate classification groups has been proposed for hyalinizing 
trabecular tumors, which typically have a benign course, despite sharing several histological fea-
tures with papillary carcinoma  [ 7 ] . Similarly, the term “well-differentiated tumor of uncertain 
malignant potential” should be reserved for those encapsulated tumors showing either questionable 
capsular invasion or only partially developed nuclear features of papillary carcinoma  [ 8 ] . 
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 Thyroid cancer is rare in children, but its incidence begins to rise sharply in the second decade 
of life and peaks in women during the late reproductive age and in men during the sixth decade of 
life  [ 1 ] . This age distribution reflects the incidence of the three most common types of thyroid can-
cer: papillary carcinoma that constitutes approximately 80% of all thyroid cancer cases, follicular 
carcinoma (15%), and medullary carcinoma (3%)  [ 5 ] . ATC, which accounts for less than 2% of 
thyroid tumors, typically occurs in the older age group  [ 5 ] . The thyroid cancer increased incidence 
is almost entirely attributed to papillary carcinoma both in its classic and follicular variant (FVPTC) 
form, due to the detection of cancers smaller than 2 cm  [ 9 ] . Thus, about half of the increase is due 
to tumors <1 cm in size and another 40% is due to tumors 1–2 cm. On the contrary, the rates of 
follicular, medullary, and anaplastic cancer did not change significantly  [ 1 ] . 
 Molecular Genetics of Thyroid Cancer 
 The microscopic diagnosis of poorly differentiated and anaplastic thyroid cancer is straightforward; 
conversely most of the new developments in molecular diagnostics are centered on well differenti-
ated thyroid cancers. In fact on cytology microscopic diagnosis and on histology the prognostication 
may be challenging  [ 10 ] . Although several molecular markers are promising, only those molecular 
tests that have an unquestionable biological and clinical significance and that are sufficiently robust 
and reproducible in multiple laboratories are suitable for a widespread clinical implementation  [ 11 ] . 
In particular testing for somatic mutations and gene rearrangements has already completed most of 
the steps required to bring a molecular assay from early exploratory studies to widespread imple-
mentation  [ 11 ] . 
 In fact, several genetic abnormalities have been associated to thyroid carcinoma underlying a 
close correlation between specific genetic lesions and histologic phenotype  [ 12 ] . Papillary carcino-
mas show frequently either specific gene rearrangements which gives rise to the formation of the 
RET/PTC, or more rarely NTRK1, chimeric genes or B-type Raf kinase (BRAF) activating point-
mutations  [ 13,  14 ] . In addition, only in the follicular variant, activating point-mutations in the RAS 
oncogenes also occur  [ 14 ] . From a molecular point of view, there are two groups of FTC; one is 
associated with activating mutations in RAS and the other with gene rearrangements between the 
peroxisome proliferator-activated receptor  g (PPAR g ) and the PAX8 (or more rarely the CREB3L2) 
 Table 11.1  Histological classifi cation of thyroid tumors arising from 
follicular epithelial cells 
 A. Benign 
 Follicular adenoma 
 Conventional type 
 Oncocytic type 
 B. Uncertain Malignant Potential (UMP) 
 Hyalinizing trabecular tumor 
 UMP with questionable papillary carcinoma-type nuclear changes 
 UMP with questionable capsular penetration without nuclear changes 
 C. Malignant 
 Papillary carcinoma 
 Follicular carcinoma 
 Conventional type 
 Oncocytic type 
 Poorly differentiated carcinoma 
 Anaplastic (undifferentiated) carcinoma 
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transcription factor  [ 15 ] . RAS mutations are common in PDTC  [ 16 ] . ATC is associated to BRAF 
and RAS mutations  [ 17 ] ; in addition, it often features mutations in TP53, PTEN, PIK3CA and 
CTNNB1  [ 10,  18 ] . Finally, point mutations of the RET gene are found in familial endocrine syn-
dromes (FMTC; MEN2A, and MEN2B), a common feature of which is the medullary thyroid car-
cinoma, a malignant tumor derived from parafollicular C-cells  [ 19 ] . 
 BRAF Mutations as Molecular Marker of PTC 
 The BRAF mutation was recently discovered to be the most common (up to 45%) genetic alteration 
in PTC  [ 3 ] . This is a somatic genetic mutation and is not a germline alteration in familial thyroid 
cancer  [ 20 ] . The BRAF mutation exclusive occurs in PTC and PTC derived ATC, whereas it does 
not occur in follicular carcinoma and other types of thyroid tumors  [ 3 ] . The high prevalence and 
high specificity of BRAF mutation for PTC underlines the potential clinical utility to diagnosis in 
those settings, in which morphology is unclear  [ 10 ] . 
 The presence of only one “hotspot” (codon 600 in exon 15) renders PTC-associated BRAF muta-
tions easily detectable on a technical point of view  [ 4,  5 ] . Moreover, as a stable DNA molecular 
marker, BRAF mutation can be easily detected on common DNA specimens, even in low quantities, 
such as those obtained by FNA needle rinsing  [ 21 ] . BRAF mutation detection can be achieved by a 
variety of molecular techniques including real-time PCR amplification and post-PCR melting curve 
analysis, allele specific PCR, direct nucleotide sequencing, restriction fragment polymorphism 
analysis, and others  [ 22 ] . All of these methods demonstrate reliable detection of BRAF mutation in 
different types of thyroid specimens  [ 23 ] . 
 The most employed method for BRAF testing remains direct sequencing of PCR amplification 
products  [ 11,  24 ] . Direct sequencing relies on the Sanger chain termination method; the incorpora-
tion of a chemically modified nucleotide (dideoxynucleotide) terminates extension of the DNA 
strand at the point of incorporation  [ 24 ] . This results in a mixture of DNA fragments of different 
lengths. Each dideoxynucleotide (A, T, C, or G) is labeled with a different fluorescent dye, allow-
ing their individual detection  [ 24 ] . The newly synthesized and labeled DNA fragments are sepa-
rated by size through capillary gel electrophoresis. The fluorescence is detected by an automated 
sequence analyzer and the order of nucleotides in the target DNA illustrated as a sequence electro-
pherogram  [ 24 ] . 
 For real-time PCR amplification, two probes complementary to wild-type sequences are designed 
to span the mutation site for the mutational hot spot (exon 15). If no mutation is present, probes will 
bind perfectly to sample DNA and melt at a higher temperature, showing a single peak on post-PCR 
melting curve analysis. In contrast, if a heterozygous mutation is present, probes will bind to mutant 
DNA imperfectly (i.e., with one nucleotide mismatch) and will melt (dissociate) earlier, producing 
two melting peaks (one for the wild-type allele and one for the mutant allele) or one melting peak 
at lower temperature if the mutation is homozygous. Each nucleotide substitution produces a melt-
ing peak at specific  T 
m
 . This method showed similar sensitivity in detection of BRAF mutation in 
thyroid tumors when compared with direct nucleotide sequencing as the criterion standard  [ 25 ] . 
 Since the initial discovery of BRAF mutation in human cancers  [ 24 ] , there have been more than 
40 mutations identified in the BRAF gene, among which the T1799A point BRAF mutation is the 
most common and accounts for more than 90% of all the mutations found in the BRAF gene  [ 21 ] . 
The T1799A BRAF mutation causes a V600E amino acid change in the BRAF protein, resulting in 
the constitutive and oncogenic activation of the mutated BRAF kinase  [ 21 ] . A few other activated 
BRAF mutants are only rarely found in thyroid cancer, such as the BRAF K601E, resulting in the 
substitution of lysine with glutamate. This latter was found with a remarkable frequency (up to 9%) 
in the FVPTC  [ 26 ] . 
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 Molecular Diagnostics and Histological Diagnosis of PTC 
 Demonstration of the V600E BRAF mutation or of clonal RET/PTC has strong diagnostic value as 
an indicator of PTC  [ 21,  27 ] . Unfortunately, searching for these mutations on histological samples 
has little diagnostic use  [ 12 ] . In fact, PTC carrying these mutations regardless from displaying clas-
sic, tall or oncocytic features is marked by a prevalent papillary pattern of growth  [ 26 ] . This makes 
its microscopic recognition straightforward, contributing to diminish the potential diagnostic impor-
tance of the detection of BRAF mutations. Conversely, the diagnosis of a follicular patterned tumor, 
characterized by total encapsulation and no formation of papillae, is challenging  [ 5 ] . Usually, cap-
sular invasion is evaluated to separate a benign (follicular adenoma/nodular adenomatous) from a 
minimally invasive follicular carcinoma  [ 5 ] ; similarly, nuclear characteristics separate a benign 
nodule from an encapsulated FVPTC  [ 5 ] . However, these morphological criteria are difficult to 
assess  [ 28,  29 ] . Recent reports have suggested that the FVPTC subtype is frequently misdiagnosed 
by pathologists. Even experts in thyroid pathology expressed a fully concordant diagnosis only in 
39% of FVPTC demonstrating that in the absence of clear-cut invasive growth this histological 
diagnosis is often questionable  [ 28 ] . Once recognized these tumors should undoubtedly be desig-
nated as papillary carcinomas, as they represent a distinct variant of papillary carcinoma with a 
number of characteristic molecular and biological features, some of which are closer to follicular 
tumors  [ 30 ] . These PTCs with a follicular architecture (follicular variant of PTC and oxyphilic vari-
ant and papillary microcarcinoma cases with a follicular architecture) usually lack the V600E muta-
tion; a different type of activating B-RAF mutation K601E was found in about 7% of the cases  [ 26 ] . 
FVPTC also frequently harbor RAS mutations, which are common in follicular tumors and are rare 
in classic papillary carcinoma  [ 31 ] . However, RAS mutation cannot be used to define malignancy 
since it can also be found in follicular adenomas  [ 16 ] . 
 Thyroid Cytology 
 In the general population, the incidence of thyroid nodules detected by clinical examination is very 
high (5–20%)  [ 32 ] ; this figure becomes even higher by ultrasound screening  [ 1 ] . Most of the thyroid 
cancers present as a nodule. However, thyroid nodules very rarely represent cancer. The extremely 
large number of benign thyroid nodules and the small number of admixed malignant ones requires 
an accurate screening tool. The aim is to determine when surgery is needed and also the correct 
surgical procedure. FNA cytology efficiently identifies those clinically relevant nodules whose 
treatment unequivocally requires surgery  [ 33 ] . The validity of this statement is proven by several 
large series of concordant matched cytological and histological specimens  [ 34– 36 ] . Thanks to the 
widespread use of FNA the number of patients requiring thyroid surgery has reduced by more than 
50%  [ 34– 36 ] ; the rate of surgically resected thyroid nodules found to be malignant has increased by 
two to three times and the overall cost of managing a thyroid nodule has decreased by more than 
25%  [ 36 ] . However, FNA performance is highly dependent on the operator’s experience, on accu-
rate cytopreparation methodology and on effective communication between physicians  [ 37– 40 ] . 
 The Bethesda System for Reporting Thyroid Cytopathology 
 To avoid confusion among clinicians, special care should be taken to report thyroid FNA in a con-
sistent manner  [ 37– 40 ] . The Bethesda System for Reporting Thyroid Cytopathology (BSRTC) has 
been proposed at the 2007 National Cancer Institute (NCI) state of art thyroid FNA conference  [ 41 ] . 
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This classification scheme divides adequate cases (containing at least six groups of thyreocytes) 
into a five-tiered risk based system  [ 42 ] . At the end of this spectrum are those classes termed as 
“benign” or “malignant”; here, diagnosis is certain and the related post-FNA options are clear. 
Benign lesions identified by FNAC are generally left untreated, and patients undergo periodic 
clinical and ultrasound examination, whereas patients with malignant nodules undergo total thy-
roidectomy  [ 43 ] . Between “benign” and “malignant” there are three diagnostic categories relative 
to indeterminate cytology; each features a different probability of malignancy  [ 43 ] . The associated 
risk is low (5–10%) for “Follicular lesion of undetermined significance” (FLUS), intermediated 
for “suspicious for follicular neoplasm” (15–30%), and high for “suspicious for malignancy” 
(60–75%)  [ 38 ] . 
 Molecular Testing on Cytology 
 There is little doubt that patients with indeterminate cytology will benefit from testing for those 
somatic mutations that occur in about two-thirds of PTC (BRAF mutations and RET/PTC rear-
rangements) and FTC (RAS mutations and PAX8/PPAR g rearrangements)  [ 44 ] . Thus, some malig-
nant cases that cannot be diagnosed with cytology can be identified and cured  [ 45 ] . Our group 
extensively tested BRAF and RET/PTC either on archival cytological slides or prospectively by a 
FNA dedicated pass  [ 44,  46,  47 ] ; in these studies and in several other series (Table  11.2 ) all BRAF 
positive FNA samples studied prospectively and retrospectively were papillary carcinomas. The 
high specificity of BRAF mutation for PTC underlines its potential clinical utility to refine undeter-
mined cytological diagnosis  [ 21 ] . However, BRAF testing cost-effectiveness is high only when PTC 
is strongly suspected on cytology  [ 21,  56 ] . Deveci et al. in a detailed analysis relative to the histo-
pathologic follow-up of “follicular neoplasm” ( n = 339) and “suspicious for papillary thyroid carci-
noma” (PTC) ( n = 120) FNAs showed that these BSRTC classes have a very different malignancy 
rate (MR)  [ 56 ] . The MR of “follicular neoplasms” was 22%, whereas that of “suspicious for PTC” 
was much higher (72%). In both classes most of the malignant cases were FVPTC that represented, 
respectively, 11% and 54% of cases. Conversely, classic PTC was 2% and 12% of the cases  [ 56 ] . 
 Table 11.2  Prospective and retrospective studies on the diagnostic value of V600E to refi ne PTC diagnosis on FNAs 
 Study  Design 
 Total series 
case  n Undetermined 
 Undetermined 
with V600E (%) 
 Specificity 
for PTC 
 Salvatore et al.  [ 47 ]  Retrospective  95  11  4 (27)  4/4 
 Sapio et al.  [ 44 ]  Prospective  132  16  4 (25)  4/4 
 Sapio et al.  [ 46 ]  Prospective  144  94  10 (11)  10/10 
 Nikiforov et al.  [ 10 ]  Prospective  328  51  7 (13)  7/7 
 Kumagai et al.  [ 48 ]  Prospective  208  22  3 (14)  3/3 
 Xing et al.  [ 5 ]  Prospective  45  25  2 (8)  2/2 
 Pizzolanti et al.  [ 49 ]  Prospective  156  19  2 (10)  2/2 
 Jo et al.  [ 50 ]  Prospective  101  24  7 (29)  7/7 
 Zatelli et al.  [ 51 ]  Prospective  469  22  10 (45)  10/10 
 Cohen et al.  [ 52 ]  Retrospective  91  55  5 (9)  5/5 
 Rowe et al.  [ 53 ]  Retrospective  19  19  3 (16)  3/3 
 Xing et al.  [ 54 ]  Retrospective  190  Not specified  Not specified  – 
 Chung et al.  [ 55 ]  Prospective  137  25  4 (16)  3/4 a 
 
a
 The Authors justify the only false-positive FNAB describing a putative PTC precursor lesion “atypical hyperplasia” 
on matching surgical specimen 
170 U. Malapelle et al.
Since follicular variant PTC do not or only rarely harbor the V600E and only in rare instances the 
K601E mutation the diagnostic sensitivity of BRAF mutation testing alone is very low for “suspicious 
of follicular neoplasms” thyroid nodules and only slightly higher for “suspicious for PTC” classes 
 [ 12 ] . In an earlier study on archival smears we were able to refine an undetermined diagnosis in 
27% of cases  [ 47 ] and subsequently this rate (25%) was confirmed also in a study of prospectively 
collected FNAs  [ 44 ] . Although only a limited portion of patients within the gray zone FNA diag-
noses who need surgery may be identified  [ 57 ] , molecular testing has a very high positive predic-
tive value (PPV)  [ 45 ] . The high specificity of BRAF for PTC has led some Institution to consider 
BRAF-positive FNA, even in absence of microscopically observed atypical, as the sole indication 
for initial thyroidectomy  [ 10 ] . Thus, BRAF is a low sensitive but 100% specific marker; in a recent 
analysis we used BRAF together with a less specific, but more sensitive, immunocytochemical 
marker of thyroid cancer – galectin-3 (Gal-3)  [ 58– 60 ] . This is rarely detected in normal thyroid 
tissue and benign nodules, while its expression has frequently been demonstrated in malignant 
thyroid tumors. While Gal-3 sensitivity is high, there is some concern about its specificity because 
Gal-3 expression has been found in adenomatous goiter and Hashimoto’s thyroiditis by immuno-
histochemistry  [ 61 ] . The BRAF/Gal-3 combined analysis yielded a modest improvement of the 
positive predictive (from 73.9 to 78.6%), while the negative predictive value increased from 70.8% 
for Gal-3 alone to 89.5% for Gal-3 and/or BRAFV600E  [ 46 ] . Thus, a reduction of false-negative 
cases was achieved  [ 46 ] . 
 Novel Malignant Thyroid Markers Identified by Gene Profiling 
 The BSRTC class diagnostic criteria for the “follicular neoplasm” category refer to a monotonous 
population of three-dimensional groups of follicular cells with scarce colloid; as discussed before, 
these uncertain features do not correspond to a single entity, but rather to a wide range of inflam-
matory, hyperplastic, and neoplastic histological lesions  [ 35 ] . These latter, including follicular 
adenoma, follicular carcinoma, and follicular variant of PTC, do not or only rarely harbor RET)/
PTC rearrangements or BRAF mutations  [ 62 ] . Thus, panels of mRNA and protein cancer markers 
are needed to refine indeterminate diagnosis. Microarray studies are widely used to define diagnos-
tic and prognostic signatures in cancers and they have led to the identification of a large list of 
carcinoma-regulated genes also in thyroid cancers  [ 63 ] . To look for genes potentially involved in 
the neoplastic transformation of the thyroid gland, we extracted RNAs from normal human thyroid 
primary cells and six human thyroid carcinoma cell lines (WRO cell line from FTC, TPC-1 and 
FB-2 cell lines from PTC, NPA cell line from a poorly differentiated PTC, and ARO and FRO cell 
lines from ATC) and hybridized them to U95Av2 Affymetrix oligonucleotide arrays (Affymetrix) 
containing 12,625 transcripts  [ 64,  65 ] . We looked for genes whose expression was drastically (at 
least tenfold) up- or downregulated in all the six thyroid carcinoma cell lines versus normal thyroid 
primary cell culture, on the assumption that genes whose expression was altered in all carcinoma 
cell lines could be involved in thyroid cell transformation  [ 64,  65 ] . 
 UbcH10 Deregulation Occurs in Thyroid Cancer 
 Genes that regulate cell-cycle progression may be differentially expressed in malignant versus 
benign thyroid nodules  [ 65 ] . UbcH10 (alias E2C or UBE2C) is a cell cycle-related protein involved 
in mitosis completion  [ 66 ] . Its ubiquitin-conjugating enzymatic activity is exerted from G2/M-phase 
17111 Thyroid Carcinoma: Molecular Signature by Histotype-Specific Mutations and Gene Expression…
to early G1 phase, when UbcH10 together with ubiquitin ligase transfers ubiquitin to the mitotic 
cyclins, thereby promoting their degradation by the proteosome. Once mitotic cyclins are ubiqui-
nated, UbcH10 triggers its own destruction  [ 67 ] . This event marks mitotic completion and provides 
the molecular switch that allows cells to bring cell division to an end and to proceed to the new 
round of DNA duplication. Thus, UbcH10 is essential in cell cycle progression  [ 68 ] . Our attention 
was focused on this gene, since it was upregulated about 150-fold in all of the cell lines tested by 
the Affymetrix HG_U95Av2 oligonucleotide array cDNA microarray  [ 65 ] . These results were fur-
ther confirmed by Western blot analyses, as the expression level of UbcH10 was extremely low in 
the normal thyroid primary culture cells, but strong in all the cancerous cell lines  [ 65 ] . 
Immunohistochemical and RT–PCR analyses on a large panel of thyroid neoplasms of different 
histotypes revealed that UbcH10 is barely detectable in normal thyroid tissues, goiters, and ade-
nomas, whereas it increases in papillary and follicular tumors, reaching the highest level of expres-
sion in ATC (Fig.  11.1 )  [ 65 ] . The block of UbcH10 protein synthesis by RNA interference inhibited 
the growth of two thyroid carcinoma cell lines. These evidences suggested that UbcH10 deregula-
tion led to the increased thyroid cancer cell proliferation concur with consistent data we generated 
also in ovarian, breast, and lymphoid neoplasms  [ 66,  68,  69 ] . 
 Fig. 11.1  UbcH10 staining pattern in normal, inflammatory, and neoplastic thyroid tissues. Follicular epithelial cells 
of normal thyroid ( a ) and oxyphilic cells of Hashimoto’s thyroiditis (HT) ( b ) do not stain for UbcH10, with occasional 
mitotic figures ( a ,  arrow ) and lymphoid centroblasts of HT ( b ,  arrow ) providing the appropriate internal positive 
control. In neoplastic thyroid, UbcH10 staining pattern is strongly related to tumor grade, being weak in follicular 
 adenoma ( c ), slightly more evident in well-differentiated papillary ( d ) and follicular ( e ) carcinomas, whereas stronger 
in poorly differentiated ( f ) and in anaplastic ( g ) carcinomas. In the latter, most of neoplastic cells show a very intense 
labeling, with intense nuclear staining ( h ), whereas signal disappeared by antigen incubation ( i ) 
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 UbcH10 on FNAS 
 Microarray analysis has been extensively used as a first step to identify molecular markers useful in 
the distinction of malignant from benign tumors  [ 70 ] . However, application of these diagnostic 
genes/proteins in combination with routine FNA cytology requires a complex validation process 
 [ 45 ] . In this setting, the 3-gene mRNA assay, which included cyclin D2 (CCND2), protein con-
vertase 2 (PCSK2), and prostate differentiation factor, allowed molecular classification of follicular 
carcinoma and follicular adenoma  [ 10,  71 ] . In a recent study, we applied UbcH10 to follicular neo-
plasm and suspicious for malignancy thyroid FNA  [ 72 ] UbcH10 expression was evaluated at both 
transcriptional and translational levels. At the mRNA level, its diagnostic performance was com-
pared with those of the best performing components (CCND2, PCSK2) of the 3-gene diagnostic 
assay; similarly, at the protein level UbcH10 was compared with the standard proliferation marker 
Ki-67 (Fig.  11.2 ). Our results suggested that UbcH10 mRNA assessment can be translated into a 
diagnostic test. FNAs associated to malignancy had UbcH10 mRNA levels higher than those associ-
ated with benign histology. CCND2 and PCSK2, the most performing components of the 3-gene 
assay, were used for comparison. The UbcH10 diagnostic accuracy was similar to that of CCND2 
and higher than that of PCSK2  [ 72 ] . Moreover, the UbcH10–CCND2 combination further increased 
the quantitative RT-PCR diagnostic accuracy (Fig.  11.3 ), and those cytopathology laboratories that 
have acquired expertise in evaluating thyroid cancer marker at the mRNA level could include 
UbcH10 in their diagnostic panels  [ 72 ] . 
 Fig. 11.2  UbcH10 and Ki-67 expression in fine-needle aspiration-derived cell blocks correspond to ( a and  b ) histo-
logically diagnosed follicular adenoma and ( c and  d ) papillary thyroid carcinoma (PTC). Both Ki-67 and UbcH10 
were found to label more cells in PTC compared with follicular adenoma (H&E counterstain, original magnification, 
×10). ( c and  d ) At higher magnification, it is interesting to note that UbcH10 and Ki-67 shared a similar staining 
pattern, as shown on parallel cell block sections (H&E counterstain, original magnification, ×20) 
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 CBX7 Deregulation Occurs in Thyroid Cancer 
 In addition to UbcH10, among the genes found to be deregulated by our gene profiling screening, 
we decided to concentrate our studies on a protein belonging to the polycomb group (PcG), the 
CBX7 protein  [ 73 ] . The PcG proteins are a class of epigenetic regulators, which always form mul-
tiprotein complexes to exert their functions in regulating cell proliferation, senescence, and tumori-
genesis via well-known growth regulatory pathways  [ 10,  74 ] . Several studies have implicated the 
deregulation of different PcG proteins in carcinogenesis and neoplastic progression  [ 74 ] . CBX7 is 
a chromobox family protein and a member of the polycomb repressive complex 1 (PRC1), which 
together with the PRC2 maintains developmental regulatory genes in a silenced state  [ 75 ] . Mouse 
Cbx7 associates with facultative heterochromatin and inactive X chromosome, suggesting a role of 
the Cbx7 protein in the repression of gene transcription  [ 75 ] . Data are controversial and the func-
tions and mechanisms of CBX7 in carcinogenesis are still far from clear. Earlier data showed that 
CBX7 inhibits cellular senescence and extends the lifespan of normal human cells via downregulat-
ing the expression of INK4a/ARF locus, and cooperates with c-Myc in lymphomagenesis  [ 76 ] ; 
more recent studies showed that decrease or loss of CBX7 protein expression correlated with a more 
aggressive phenotype in pancreatic  [ 64 ] , bladder  [ 77 ] , and colorectal cancer  [ 78 ] , which suggested 
that CBX7 might act as a potential tumor suppressor. According to this latter possibility, our cDNA 
microarray analysis data showed that CBX7 is one of the genes with the highest downregulation in 
all the carcinoma cell lines  [ 73 ] . In a large panel of cases, CBX7 tissue immunostaining decreased 
going from benign adenomas to carcinomas (Fig.  11.4 ). The block of CBX7 expression occurs at 
 Fig. 11.3  Area under the 
curve for individual UbcH10, 
cyclin D2 (CCND2), and 
protein convertase 2 (PCSK2) 
expression and their 
combination using logistic 
regression analysis is shown. 
( a ) The receiver operating 
characteristic (ROC) curve 
for any single gene is shown. 
( b ) The ROC curves for 
singly and combined UbcH10 
and CCND2 genes are shown 
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mRNA levels since the qRT-PCR analysis of surgically removed thyroid cancer confirmed the 
immunohistochemical data. Less-differentiated tumors, namely PDC and TCV PTC and ATC com-
pletely lacked CBX7 expression and in most cases LOH at the CBX7 locus (22q13.1) occurred. As 
the most important application of novel molecular markers is that on FNAs, we applied CBX7 on 
cytological samples  [ 73 ] . 
 Immunocytochemistry and qRT-PCR were carried out on cell block specimens obtained from 
FNC diagnosed as PTC confirmed that CBX7 loss is a reliable novel marker of thyroid cancer also 
useful in the preoperative setting  [ 74 ] . 
 Fig. 11.4  Normal and neoplastic thyroid tissues analyzed for CBX7 protein expression by immunohistochemistry. 
CBX7 nuclear staining was intense in benign follicular epithelial cells of normal thyroid (1) and follicular adenoma 
(2), whereas it was weaker in malignant lesions (3), where normal thyroid and papillary carcinoma are adjacent. The 
decrease of CBX7 in neoplastic lesions was progressive going from well-differentiated cancer, such as minimally 
invasive follicular carcinoma (4) and “classic variant” papillary carcinomas (PTC; 5) to the “tall cell variant” of PTC 
(6), whose nuclei are magnified to better show lack of signal, to poorly differentiated (7) and anaplastic (8) carci-
nomas. The signal disappeared after incubation of the sample with antigen (9). Arrows with letters indicate the 
following sample features:  P →, nuclei showing cytologic features of PTC negative for CBX7 expression;  N→, 
normal thyroid adjacent to papillary cancer;  L→, lymphocyte showing CBX7 expression and providing positive 
internal control 
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 From the Bench to the FNA: Sampling and Cytopreparatory Issues 
 Although the most important application of novel molecular markers is that on cytology, translation 
from the bench to the FNA is complex  [ 45 ] . To make DNA- and/or RNA-based testing cost-effective 
on cytology a close integration with morphology is needed  [ 79 ] . Thus, the informativeness of the 
sample for cytology needs to be preserved to keep the accuracy of microscopy high. To this end, 
each of the steps of traditional cytology, such as preparation of FNA material, search for morpho-
logical criteria, assignment to the correct diagnostic class, and suggestion of the appropriate post 
FNA options should not be altered by molecular analysis. Then, this latter can refine cytology. The 
final result is to effectively stratify into high-risk and low-risk categories, and the indeterminate 
cytology classes identified by the BSRTC  [ 45 ] . Thus, cytological specimens should be properly 
handled to provide both morphological and molecular information  [ 79 ] . Our method of preparation 
of FNA to harvest material sufficient for both tests was recently validated on a series of 128 rou-
tinely performed FNA  [ 11 ] . The rationale behind our sample collection method was to ensure first 
an adequate cytological diagnosis and, then, to exploit part of the diagnostic material for molecular 
testing  [ 11 ] . Thus, two passes from different areas of the lesion are performed. A representative 
air-dried Diff-Quik stained smear is prepared within few minutes and reviewed on site  [ 11 ] . In 44 
cases, the cytological evidences were sufficient for morphological assessment and the third pass was 
directly collected in RNA or DNA buffer extraction. Conversely, in 84 cases the specimen was 
either deemed inadequate by the onsite evaluation or required an additional ethanol-fixed 
Papanicolaou-stained smear to better evaluate nuclear morphology. Thus, a third pass was dedi-
cated to the preparation of an additional smears and only needle rinsing was collected for BRAF 
testing. Higher average of extracted DNA concentration was observed in the dedicated pass group 
(25.9 vs. 7.95 ng/ m l). However, the rate of successful exon 15 BRAF amplification was similar with 
(43/44; 97.7%) or without (79/84; 94%) the dedicated pass. Thus, our protocol is suitable for both 
tests. When necessary, BRAF testing may also be performed on the residual samples of thyroid 
nodules, without interfering with routine cytology. Similarly, as far as mRNA markers are con-
cerned, we have shown that in most samples, qRT-PCR analysis does not interfere with cytology 
 [ 11 ] . In fact, in a recent study on UbcH10 expression, including 84 cases with a cytological diag-
nosis of either follicular neoplasm ( n = 57) or suspicious for malignancy ( n = 27), we found that most 
(73.8%) cases were adequate for both tests  [ 11 ] . 
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